Chittaranjan National Cancer Institute (An Autonomous Body under Ministry of Health & Family Welfare, Govt. of India) 37, S. P. Mukherjee Road, Kolkata ‐ 700026 INDIA Tel: 033‐2476 5101/02/04/20/22; Fax: 91‐33‐2475 7606 E‐mail: [email protected]; Website: www.cnci.org.in

II | CNCI Annual Report 2018‐19

Table of Contents Department Page No. Governing Body of CNCI V Structural Scheme of CNCI VI, VII Message from the Desk of the Director VIII Reports from the Research Wing Anticancer Drug Development & Chemotherapy 1 Cancer Chemoprevention 3 Environmental Carcinogenesis & Toxicology 6 Epidemiology & Bio‐Statistics 10 Immunoregulation and Immunodiagnostics 12 In‐Vitro Carcinogenesis and Cellular Chemotherapy 19 Neuroendocrinology and Experimental Hematology 24 Oncogene Regulation 26 Pathology and Cancer Screening 33 Receptor Biology and Tumor Metastasis 35 Signal Transduction & Biogenic Amines 42 Viral Associated Human Cancer 49 Academic Cell 51 Animal Care and Maintenance 53 Central Research Instrumentation Facility 56 Library 57 Clinical and Translational Research 59 Reports from the Hospital Wing Anaesthesia and ITU 63 ENT‐Head & Neck Oncology 64 Gynaecological Oncology 67 Medical Oncology 71 Medical Physics 73 Pathology 77 Radiation Oncology 80 Radiodiagnosis 84 Surgical Oncology 86 Pain and Palliative Care Unit 89 Medical Records 91 Dietetics 92 Division of Preventive Oncology 94

… Contd. next

CNCI Annual Report 2018‐19 | III

Table of Contents contd. ⋯ Annexures Running Projects i Publications vi Patents xi Gene Bank Submission xi Conference Presentations xii Awards or Special Achievements xix PhD awarded xxi DNB awarded xxii Conference/Symposium/Workshop organized xxii Administration of funds granted by Government of India & Government of West Bengal xxii for welfare of cancer patients Patient Care Facilities xxiii Staffs of General Administration, Accounts & Ancillary Departments xxiv

IV | CNCI Annual Report 2018‐19

Governing Body Chittaranjan National Cancer Institute, Kolkata 1. Chairman Union Minister of Health & Family Welfare 2. Alternate Chairman Minister of Health & Family Welfare, Govt. of West Bengal 3. Member Secretary, Ministry of Health & Family Welfare, Govt. of India or his Nominee 4. Member Director General of Health Services, Directorate General of Health Services, Govt. of India, New Delhi 5. Member Financial Adviser, Ministry of Health & Family Welfare, Govt. of India, New Delhi 6. Member Secretary, Department of Health & Family Welfare, Govt. of West Bengal, Kolkata 7. Member Secretary, Finance Department, Govt. of West Bengal, Kolkata 8. Member Director of Health Services, Govt. of West Bengal, Kolkata 9. Member Director General or his Nominee, Indian Council of Medical Research, New Delhi 10. Member Director or his Nominee, Post Graduate Institute of Medical Education & Research, Chandigarh 11. Member Director or his Nominee, Institute of Post Graduate Medical Education & Research, Kolkata 12. Member Director, Saha Institute of Nuclear Physics, Kolkata 13. Member Director, School of Tropical Medicine, Kolkata 14. Member Nominee of the Department of Atomic Energy 15. Member Director, All India Institute of Hygiene & Public Health, Kolkata

Amendment 16. Member Vice‐Chancellor, West Bengal University of Health Services (11th Meeting of the Governing Body, held on 26.04.2005) 17. Special Invitee Vice‐Chancellor, University of Calcutta, (12th Meeting of the Governing Body, held on 21.08.2010) 18. Member Chairman, Standing Finance Committee (10th Meeting of the Governing Body, held on 02.08.2003) 19. Member Two Experts in Biological Sciences related to Oncology ‐ one to be 20. nominated by the Union Health Minister and the other by the State Health Minister 21. Member Two Faculty Members of Chittaranjan National Cancer Institute 22. 23. Member By rotation to be nominated by the Standing Academic Committee 24. Member Director, Chittaranjan National Cancer Institute

CNCI Annual Report 2018‐19 | V

Chittaranjan National Cancer Institute

DIRECTOR Dr. Jayanta Chakrabarti

RESEARCH WING HOSPITAL WING Ruplal Nandy Memorial Cancer O.I.C.(R) M.S. & A.M.O. Research Centre, Chandannagar

Scientific Departments Ancillary Depts./ Major Departments Ancillary Depts./ Units/Sections Units/Sections 1. Anticancer Drug 1. Central Research 1. Anesthesiology 1. Pain & Palliative Development Instrumentation HoD: Dr. S Ray Care Unit In‐Charge: Dr. C K Panda Facility 2. ENT‐Head & Neck HoD: Dr. R K Mandal 2. Cancer In‐Charge: Dr. C K Oncology 2. Dental Surgery Chemoprevention Panda HoD: Dr. A Dam In‐Charge: Dr. S N HoD: Dr. P. Saha 2. Academic Cell 3. Gynecological Basak 3. Environmental Academic Oncology Medical Records Carcinogenesis & 3. Coordinator: Dr. S HoD: R K Mandal HoD: Dr. S S Mandal Toxicology Mukherjee HoD: Dr. M Roy 4. Medical Oncology 4. Dietetics 3. Animal Care & HoD: Dr. K K Mukherjee Dietitian: Ms. P Das 4. Epidemiology & Maintenance 5. Paediatric Oncology Dutta Biostatistics HoD: Dr. A Rakshit HoD: Dr. R K Mandal / Section 5. Nursing Services 4. Library Section In‐Charge: Dr. K Asst. Nursing Supdt: Dr. S S Mandal ALIO: Mr. S K Mukherjee Ms. M Barui 5. Immuoregulation & Chakraborty & Immunodiagnostics 6. Medical Physics (Mukherjee) Mr. G Gorai HoD: Dr. D K Ray HoD: Dr. R Baral 6. Rehabilitation 5. Computer Section 7. Pathology Services 6. In Vitro Carcinogenesis & In‐Charge: Mr. K S Cellular Chemotherapy HoD: Dr. S Mitra Roychowdhury In‐Charge: Dr. C K Panda Mustafi 6. Maintenance 7. Neuroendocrinology 8. Radiation Oncology Department Experimental HoD: Dr. T Maji In‐Charge: Dr. A Hematology 9. Radiodiagnosis Rakshit In‐Charge: Dr. C K Panda HoD: Dr. S Mazumder 8. Oncogene Regulation 10. Surgical Oncology HoD: Dr. C K Panda HoD: Dr. J Chakrabarti

9. Pathology & Cancer 11. Dental Surgery Screening In‐Charge: Dr. S N Basak HoD: Dr. P Nath 12. Division of Preventive 10. Receptor Biology & Oncology Tumor Metastasis HoD: R K Mandal HoD: Dr. D Sinha

11. Signal Transduction & Biogenic Amines HoD: Dr. N Murmu 12. Viral Associated Human Cancer HoD: Dr. C K Panda 13. Clinical & Translational Research HoD: Dr. K K Mukherjee VI | CNCI Annual Report 2018‐19

Chittaranjan National Cancer Institute

Administrative Set-up

DIRECTOR

ADMINISTRATION ACCOUNTS

Senior Administrative Officer Accounts Officer

Assistant Accounts Officer

Office Superintendent ‐ Research Accountant Office Superintendent ‐ Hospital

CNCI Annual Report 2018‐19 | VII

Message from the Desk of the Director

1. Starting Diagnostic CT scans and also CT planning for Radiotherapy with the newly acquired CT Simulator. 2. Renovation of the Major operation Theatre Complex with inclusion of modern gadgets in anesthesia and Surgery. 3. Beautification of Hospital building premises, renovation of store, LED light illumination of wards with music system, Introduction of semi‐motorised beds in the wards from Swachhta Action Plan (SAP) funds released by the Govt. of India. 4. Empanelment of CNCI in Swasthya Sathi (state sponsored medical insurance scheme) for all modalities of Cancer treatment as an “A” category hospital. We have already treated more than 2000 patients with this scheme in the last eight Dr. Jayanta Chakrabarti, Director months. Chittaranjan National Cancer Institute 5. Rashtriya Arogya Nidhi (RAN) fund is poised to play a vital role in the treatment of amounting to 1.12 crore INR has been Cancer along with cancer research in the near utilized in the last year to provide free future. The Institute being already rich with the chemotherapy for patients with BPL status. legacy of Comprehensive Cancer care and In addition we have started to avail research in unison, is coming up with a state of chemotherapy at free of cost to those who the art Second Campus at Rajarhat, Kolkata which are financially deprived. would add 460 beds to the existing 200 beds in its 6. Introduction of quarterly Performance existing campus. Needless to reiterate that with a audit of clinical as well as supportive range of modern equipments in the field of cancer disciplines with an aim to improve and diagnosis and treatment it would be the most maintain the standard of patient care sought for destination for cancer treatment in this services. region. With the civil work nearly completed it is only a matter of few months that the major 7. We started an annual evaluation of the equipments and manpower would usher in a new scientific projects in the Research Division horizon in oncology. by External Experts to stimulate and propel the ongoing research works in the coveted In the last one year we have also strived to path of success. upgrade our existing campus, and give new dimensions to it. We have always believed in It’s our submission that the list is very small as “Service before Self” and each of us has compared to the wish list that would really have contributed to our motto with extreme zeal, an impact on the million lives affected with the passion and discipline. Few of our disease, but we would not let our determination accomplishments are as follows wane off at any cost to create survivor from a patient.

VIII | CNCI Annual Report 2018‐19

CNCI Annual Report 2018‐19 | ix

x | CNCI Annual Report 2018‐19

CNCI Annual Report 2018‐19 Research Wing

Anticancer Drug Development and Chemotherapy

In‐Charge Dr. Chinmay Kumar Panda Senior Assistant Director Grade

Team minor groove binding and forms a stable complex. We are trying to utilize that finding Faculty in the current phase of our research focus. We Dr. Supratim Ghosh, Senior Scientific Officer II believe that simultaneous use of multiple anti- Junior Research Fellow cancerous modalities should help to eliminate Ms. Upasana Das malignant cell by one or the other, without providing them further opportunity to spread Supporting Staff Mrs. Rina Bose, GDMO after the therapeutic procedure. As mentioned in our previous year’s report, we are further expanding our research towards the field of novel organo-metallic complexes for Objectives progressive cancer treatment. Recently we Our research interest in the Department of have developed a mercury based organo- Anti-Cancer Drug Development & metallic complex for leukemia therapy and a Chemotherapy (ACDD/C) is focused on the molybdenum based complex for epithelial development of multi-modality nano- malignancy treatment. Provisional Indian conjugate as well as natural product based patent have been filed for both of the therapeutics for advanced cancer treatment. complexes. Details are mentioned below. In our multi-modality nano-conjugate development project, we are conjugating a polymer of the chemotherapeutic molecule 5- Work done Fluorouracil on gold coated iron nanoparticle

for magnetic field guided targeted cancer treatment, including hyperthermia. Selective Projects running (Extramural) thermal ablation in combination with 1. Development of an advanced class of chemotherapy is emerging as a pragmatic multi-modality nanoparticle for concept for the treatment of localized progressive cancer therapy aggressive growth, such as squamous cell P.I.: Dr. Supratim Ghosh carcinoma or lymphoma, in the neck region. First phase of the work, i.e. synthesis of the Funding agency: DST ferromagnetic nano-conjugate is under progress. We are also planning to conjugate Projects running (Internal) poly-FdUMP (a polymeric derivative of 5- 1. Project Title: Development of novel FU), along with curcumin on the nanoparticle organo-metallic complex for acute surface to overcome chemo-resistance, leukemia treatment especially in case of aggressive malignancies. P.I.: Dr. Supratim Ghosh We have reported in our previously published research article that curcumin can Publications interact with DNA hairpin structure through 1. Upasana Das1, Aditi Sahoo2, Subhas 1

CNCI Annual Report 2018‐19 Research Wing

Haldar3, Shyam Sundar Mandal1, Sudin 201931006856 (Feb, 2019) Bhattacharya1, William H. Gmeiner4, 2. An Organometallic Complex of Supratim Ghosh1* “Secondary Structure Molybdenum for the Treatment of Cancer Dependent Physicochemical Interaction of Supratim Ghosh and Upasana Das, Oligonucleotides With Gold Nanorod and Chittaranjan National Cancer Institute, Photothermal Effect for Future Provisional Indian Patent Filed; Applications: A New Insight” ACS omega 3 Application no 201931006875 (Feb, 2019) (10), 14349-14360. Patents Other academic activities 1. An Organometallic Complex of Mercury Students undergoing PhD for the Treatment of Cancer Supratim 1. Ms. Upasana Das. Ghosh and Upasana Das, Chittaranjan National Cancer Institute Provisional Indian Patent Filed; Application no

2

CNCI Annual Report 2018‐19 Research Wing

Cancer Chemoprevention

Head Dr. Prosenjit Saha Senior Scientific Officer Grade‐I

EMT and Anoikis P.I.: Dr. Prosenjit Saha Team Funding agency: ICMR Faculty Dr. Subhadip Hajra, Senior Scientific Officer Gr.II Projects running (Internal) 1. Therapeutic efficacy of eugenol thorough Research Associate Dr. Arijit Bhowmik induction of apoptosis in Ehrlich Ascites Carcinoma (EAC) cell line Senior Research Fellow Mr. Atish Barua P.I.: Dr. Prosenjit Saha Ms. Pritha Choudhury 2. Alteration of cancer stem cell self- Junior Research Fellow renewal pathway by xanthone from Mr. Souradeep Biswas ancient medicinal plant Swertia Chirata Ms. Rituparna Ghosh P.I.: Dr. Prosenjit Saha 3. Prevention of Lung cancer by eugenol and its effect on modulation of Cancer Objectives Stem Cell The sole objective of this Department is to P.I.: Dr. Prosenjit Saha prevent the cancer incidence in our society by 4. Chemopreventive potential of xanthone using natural compounds presence in our isolated from Swertia chirata against foods and beverage or in Indian medicinal DMBA induced mouse skin plants. This Department also involved in carcinogenesis model public awareness program for campaigning P.I.: Dr. Prosenjit Saha the myth and truth about CANCER. 5. Evaluation of chemopreventive and therapeutic efficacy of naturally occurring phytochemicals by targeting Work done stem cell self renewal pathways in vivo

and in vitro experimental models Projects running (Extramural) P.I.: Dr. Subhadip Hajra 1. A Way to Overcome Chemo-Resistance in Publications Colorectal Cancer Stem Cells: Therapeutic Targeting By Natural 1. Barua A, Choudhury P, Maity JK, Mandal Falvonoid Orientin SB, Mandal S, Saha P. 2019. Chemotherapeutic potential of novel non- P.I.: Dr. Prosenjit Saha toxic nucleoside analogues on EAC ascitic Funding agency: DBT tumour cells. Free Radic Res. 53(1):57-67. 2. Evaluation of chemotherapeutic efficacy 2. Pattanayak R, Barua A, Das A, Chatterjee of rutin during metastasis by targeting 3

CNCI Annual Report 2018‐19 Research Wing

T, Pathak A, Choudhury P, Sen S, Saha P, 2. Ms. Pritha Choudhury Bhattacharyya M. 2018. Porphyrins to 3. Mr. Souradeep Biswas restrict progression of pancreatic cancer by 4. Ms. Rituparna Ghosh stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer Other awards or special achievements strategy. Eur J Pharm Sci. 125:39-53. 1. Mr. Atish Barua won Outstanding Poster 3. Hajra S, Patra AR, Basu A, Saha P, Presentation Award in the 9th General Bhattacharya S. 2018. Indole-3-Carbinol Assemble and International Conference of (I3C) enhances the sensitivity of murine Asian Pacific Organization for Cancer breast adenocarcinoma cells to Prevention, 2018, Jeju Island, Korea. doxorubicin (DOX) through inhibition of 2. Ms. Pritha Choudhury won first prize in NF-κβ, blocking angiogenesis and 2nd Annual Conference on Recent Trends regulation of mitochondrial apoptotic in Cancer Research, Early Diagnosis, pathway. Chem Biol Interact. 290:19-36. Prevention and Therapy”, 5th February 4. Hajra S, Patra AR, Basu A, Bhattacharya S. 2019, CNCI, Kolkata. 2018. Prevention of doxorubicin (DOX)- induced genotoxicity and cardiotoxicity: Conference/Symposium/Workshop Effect of plant derived small molecule attended indole-3-carbinol (I3C) on oxidative stress 1. Mr. Atish Barua attended the 9th General and inflammation. Biomed Pharmacother. Assemble and International Conference of 101:228-243. Asian Pacific Organization for Cancer Prevention Conference on Other academic activities "Chemopreventive potential of Xanthone Poster presentation isolated from Swertia chirata against DMBA induced skin carcinogenesis" held from 1. Mr. Atish Barua presented a poster on 19th to 20th April 2018 at Jeju Island, Korea. “Chemopreventive potential of Xanthone th isolated from Swertia chirata against DMBA 2. Miss. Pritha Choudhury attended the 9 induced skin carcinogenesis” in 9th General Assemble and International General Assemble and International Conference of Asian Pacific Organization Conference of Asian Pacific Organization for Cancer Prevention Conference on for Cancer Prevention Conference, 19th to "Cancer Stem Cell, the root cause of lung 20th April 2018, Jeju Island, Korea. cancer and its prevention by eugenol" held from 19th to 20th April 2018 at Jeju Island, 2. Ms. Pritha Choudhury presented a poster Korea. on “Cancer Stem Cell, the root cause of lung cancer and its prevention by 3. Dr. Subhadip Hajra attended the “Annual eugenol” in 9th General Assemble and Meeting & Mini Symposium” IACR-West International Conference of Asian Pacific Bengal Chapter and CNCI, Kolkata held th Organization for Cancer Prevention from 14 September, 2018 at CNCI, Conference, 19th to 20th April 2018, Jeju Kolkata Island, Korea. 4. Dr. Subhadip Hajra attended the “East 3. Ms. Pritha Choudhury presented a poster Zonal Oncology Symposium-2019” held th on “Prevention of lung cancer by eugenol form 19 January at Saroj Gupta Cancer and its effect on modulation of cancer stem Center & Research Institute, Thakurpukur, cell” in 2nd Annual Conference on Recent Kolkata. Trends in Cancer Research, Early 5. Dr. Subhadip Hajra attended symposium Diagnosis, Prevention and Therapy”, 5th on “2nd Annual Conference on Recent February 2019, CNCI, Kolkata. Trends in Cancer Research, Early Students undergoing PhD Diagnosis, Prevention and Therapy” on World Cancer Day, 2019, held at CNCI,

4 1. Mr. Atish Barua Kolkata.

CNCI Annual Report 2018‐19 Research Wing

6. Dr. Arijit Bhowmik attended the “East Center & Research Institute, Thakurpukur, Zonal Oncology Symposium-2019” held Kolkata. form 19th January at Saroj Gupta Cancer 8. Ms. Rituparna Ghosh attended the “East Center & Research Institute, Thakurpukur, Zonal Oncology Symposium-2019” held Kolkata. form 19th January at Saroj Gupta Cancer 7. Mr. Souradeep Biswas attended the “East Center & Research Institute, Thakurpukur, Zonal Oncology Symposium-2019” held Kolkata. form 19th January at Saroj Gupta Cancer

5

CNCI Annual Report 2018‐19 Research Wing

Environmental Carcinogenesis & Toxicology

Head Dr. Madhumita Roy Senior Scientific Officer (Assistant Director Grade)

Team Work done

Faculty Dr. Sutapa Mukherjee, Senior Scientific Officer I Projects running (Extramural) Junior Research Fellow 1. Modulation of Therapeutic Targets Mr. Souvick Biswas Aurora A and B by phytochemicals in Ms. Elizabeth Mahapatra breast cancer cells Mr. Archismaan Ghosh P.I.: Dr. Sutapa Mukherjee Mr. Uday Pramanick Joint P.I.: Dr. Madhumita Roy Funding agency: DST Objectives 2. A comparative study of the population chronically exposed to arsenic in two 1. Role of Curcumin in enhancement of different demographic regions of Eastern drug sensitivity in drug resistant India: Identification of responsible genes leukemia cells. and susceptible population 2. Underlying mechanisms of acquired P.I.: Dr. Madhumita Roy chemoresistance in breast cancer cells Funding agency: DBT-Twining and overcoming the same by targeting Aurora Kinases using phytochemicals. Projects running (Internal) 3. Identification of responsible genes in a 1. Black tea in prevention of skin cancer: A population residing in arsenic affected mechanistic study areas of West Bengal. P.I.: Dr. Madhumita Roy 4. Elucidation of the underlying 2. Phenethylisothiocyanate: Role in mechanisms during development of in enhancing platinum accumulation in vivo model of cervical carcinoma using a cervical cancer chemical carcinogen with particular P.I.: Dr. Sutapa Mukherjee emphasis on inflammation. 3. Prevention of arsenic induced renal 5. Elucidation of the role of black tea in carcinogenesis by black tea prevention of arsenic induced skin P.I.: Dr. Madhumita Roy cancer. Publications 6. Prevention of arsenic induced renal carcinoma by black tea. 1. Mukherjee A, Mukherjee K K, Mukherjee S and Roy M (2018) Curcumin may enhance 6

CNCI Annual Report 2018‐19 Research Wing

the efficacy of anti-leukemia drugs in platinum resistance in cervical cancer’ in Myeloid Leukemia. Int. J. Curr. Microbiol. National Conference on New Horizons in App. Sci 7(5): 3274-3283. Cancer Biology, Ahmedabad Management Association, Ahmedabad, March 16-17, 2. Mukherjee S, Roy M, Biswas J (2018). 2018. Oncogenesis and Telomerase Activity in Cancer: Rediscovering Cancer: From 2. Dr Sutapa Mukherjee presented a paper Mechanism to Therapy, Part I, Chapter 3; entitled “Indian Spice Curcumin: A Rescue pg 21-58. ISBN No 978-1-77188-690-1 in Overcoming Chemoresistance in Breast (Apple Academic Press). Cancer Cells by Targeting Aurora Kinases” in International Conference on Advancement in 3. Roy M, Sarkar R, Mukherjee A, Mukherjee Science & Technology, Visva Bharati, S & Biswas J (2018) Phytochemicals as Santiniketan, September 3-4, 2018. Chemosensitizers in Breast Cancer; Cancer Cell Chemoresistance and 3. Dr Sutapa Mukherjee presented a paper Chemosensitisation. Chapter 6, pg 129-162. entitled “Serine Threonine Kinases: Publisher: World Scientific Publishing, Implications in Breast Cancer Using in rd Singapore, edited by Dr Ajaikumar B. vitro Model” in 43 Annual Conference of Kunnumakkara, Bordoloi Devivasha, Environmental Mutagen Society of India Monisha Javadi. (EMSI) and International Symposium on “Impact of Environmental Mutagenesis in 4. Mukherjee S, Mukherjee A, Biswas S, Roy the Human Genome”, Organized by M (2018). Apoptosis: A Regulatory School of Bio Sciences & Technology, Mechanism in Cancer: Rediscovering Vellore Institute of Technology (VIT), Cancer: From Mechanism to Therapy, Part Vellore, India, 31st January-2nd February, I, Chapter 3; pg 201-222. ISBN No 978-1- 2019. 77188-690-1 (Apple Academic Press). Other oral presentation 5. Roy M and Mukherjee S (2019) Black Tea Extract prevents 4-nitroquinoline 1-oxide 1. Mr. Souvick Biswas presented a paper induced oral tumorigenesis in mice by entitled “Curcumin, a natural targeting Protein Tyrosine Kinases and phytochemical, reverses acquired associated biological response, Available chemoresistance in breast cancer cells by online at www.sciencerepository.org, targeting Aurora Kinases” in One day Clinical and Oncology Research, 2(1): 2-7. symposium of Society of Biological Chemists, Kolkata Chapter, Amity 6. Ghosh A, Mukherjee A, Mukherjee S and University, Kolkata, September 8, 2018. Roy M (2019) Role of Black Tea in prevention of Skin Carcinogenesis, LAP 2. Mr. Archismaan Ghosh presented a paper LAMBERT Academic Publishing. entitled “Prevention of Arsenic induced skin carcinogenesis by black tea” at 2nd 7. Mukherjee A, Mukherjee S and Roy M Annual Conference on Recent Trends in (2019) Curcumin plays a dual role: in Cancer Research, Early Diagnosis, adjuvant therapy and reversal of drug Prevention and Therapy, World Cancer resistance in Acute Myelogenous Day, Chittaranjan National Cancer Leukemia, International Journal of Current Institute, 2019. Medical and Pharmaceutical Research, 5(02A), 4078-4084. Poster presentation 1. Mr. Souvick Biswas presented a paper Other academic activities (poster presentation) entitled “Aurora Paper presented Kinases: Implication in chemoresistance and its reversal by Curcumin” in 43rd Invited talk Annual Conference of Environmental Mutagen Society of India (EMSI) and 1. Dr Madhumita Roy presented a paper International Symposium on “Impact of entitled ‘Isothiocyanates may overcome Environmental Mutagenesis in the Human 7

CNCI Annual Report 2018‐19 Research Wing

Genome”, Organized by School of Bio Mutagen Society of India (EMSI) and Sciences & Technology, Vellore Institute of International Symposium on “Impact of Technology (VIT), Vellore, India, 31st Environmental Mutagenesis in the Human January-2nd February, 2019. Genome”, Organized by School of Bio Sciences & Technology, Vellore Institute of Students undergoing PhD Technology (VIT), Vellore, India, 31st 1. Ms. Apurba Mukherjee - PhD work January - 2nd February, 2019. completed, thesis under preparation. 6. Mr. Archismaan Ghosh attended the 2nd 2. Proposed thesis works of Mr. Souvick Annual Conference on Recent Trends in Biswas, Ms. Elizabeth Mahapatra, Mr. Cancer Research, Early Diagnosis, Archismaan Ghosh and Mr. Uday Pramanick Prevention and Therapy, World Cancer have been registered. Day, Chittaranjan National Cancer Institute, 2019. Other awards or special achievements Interesting observations 1. Mr. Souvick Biswas was awarded the 1st prize in Poster Competition from Springer Observation 1: Cytokines and their associated Nature at 43rd Annual Conference of signaling proteins, involved in Environmental Mutagen Society of India leukemogenesis are even more aberrantly and International Symposium on Impact expressed in resistant myeloid leukemia cells, of Environmental Mutagenesis in the as compared to the parental cells. A potent Human Genome at VIT, Vellore, India problem of Myeloid Leukemia therapy is during the period of 31st January-2nd development of drug resistance which is a February, 2019. challenge in clinical practice and a key issue to address in leukemia research. Curcumin Conference/Symposium/Workshop helps to revert drug resistance by sensitizing attended the cells to anti-leukemia drugs via modulation of various markers. In a nut shell, 1. Dr Madhumita Roy attended the National curcumin may be regarded as an effective Conference on New Horizons in Cancer adjuvant therapy that tackles the severe side Biology, Ahmedabad Management effects of conventional anti-cancer drugs in Association, Ahmedabad, March 16-17, one hand and overcoming drug resistance on 2018. the other. 2. Dr Sutapa Mukherjee attended the Observation 2: Overexpression of drug International Conference on Advancement resistant markers (MRP1, Pgp1, Aurora A and in Science & Technology, Visva Bharati, B were observed in the isolated sublines Santiniketan, September 3-4, 2018. compared to parental one). Predominant localization of both Aurora A and B were 3. Mr. Souvick Biswas attended the One day observed in resistant sublines in comparison symposium of Society of Biological to parental one as observed under confocal Chemists, Kolkata Chapter, Amity microscope following ICC/IF technique. University, Kolkata, September 8, 2018. Doxorubicin inhibits the progression of 4. Dr Sutapa Mukherjee attended the 43rd topoisomerase II; which was also reflected in Annual Conference of Environmental the findings where increased Topo II α Mutagen Society of India (EMSI) and expression was apparent in resistant subline. International Symposium on “Impact of Accumulation of drug has been shown to Environmental Mutagenesis in the Human decrease with incremental stages of Genome”, Organized by School of Bio doxorubicin administration during Sciences & Technology, Vellore Institute of development of resistant subline ensuring Technology (VIT), Vellore, India, 31st resistance. Treatment with curcumin reverses January-2nd February, 2019. chemoresistance in MCF-7Dox/R subline. Curcumin acted as resistance modifying agent 5. Mr. Souvick Biswas attended the 43rd (RMA). It was apparent from the 8 Annual Conference of Environmental

CNCI Annual Report 2018‐19 Research Wing

experimental result that curcumin superseded cervical carcinoma as observed by consistent its effect in reversing chemoresistance dysplastic changes in the cervical tissue towards doxorubicin in comparison to either architecture. of the specific inhibitors of resistant markers Observation 4: Arsenic leads to (Zosuquidar, a Pgp1 inhibitor; Ko-143, a carcinogenicity of the skin. Impairment of specific ABCG2 inhibitor; Reversan, a specific DNA repair enzymes and Epithelial to MRP1 inhibitor. Mesenchymal (EMT) transition plays a lead Observation 3: Progression of carcinogenesis role in the development of skin cancer. and successful development of the cervical Administration of Black tea enhances the cancer model in Swiss Albino mice (Mus expression of these repair enzymes and musculus) was assessed by studying prevents carcinogenesis. Due to arsenic cytopathological parameters which showed exposure, the epithelial characteristics of the high leucocytic index and some visible cells are gradually diminished and cells changes in the cervical epithelial cells. 3MCA acquire mesenchymal characteristics to treatment leads to gradual loss in body promote their invasive behavior. Present weight till 12th week. On reaching 16th week findings indicate that transcriptional factors of treatment, there is a gain in body weight like Slug, Snail and Zeb1 repress the observed. The probable reason for such an expression of epithelial proteins and promote observation is the appearance of tumor near the expression of mesenchymal proteins. cervix which catered into rise in the weight of Black tea therefore can prevent skin the organ and thus the body weight. Some carcinogenesis by reversing EMT. visible changes in the appearance of the Observation 5: This is a preliminary study. female reproductive organs were observed Loss of VHL is implicated in renal due to chronic treatment of 3MCA. These carcinogenesis. Arsenic has been found to changes were reflected in the cytopathology repress VHL expression in bladder tumor of and histopathology of the cervix of animals mice treated chronically with arsenic. Initial which received chronic treatment with 3MCA finding shows black tea may be beneficial in for 30 weeks. Inflammatory changes as this regard. observed by Pap smear test clearly correlates with elevated levels of free radical and Training Program associated DNA damage as observed by Twenty students from different colleges and quantitative estimation of ROS, RNS and universities from various parts of India comet assay followed by liver function test. completed their short term projects in this Prolonged treatment stress led to department. compromised antioxidant scavenger activity as measured by total antioxidant activity in Miscellaneous the serum. Inflammatory changes so observed Dr Madhumita Roy: corroborates with alterations in splenic and hepatological histologies. Furthermore, the • was invited to examine thesis reduced expression of the tumor suppressor • acted as a reviewer of international peer genes such as p53, p21 and elevated reviewed journals proliferative index of the cervical cells particularly in the 24th and 30th week of • was invited to write a book: Role of Black treatment indicated that loss in physiological Tea in prevention of Skin Carcinogenesis hormesis paved a way for development of [ISBN # 978-3-330-08681-4].

9

CNCI Annual Report 2018‐19 Research Wing

Epidemiology and Biostatistics

Head Dr. Ranajit Kumar Mandal Associate Professor (Specialist Grade I) ­ up to August 2018 Dr. Syamsundar Mandal Statistical Officer ­ September 2018 onwards

Team wards of Kolkata Municipal Corporation covering 185 sq. km. Project Staff • Ms. Soumya Roy, Social Investigator Third wing is working in the rural Mr. Biswajit Bhattacharya, Data Entry Operator cum community to assess the cancer burden in Social Investigator Community Development Block Daspur-II Ms. Indrani Nandi, Social investigator in the district of Paschim Medinipur, West Ms. Pranati Sarker, Social investigator Bengal under Rural Population Based Mr. Biswanath Ghosh, Social investigator Cancer Registry (Rural PBCR), Daspur-II Ms. Soma Das, Social investigator since 01-01-2019 and to create cancer awareness among the common people including Asha Workers and to train Objectives common people self detection of Breast The department is working for both in the Cancer through Breast Self Examination field of Epidemiology and Biostatistics. It has (BSE) and self oral examination for pre- three wings of which - cancerous and cancerous lesions. In the initial phase these programmes are based In the field of Epidemiology on 87 villages comprising of 2.39 lakh (0.239 million) covering 165.45 sq. km of • First wing is working for study on the Daspur-II. cancer patients reported to the hospital of this institute under the extramural projects entitled Hospital Based Cancer Registry (HBCR) and Hospital Based Pattern of Care and Survival Studies on Cancer Cervix, Breast, Head & Neck Cancers, Gall Bladder Cancer and implementation of NCDIR e-Mor Software to strengthen the Medical Certification of Cause of Death (MCCD). • Second wing is working in the urban community to assess the cancer burden in Kolkata under Population Based Cancer Registry (PBCR), Kolkata and Pattern of Meeting with inhabitants of Daspur-II regarding Care and Population Based Survival initiated of Rural PBCR by the Director, CNCI on 30- Studies on Cancer Cervix, Breast, Head & 03-2019 10 Neck Cancers based on 4.5 million of 141 • The Director, NCDIR inaugurated the

CNCI Annual Report 2018‐19 Research Wing

Rural PBCR on 06-01-2018 but it could not 2. HBCR and POCSS, CNCI be initiated in 2018 due to lack of financial 3. Rural PBCR, Daspur-II, Paschim grant. Then after repeated meeting with Medinipur the representatives of Panchyats, Block Development and Block Medical Officer it 4. Implementation of NCDIR e-Mor Software started with self reporting of new cancer to strengthen the Medical Certification of cases to the respective Panchayats and Cause of Death (MCCD). Asha Workers are also reporting the new 5. Educational Intervention to promote cases. The work initiated by the Director, cancer patients’ compliance to treatment CNCI on 30-03-2019 in a meeting of about and follow-up. 5000 common people of that registry area. Out of 5000 people about 96% were Other academic activities women. • Under the above achievements ICMR- Oral presentation NCDIR declared CNCI as a Centre of Number of oral presentations was delivered Cancer Registries. lectures on cancer registrations, cancer • Evidence Based Interventions for Cancer survival and cancer awareness by the HOD in Screening and Management in the district different meetings. of Paschim Medinipur, West Bengal. In Special achievements this pilot project Paschim Medinipur, West Bengal is one of 6 districts of India. HOD 1. ICMR-NCDIR declared CNCI as a Centre of this department has been as the Team of Cancer Registries. Leader of eastern India by the MoHFW, 2. HOD of this department has been as the Government of India. Team Leader of eastern India by the In the field of Biostatistics MoHFW, Government of India. 3. The number of cancer cases was estimated • The department conducts classes for DNB by this department on request from the Students, Research Scholars and students Department of Health and Family Welfare, of Medical Physics. Government of West Bengal. On the basis • The department is helping both clinical of the estimation Government of West and basic researchers for their design and Bengal declared number of facilities for the analysis of data of research works. cancer patients of West Bengal. Future Proposal Work done To start research on Artificial Intelligence in

the field of diagnosis and treatment of cancers. Projects running 1. PBCR and PBCS, Kolkata

11

CNCI Annual Report 2018‐19 Research Wing

Immunoregulation and Immunodiagnostics

Head Dr. Rathindranath Baral Senior Scientific Officer (Assistant Director Grade)

role of Neem Leaf Glycoprotein (NLGP) is extensively studied in different murine Team and human tumor models. • To understand metabolic regulation in the Faculty Dr. Saptak Banerjee, Senior Scientific Officer II biology of breast cancer stem cells Women Scientist Dr. Anamika Bose, Women Scientist A (DST) Dr. Tapasi Das, Women Scientist (DHR) Work done National Postdoctoral Fellow • Molecular alterations in various cell types, Dr. Sudeshna Mukherjee, SERB like, T cells, B cells, monocytes, Senior Research Fellow macrophages, dendritic cells, regulatory T Mr. Avishek Bhuniya, CSIR-NET cells, myeloid derived suppressor cells in Ms. Ipsita Guha, CNCI murine and human cancers are studied Ms. Shayani Dasgupta, UGC-NET with special reference to its modulation by Mr. Partha Nandi, DST-INSPIRE Ms. Juhina Das, CSIR-NET NLGP. Ms. Mohona Chakravarti, UGC-NET • NLGP mediated normalization of Mr. Anirban Sarkar, UGC-NET metastasis is studied in murine melanoma Junior Research Fellow and carcinoma models. Ms. Akata Saha, CNCI Ms. Sukanya Dhar, DST-INSPIRE • Role of non-hematopoietic stromal cells, Mr. Aritra Gupta, CSIR-NET e.g. pericytes, mesenchymal stem cells, Mr. Saurav Bera, WB-DBT adipocytes in immune alteration, thereby, Ms. Tithi Bhattacharya, WB-DBT progression of cancer are studied in Mr. Nilanjan Ganguly, Fellow, Anupama Mullick Trust relation to NLGP. Supporting Staff • Influence of tumor-associated pericytes is Mr. Diptendu Ghosh, Laboratory Technician investigated on CD4+ and CD8+ T cell functions. Objectives • Molecular mechanism of downregulation of VEGF and HIF1a by NLGP in cancer • To understand the molecular changes in cells is investigated in normoxic and intra-tumor and extra-tumor (systemic) hypoxic conditions. immune functions in cancer host and to • Significance of thymic atrophy in cancer modulate altered immunity to obtain and its modulation by NLGP, in relation to maximum anti-tumor benefits. age associated thymic alterations, are • To achieve this aim, immunomodulatory under study. 12

CNCI Annual Report 2018‐19 Research Wing

• Role of RGS5 in differential apoptotic 2. Studies on the role of cancer-associated behavior of tumor associated pericytes in adipocytes in progression of mammary tumor and non-tumor microenvironment carcinogenesis in relation to obesity: is studied. Emphasis on Immune Evasion • Tumor induced homing of mesenchymal P.I.: Dr. Sudeshna Mukherjee stem cells in tumor draining lymph nodes Funding agency: DST-SERB and its consequences on tumor 3. An attempt to characterize the protein progression and its modulation by Neem and carbohydrate moieties of Neem Leaf Leaf Glycoprotein. Glycoprotein with special emphasis on structure-function relationship • Role of NLGP in intervening the initiation- promotion protocol during 4- P.I.: Dr. Tapasi Das nitroquinoline-1-oxide mediated tongue Funding agency: DHR-ICMR carcinogenesis, especially during epithelial 4. Elucidation of the role of tumor residing mesenchymal transition are also being immune suppressor cells in generation of evaluated. multi drug resistance in murine • Role of T cells in regulation of cancer stem lymphoma with immune modulation by cells under the immunomodulation of Neem Leaf Glycoprotein (Azadirachta NLGP are under study. indica) P.I.: Dr. Rathindranath Baral • Molecular mechanisms of cancer progression in tumor hosts with type Co-P.I.: Dr Swapan Kumar Ghosh I/type II diabetes with reference to the Funding agency: DBT, Govt. of West alteration in cancer immune-surveillance Bengal and its correction by NLGP are being 5. Understanding of the intra/extra-tumoral investigated. trafficking of mesenchymal stem cells and modulation of its • The role of tumor residing immunosuppressive character by neem immunosupressor cells in generation of leaf glycoprotein multidrug resistance in murine lymphoma and immunomodulation by NLGP are P.I.: Dr. Rathindranath Baral under study. Funding agency: ICMR • Influences of cardiovascular disease-linked Students’ Projects running statin(s) treatment on cancer immunoediting process and its 1. Studies on tumor induced thymic modulation by NLGP. atrophy in mice in relation to T cell differentiation and death: Critical • Studies on experimental and human oral modulation by Neem Leaf Glycoprotein carcinogenesis on formation of cancer stem Name of the Student: Ipsita Guha cell niche Funding agency: CNCI • Understanding the metabolic regulation of 2. Analysis of tumor-induced regulator of Breast cancer stem cells and its impact on G-protein Signaling 5 (RGS5) mediated immunelandscape alterations in tumor pericytes: • Evaluation of combined effect of 2DG and Therapeutic modulation by Neem Leaf NLGP on breast cancer and BCSCs. Glycoprotein Name of the Student: Shayani Dasgupta Projects running (Extramural) Funding agency: UGC 1. Understanding the role of T cell subset(s) 3. Studies on the mechanism of Neem Leaf in regulation of cancer initiating stem Glycoprotein (NLGP) mediated down- like cells regulation of VEGF in tumors: Special P.I.: Dr. Anamika Bose emphasis on HIF degrading pathway Funding agency: DST-WOS Name of the Student: Akata Saha 13

CNCI Annual Report 2018‐19 Research Wing

Funding agency: CNCI/CSIR Publications 4. Studies on tumor induced homing of Ghosh S, Choudhury S, Mukherjee S, mesenchymal stem cells in tumor 1. draining lymph nodes and its Gupta P, Chowdhury O, Baral R, consequences on tumor progression: Chattopadhyay S. (2018) Fluoxetine Modulation by Neem Leaf Glycoprotein triggers selective apoptosis in inflammation-induced proliferating (Ki-67 Name of the Student: Partha Nandi high) thymocytes, Immunology & Cell Funding agency: DST Biology. Wiley Online Library. 5. Intervention by neem leaf glycoprotein doi.org/10.1111/imcb.12227 on the initiation-promotion protocol

during 4-nitroquinoline-1-oxide 2. Ghosh S, Jawed J, Halder K, Banerjee S, mediated tongue carcinogenesis: Special Paul Chowdhury B, Saha A, Juin S, emphasis on epithelial mesenchymal Bhattacharyya Majumdar S, Bose A, Baral transition R, Majumdar S. (2018) TNFα mediated ceramide generation triggers cisplatin Name of the Student: Juhina Das induced apoptosis in B16F10 melanoma in Funding agency: DBT a PKCδ independent manner. Oncotarget, 6. Identification of signaling gateway of 9(102), p.37627. neem leaf glycoprotein on macrophages

and dendritic cells 3. Patra AR, Roy SS, Basu A, Bhuniya A, Bhattacharjee A, Hajra S, Sk UH, Baral R, Name of the Student: Nilanjan Ganguly Bhattacharya S. (2018) Design and Funding agency: CSIR synthesis of coumarin-based 7. Understanding the mechanism of cancer organoselenium as a new hit for progression in tumor hosts with type myeloprotection and synergistic I/type II diabetes with reference to therapeutic efficacy in adjuvant therapy. alteration in cancer immune-surveillance: Sci Rep, 8, 2194. Correction by NLGP 4. Maity P, Bepari M, Pradhan A, Baral R, Name of the Student: Anirban Sarkar Roy S, Maiti Choudhury S, (2018) Funding agency: UGC Synthesis and characterization of biogenic 8. Understanding the role of T cells in metal nanoparticles and its cytotoxicity regulation of cancer stem cells: Influence and anti-neoplasticity through the of NLGP driven immunomodulation induction of oxidative stress, Name of the Student: Mohona Chakrovarti mitochondrial dysfunction and apoptosis. Colloids Surf B Biointerfaces 161, 111-20. Funding agency: UGC 9. Study of the role of tumor residing Book Chapter Immunosupressor cells of the generation 1. Bose A, Baral R. (2018) Neem Leaf of multidrug resistance in murine Glycoprotein in Cancer Immunotherapy. lymphoma with the immunomodulation In: “New Look to Phytomedicine” by by Neem Leaf Glycoprotein Elsevier Publications, 391-408. Name of the Student: Sukanya Dhar Funding agency: DST Other academic activities

10. Understanding the influence of Paper presented cardiovascular disease-linked statin(s) treatment on cancer immunoediting Invited talk process: Modulatory role of Neem Leaf Glycoprotein 1. Dr. R. Baral was invited to speak in 30th Annual Conference of the Physiological Name of the Student: Aritra Gupta Society of India, 22-24th November, 2018, Funding agency: CSIR held at Serampore College, Serampore. Topic: NLGP ameliorates tumor-induced 14 arrest of DN2b to DN3a pro-T cell

CNCI Annual Report 2018‐19 Research Wing

transition and diversion of pro-T cells to promotes type-I diabetes mediated Dendritic cells by regulating Notch1 and immune dependent tumor restriction by Ikaros signaling. modulating T-cell metabolism and normalizes diabetes associated hepatic 2. Dr. R. Baral was invited to speak in 1st inflammation. In 2nd Annual Conference World Neem Organization Seminar. Topic: on Recent Trends in Cancer Research, A Glycoprotein from Neem Leaves holds Early Diagnosis, Prevention and Therapy Promise in Immune Dependent Cancer organized by CNCI, 4-5th Feb, 2019. Therapy, Bangalore, December 2018. 8. Sarkar A, Guha I, Nandi P, Saha A, 3. Dr. R. Baral was invited to speak in 38th Ganguly N, Das J, Gupta G, Mukherjee S, Annual Convention of Indian Association Baral R, Bose A, NLGP immunotherapy for Cancer Research (IACR). Topic: NLGP promotes Type-I diabetes mediated Ameliorates Tumor-Induced Arrest Of immune dependent tumor restriction by Dn2b To Dn3a Pro-T Cell Transition And modulating T cell metabolism and Diversion Of Pro-T Cells To Dendritic normalizes diabetes associated hepatic Cells By Regulating Notch1 And Ikaros inflammation. 38th Annual Convention of Signaling, PGIMER Chandigarh, 2019. Indian Association for Cancer Research, Other oral presentation March 1-3, 2019, PGIMER, Chandigarh. 4. Sarkar A, Guha I, Nandi P, Saha A, 9. Dasgupta S, Ghosh T, Dhar J, Nandi P, Ganguly N, Das J, Gupta A, Mukherjee S, Chakravarti M, Guha I, Saha A, Alum N, Baral R, Bose A. NLGP Immunotherapy Majumdar S, Chakraborti P, Baral R, Bose Normalizes Diabetes-associated Hepatic A, Dual presence of pro-apoptotic RGS5- Inflammation and Promotes Type-I TGFB supports proliferation of tumor- Diabetes Mediated Immune Dependent pericytes in tumor microenvironment. 38th Tumor Restriction by Modulating T Cell Annual Convention of Indian Association Metabolism. In International Conference for Cancer Research, March 1-3, 2019, on Immunology at Tamil Nadu, 26-28th PGIMER, Chandigarh. Sept, 2018. 10. Bhuniya A, Gupta A, Saha A, Nandi P, 5. Nandi P, Ghosh T, Dasgupta S, Das A, Ganguly N, Bose A, Baral R. Tumor Kundu S, Saha A, Dutta M, Majumder S, educated activated platelets promote Baral R, Bose A. NLGP Prevents Tumor- vascular mimicry in mesenchymal stem induced Homing of Mesenchymal Stem cells for metastasis. International Cells in Tumor-draining Lymph Nodes by Conference on Microscope & XXXIX Down-regulating ERK-Akt-mediated Annual Meeting of Electron Microscope CCR7 Signaling in B16 Melanoma. In 30th Society of India at Bhubaneshwar, July 18- Annual Conference of the Physiological 20, 2018. Society of India, 22-24th November, 2018. Poster presentation 6. Dasgupta S, Ghosh T, Dhar J, Nandi P, 1. Bhuniya A, Gupta A, Saha A, Nandi P, Chakravarti M, Guha I, Saha A, Majumdar Ganguly N, Bose A, Baral R. Tumor S, Chakrabarti, Baral R, Bose A. Dual educated activated platelets promote presence of pro-apoptotic RGS5-TGFb vascular mimicry in mesenchymal stem supports proliferation of tumor-pericytes cells for metastasis. International in tumor microenvironment. In 2nd Conference on Microscope & XXXIX Annual Conference on Recent Trends in Annual Meeting of Electron Microscope Cancer Research, Early Diagnosis, Society of India at Bhubaneshwar, July 18- Prevention and Therapy organized by 20, 2018. CNCI, 4-5th Feb, 2019. 2. Nandi P, Ghosh T, Dasgupta S, Das A, 7. Sarkar A, Guha I, Nandi P, Saha A, Kundu S, Saha A, Dutta M, Majumder S, Ganguly N, Das J, Gupta A, Mukherjee S, Baral R, Bose A. NLGP prevents tumor Baral R, Bose A. NLGP immunotherapy induced homing of mesenchymal stem 15

CNCI Annual Report 2018‐19 Research Wing

cells in tumor draining lymph nodes by Promote Generation of Drug-Resistance in down regulating ERK/AKT mediated Non-Hodgkin’s Lymphoma Patients. 38th CCR7 signalling in B16 melanoma. In Annual Convention of Indian Association international Conference on Microscope & for Cancer Research, March 1-3, 2019, XXXIX Annual Meeting of Electron PGIMER, Chandigarh. Microscope Society of India at 9. Mukherjee KK, Dhar S, Chakravarti M, Bhubaneshwar, July 18-20, 2018. Bhattacharjee R, Bhanja S, Das S, Ghosh S, 3. Shayani Dasgupta et al., “TGFb within Sarkar M, Dasgupta S, Ghosh D, Bose A, tumor-microenvironment promotes Baral R, Tumor-Associated Myeloid survival of altered pericytes by targeting Derived Suppressor Cells of Granulocytic RGS5-induced pro-apoptotic signaling” on Nature is a Potential Biomarker for the occasion of 39th Annual Meeting of Prognostication of Response in Treatment Electron Microscope Society of India at of Diffused Large B Cell Lymphoma. To be Mayfair Convention Center, Bhubaneswar, presented in: Annual Meeting of American 18-20th July, 2018. Society of Clinical Oncology, May 31-June 4, 2019, Chicago, Illinois. 4. Dasgupta S, Ghosh T, Dhar J, Nandi P, Guha I, Saha A, Majumder S, Chakarbarti PhD awarded P, Baral R, Bose A. NLGP rescue TGFbeta

mediated switching of pro- to-anti 1. Ms. Tithi Ghosh was awarded PhD apoptotic signaling of RGS5 to normalize (Science) degree in the year 2019 from pericytes in tumor. In “Cell Death” University of Calcutta for her thesis Gordan Research Conference 2018, Newry entitled "An effort to reduce the immunosuppressive effects of mesenchymal Maine, USA, August 6-11, 2018. stem cells in cancer by neem leaf glycoprotein: 5. Bhuniya A, Gupta A, Saha A, Sarkar A, Focus on T cells" under the supervision of Bose A, Baral R. Tumor Educated Platelets Dr. Rathindranath Baral. Promote Metastasis by Inducing Vascular Mimicry in Mesenchymal Stem Cells. In Students undergoing PhD 14th Indo-Australian Biotechnology 1. Ms. Madhurima Sarkar has submitted her Conference, Navi Mumbai, 22-23rd thesis entitled "Targeting myeloid derived October, 2018. suppressor cells and T cells crosstalk with 6. Chakravarti M, Gupta A, Sarkar A, Nandi neem leaf glycoprotein to prevent P, Guha I, Saha A, Dasgupta S, Alum N, immunosuppression in cancer" under the Chakraborti J, Baral R, Bose A, Tumor supervision of Dr. Rathindranath Baral to Residing PD1high CD8+ T Cells Promote the University of Calcutta for degree of Expansion of Cancer Initiating Stem Like PhD (Science). Cells, 38th Annual Convention of Indian 2. Mr. Avishek Bhuniya - PhD work Association for Cancer Research, March 1- completed, thesis under preparation. 3, 2019, PGIMER, Chandigarh. 3. Proposed thesis work of Ms. Ipsita Guha, 7. Saha A, Nandi P, Dasgupta S, Chakravarti Mr. Anirban Sarkar and Ms. Sukanya Dhar M, Gupta A, Sarkar A, Dhar S, Bera S, have been registered with Jadavpur Banerjee S, Baral R, Bose A, Intra-tumoral University. VEGF promotes switching of Th17 cells 4. Proposed thesis work of Ms. Shayani towards Treg cells, 38th Annual Dasgupta, Ms. Akata Saha, Mr. Partha Convention of Indian Association for Nandi, Mr. Nilanjan Ganguly, Ms. Juhina Cancer Research, March 1-3, 2019, Das and Ms. Mohona Chakrovarti have PGIMER, Chandigarh. been registered with the University of 8. Dhar S, Chakravarti M, Ghosh S, Sarkar M, Calcutta. Dasgupta S, Ghosh D, Bose A, Baral R, 5. Mr. Aritra Gupta - thesis work has been Mukherjee KK, Tumor-Associated initiated to get registered with the 16 Myeloid Derived Suppressor Cells University of Calcutta

CNCI Annual Report 2018‐19 Research Wing

6. Mr. Saurav Bera - thesis work has been altered pericytes by targeting RGS5 initiated to get registered with Jadavpur induced pro-apoptotic signaling ” on the University. occasion of International Conference on Microscope & XXXIX Annual Meeting of Other awards or special achievements Electron Microscope Society of India at 1. Mr. Anirban Sarkar got the 1st prize for Bhubaneswar, July 18-20, 2018. best oral presentation on the work 6. Ms. Sukanya Dhar was awarded the entitled, “NLGP Immunotherapy Third prize for poster presentation Normalizes Diabetes-associated Hepatic (Rosche Scholar in Training) on the work Inflammation and Promotes Type-I entitled, “Tumor-Associated Myeloid Diabetes Mediated Immune Dependent Derived Suppressor Cells Promote Tumor Restriction by Modulating T Cell Generation of Drug-Resistance in Non- Metabolism” on the occasion of Hodgkin’s Lymphoma Patients.” In 38th International Conference on Immunology Annual Convention of Indian Association at Tamil Nadu, 26-28th Sept, 2018. for Cancer Research, March 1-3, 2019, 2. Ms Shayani Dasgupta got the 1st prize PGIMER, Chandigarh. for best oral presentation in SRF category 7. Ms. Shayani Dasgupta had obtained CSIR on the work entitled, “Dual presence of Travel Grant and Conference fee waiver pro-apoptotic RGS5-TGFb supports from organizers for attending conference proliferation of tumor-pericytes in tumor in “Cell Death” Gordan Research microenvironment.” In 2nd Annual Conference 2018, Newry Maine, USA, Conference on Recent Trends in Cancer August 6-11, 2018. Research, Early Diagnosis, Prevention and Therapy organized by CNCI, 4-5th Feb, Conference/Symposium/Workshop 2019. organized 3. Mr. Anirban Sarkar got the 1st prize for 1. World Immunology Day was organized at best oral presentation in JRF category on CNCI on 1st May 2018 to increase the work entitled, “NLGP immunotherapy awareness on Immunology among promotes type-I diabetes mediated students. Eminent immunologists immune dependent tumor restriction by delivered lectures in this occasion. modulating T-cell metabolism and

normalizes diabetes associated hepatic 2. Annual meeting of Indian Association for inflammation.” In 2nd Annual Conference Cancer Research and a mini symposium on Recent Trends in Cancer Research, was organized at CNCI on 14th September Early Diagnosis, Prevention and Therapy 2018 where distinguished cancer organized by CNCI, 4-5th Feb, 2019. researchers are attended from different Institutions of West Bengal. 4. Mr. Anirban Sarkar got Sitaram Joglekar award for best oral presentation on the Training Program work entitled, “NLGP immunotherapy Twelve students (B.Sc, M.Sc, B.Tech, promotes Type-I diabetes mediated M.Pharm) from different universities and immune dependent tumor restriction by institutions were trained in the department modulating T cell metabolism and for 1 to 6 months’ duration. normalizes diabetes associated hepatic inflammation.” In 38th Annual Miscellaneous Convention of Indian Association for • Dr. Rathindranath Baral was invited to act Cancer Research, March 1-3, 2019, as a member of the Post Graduate studies PGIMER, Chandigarh. in Serampore College, Serampore. 5. Ms. Shayani Dasgupta was awarded the • Dr. Rathindranath Baral was invited to act 1st prize for poster presentation on the as an examiner of PhD thesis of Calcutta work entitled, “TGFbeta within tumor University, Jadavpur University, microenvironment promotes survival of Vidyasagar University, WB Health 17

CNCI Annual Report 2018‐19 Research Wing

University, Pune University, Lucknow • Dr. Rathindranath Baral acted as a University and Pondicherry University. reviewer of extramural projects submitted in CSIR, ICMR, DBT-Wellcome Trust • Dr. Rathindranath Baral was invited to act as an examiner of PG Studies, • Dr. Anamika Bose acted as an honorary Instrumentation Department, Jadavpur reviewer of international journals, like, University. Blood, Melanoma Research, J. Ethonopharmacology. • Dr. Rathindranath Baral acted as an honorary reviewer of several international • Dr. Tapasi Das acted as an honorary journals, like, Int. J. Cancer, PLoS One, reviewer of Journal of Cellular Vaccine, Int Immunopharmacol, Tumor Biochemistry. Biology etc.

18

CNCI Annual Report 2018‐19 Research Wing

In Vitro Carcinogenesis and Cellular Chemotherapy

Head Dr. Chinmay Kumar Panda Senior Asst. Director Grade and Officer­in­Charge (Research)

importance. Our laboratory is working on overcoming and understanding different Team aspects of cancer drug resistance. In search of a suitable MDR reversal agent, we previously Faculty had synthesized and characterized novel, Dr. Subhasis Barik, Senior Scientific Officer Gr.II non-toxic metal chelates that showed very Dr. Arpita Chandra, Senior Scientific Officer Gr.II high resistance modifying (RMA) properties Faculty Emeritus both in vivo and in vitro. Dr. Soumitra Kumar Choudhuri, Emeritus Medical The major impediment to successful Scientist (ICMR) chemotherapeutic treatment of cancer is the Other members occurrence of multidrug resistance (MDR) Dr. Kaushik Banerjee (Honorary Research Fellow) and hence further exploration of underlying mechanisms of MDR is of utmost importance. Our laboratory is working on overcoming and Objectives understanding different aspects of cancer drug resistance. In search of a suitable MDR The department has multidisciplinary reversal agent, we previously had synthesized approaches to target cancer. The specific areas and characterized novel, non-toxic metal include: chelates that showed very high resistance • Targeting Multi Drug Resistance, modifying (RMA) properties both in vivo and in vitro. • Targeting different aspects of immune system to combat cancer and Synthesized compounds possess ROS generating ability and also have pro-apoptotic • Targeting cancer by application of activity in different MDR cell lines. Works on different customized less toxic inorganic or these compounds and a number of other organic molecules or nano‐particles in the aspects, e.g, i. targeting the glycolytic field of chemotherapy. pathway through such chemicals; ii. Targeting the tumor microenvironment, and iii. Evaluating the efficacy of some such Work done compounds for overcome MDR are going on. Project B Project A To investigate the heterotypic interactions The major impediment to successful occurring in the various immune cell types chemotherapeutic treatment of cancer is due and to understand cellular and molecular to the occurrence of multidrug resistance signaling pathways that orchestrate the (MDR) and hence further exploration of differentiation and development process in underlying mechanisms of MDR is of utmost immune cells in cancer and other 19

CNCI Annual Report 2018‐19 Research Wing

inflammatory autoimmune diseases. indicating an important connection between CP with innate or adaptive immune response • Identification of intra-thymic mechanisms in the context of inflammatory conditions associated with T-cell commitment from T- induced by certain types of cancer. stem/progenitor cells and robust T-cell proliferation in T-cell leukemia/ To identify whether serum CP level increases lymphoma. with the tumor load, we injected mouse EAC (breast cancer cells) into Swiss albino mice at • Understanding the molecular mechanisms subcutaneously as well as in intra-peritoneal of tumor-antigen specific T-cell geeneration cavity to induce solid and ascites tumor. in thymmus and its manipulation to combat Peripheral blood was harvested from each defective immunity in cancer. mouse and isolated serum was used to • Understanding the molecular mechanisms measure Ceruloplasmin level. The data that help antigen presenting cells in self indicates that there was an increase in serum and foreign antigen discrimination and its ceruloplasmin level in both ascites as well as impact on T-cell activation to control increasing solid tumor (Figure 2). However, immunity in cancer and autoimmunity. the serum CP level was found more significantly highher in ascites than growinng Proper maintenance of human phhysiology solid tumor (Figure 2). depends on perfect synchronization of macro

molecules (like metal ion containing proteins) governing the overall metabolic activity in A B

every living cell. In fact the suboptimal levels 100 100 of metal ions in human body are directly 90 90 78.396 related to different diseases that ultimately 80 80 70 70

leading to serious health issues even death. 60 55.6474 60

50 45.45 50 Ceruloplasmin (mg/Lit) Ceruloplasmin (mg/Lit) 40 40 10123 13 16 101 2313 16 Days after tumor inoculation Days after tumor inoculation Fig. 2. Murine EAC (breast cancer cells) were injected (106cells/mouse) into Swiss albino mice in intra- peritoneal cavity as well as subcutaneously to induce ascites (A) and solid (B) tumor. Peripheral blood was harvested from each mice and isolated serum was used to measure Ceruloplasmin level.

However, the tumor growth and their Beside the active function of metal ion corresponding serum CP level was not transporters, different serum acute phase followed up to advanced stagee and this studdy proteins govern the perfect balance of needs to include more number of animals to multiple ion transport in cells of different reach into a conclusion that murine models body parts. This becomes more important shows parallel similarity with human when these acute phase proteins are up- patients. In future, we will used cell lines regulated selectively in multiple cancer other than breast cancer (i.e., ovarian and conditions. In this present study, therefore, colorectal) and at the same time the study will we have focused on ceruloplasmin (CP), a include cancers non-related to above macromolecule serving as the molecular link mentioned cancer type like sarcoma. between iron (Fe) and copper (Cu) As our preliminarry data indicates that CP is metabolism has been identified as the serum over expressed in serum of breast, ovary and multicopper protein) is found to over express colorectal carcinoma patients. At the same in different cancers like breast, ovarian and time tumor associated macrophages (TAM) colorectal cancers. However the physsiological isolated from EAC breast cancer ascites reason for its up-rege ulation is almost showed inducing CP expression that indicates unknown. Studies have revealed that liver the feasibility of the proposed study (our 20 and macrophages are the primary source

CNCI Annual Report 2018‐19 Research Wing

previous data). As TAM is a well known isolation and characterisation of different cellular entity to deceive peripheral anti- Schiff-base metal complexes. Only one tumor T cell function therefore it is hiighly complex (Co-SB) is fully characterised. X-ray possible that CP will play an important factor single crysstal study revealed that it is a mono to suppress anti-tumor immune response in a nuclear complex cobalt complex. Complex is contact independent fashion. The present formed by condensation of cyclohexane-1,2- study may disclose a number of insights of CP diamine and 2, 6-diformyl-4-methylphenol function related to cancer. The mechanistic followed by addition of cobalt nitrate hexa role of CP induced tumor progression or hydrate. The distorted octahedral geeometry of immune-dereguulation may open new avenues this complex was revealed bby X-Ray to cancer research as well as important drug crystallogrraphy. The two phenolic O atoms targets. Moreover a correlation among patient and two imine N atoms are chelated to cobalt serum CP levels at different stages of cancer ion in basal plane. The O atom of two water having different treatment modalities along molecule is present at axial position. The IR with patient prognosis, intermediately spectrum of Co-SB contains a broad band response and their post treatment survival consists of two small break at 1634 cm-1 and maay create a database and based on that one 1642 cm-1 due to presence of C=N and free can suggest a proper treatment modality C=O. The sharp bands at ~1550 cm-1and usinng serum CP level as cancer biomarker. ~1385 cm-1 are present due to skeletal vibration and nitrate ion. The UV-Vis spectral Project C study in MeOH medium shows a strong band The overarching goal of our department is to at ~410 nm due to liigand to metal charge address the shortcoming of chemotherappy in transfer. This compound was tested for its the treatment of cancer by application of anti proliferative property in EAC bearing different customized less toxic inorganic or Swiss albino mice and IC50 found to be organic molecules or nano‐particles in the 30µg/kg of body weighht. field of chemotherapy like • Targeting different cell death networks • Overcoming Multidrug resistance in cancer • Analyzing anti‐metastatic and anti‐angiogenic property • Exploring potential of resistance modifying agent or anti metastatic aagent against stem cell population Effect of Co-SB on cell cycle of EAC bearing mice • Targeting the cellular glycolytic pathway Control Co-SB Treated through such chemicals

Cell cycle analysis of the compound treated EAC cells revealed that significant increase in subG0 or apoptotic population which is concordant with the results of TUNEL. Liver Function test (SGPT, SGOT, ALP), Kidney parameters (Urea, Creatinine) and Complete Blood Count of the compound treated mice Last seven months was devoted to synthesis, 21

CNCI Annual Report 2018‐19 Research Wing

indicated that it imparts negligible toxicity to Chandigarh from March 1st-3rd 2019, the host system and may also have protective entitled “Unravelling the therapeutic role against hepatomegaly and splenomegaly. potential of novel cobalt complex”. Projects running (Extramural) 2. Dr. Subhasis Barik presented his work at – Immunocon 2018 “Immunotherapy and 1. Targeting glycolytic pathway through Advances in Immunology” at redox-active metal chelates to overcome Translational Health Science and multi-drug resistance (MDR) in cancer Technology Institute (THSTI), Faridabad, P.I.: Dr. Soumitra Kumar Choudhuri India. (1st to 3rd November, 2018). Funding agency: ICMR [74/10/2014-Pers. 3. Dr. Subhasis Barik presented his work at – (EMS)] International symposium on “Frontiers in 2. Environmental regulation on T cell development and molecular medicine: development and autoimmunity models to insights” at Biswa Bangla P.I.: Dr. Subhasis Barik Convention Center, Kolkata, West Bengal, Funding agency: DBT-Ramalingaswami Kolkata (March 1-3, 2019). Re-Entry Fellowship 2017-2018 (D.O. No. PhD awarded BT/HRD/35/02/2006 dated 19th November 2018) 1. Mr. Kaushik Banerjee was awarded PhD (Science) degree in the year 2019 from Publications Jadavpur University, Kolkata, for his thesis entitled "Evaluation of Efficacy of 1. Miller MM, Barik S, Cattin-Roy AN, Ukah Some Transition Metal Chelates as Anti- TK, Hoeman CM and Zaghouani H. A Cancer Drugs" under the supervision of new IRF-1-driven apoptotic pathway Dr. Soumitra Kumar Choudhuri. triggered by IL-4/IL-13 kills neonatal Th1 cells and weakens protection against viral Conference/Symposium/Workshop infection. Journal of Immunology. 2019 (In attended press). 1. Dr. Arpita Chandra attended “Annual 2. Barik S, Cattin-Roy AN, Miller MM, Ukah Meeting & Mini Symposium” IACR-West TK, Zaghouani H.IL-4 and IL-13 Guide Bengal Chapter and CNCI, Kolkata held at Early Thymic Progenitors to Mature CNCI, Kolkata 14th September, 2018. toward Dendritic Cells. Journal of 2. Dr. Arpita Chandra attended symposium Immunology. 2018, 201(10):2947-2958. on “2nd Annual Conference on Recent Other academic activities Trends in Cancer Research, Early Diagnosis, Prevention and Therapy” on Paper presented World Cancer Day, 2019, held at CNCI, Kolkata. Invited talk 3. Dr. Subhasis Barik attended “Annual 1. Dr. Arpita Chandra presented an invited Meeting & Mini Symposium” IACR-West Lecture in the National Seminar on Future Bengal Chapter and CNCI, Kolkata held at of India – Science & Technology, on 27th CNCI, Kolkata 14th September, 2018. February, 2019, in City College Campus on Cancer & Drug Resistance and she has also 4. Dr. Subhasis Barik attended “East Zonal chaired a Scientific Session Oncology Symposium - 2019” (under the “Medical/Veterinary & Pharmaceutical banner of IASO) at Saroj Gupta Cancer Sciences” on 27th February, 2019. Center & Research Institute, Thakurpukur, Kolkata (19th January, 2019). Other oral presentation 5. Dr. Subhasis Barik attended symposium 1. Dr. Arpita Chandra presented her work at on “2nd Annual Conference on Recent 38th Annual Convention of Indian Trends in Cancer Research, Early 22 Association for Cancer Research held in Diagnosis, Prevention and Therapy” on

CNCI Annual Report 2018‐19 Research Wing

World Cancer Day, 2019, held at CNCI, chemistry, Kolkata. • Indian journal of Medical Research (IJMR) Miscellaneous • Biometals Dr. Soumitra Kumar Chowdhuri reviewed the • European Journal of Pharmaceutical following International journals: Sciences. • Journal of Applied organometallic

23

CNCI Annual Report 2018‐19 Research Wing

Neuroendocrinology & Experimental Hematology

In‐Charge Dr. Chinmay Kumar Panda Senior Assistant Director Grade

using nanoparticle formulation and evaluated compared to original compound Team and it was found that nanoformulations have higher efficacy. Faculty Dr. Biswarup Basu, Senior Scientific Officer Gr.II • Preliminary study has been initiated on non healing ulcerating cancer wounds that Junior Research Fellow develop in some patients at later part of Mr. Sandip Ghosh Ms. Souvik Das cancer progression. Wound healing activity of insulin is being explored along with modulation of neurotransmitter Dopamine pathway to develop a faster Objectives healing modality. The objective of this department is to understand role of neuro-endocrine-immune Projects running (Internal) axis in cancer progression and to decipher 1. Study on dynamic regulation of insulin molecular pathways responsible for cancer or and Dopamine in dermal wound healing associated physiological deregulations. This and bone tissue regeneration in normal department also aims to evaluate potential of and diabetic condition natural compounds and synthetic drugs for P.I.: Dr. Biswarup Basu targeted therapy in breast and ovarian cancer. Publications 1. Kaur P, Sharma AK, Nag D, Das A, Datta Work done S, Ganguli A, Goel V, Rajput S, • Preliminary study was undertaken to Chakrabarti G, Basu B, Choudhury D. evaluate presence of different Novel nano-insulin formulation modulates neurotransmitter and hormone receptors cytokine secretion and remodeling to in breast and ovarian cancers and their accelerate diabetic wound healing. role in cancer progression is being Nanomedicine 15(1):47-57, 2019. undertaken thereafter. 2. Muthuraman, S, Sinha S, Vasavi • Therapeutic potential of different synthetic CS, Waidha KM, Basu B, Munussami drugs and natural compounds were P, Balamurali MM, Doble M, Saravana evaluated for their anticancer efficacy in Kumar R. Design, synthesis and breast and ovarian cancers. Particularly, identification of novel coumaperine Ellagic acid and Chrysin, two natural derivatives for inhibition of human 5-LOX: compounds were evaluated for their Antioxidant, pseudoperoxidase and anticancer activity. Further their stability docking studies. Bioorg Med and bioavailability were increased by Chem. 15;27(4):604-619, 2019. 24

CNCI Annual Report 2018‐19 Research Wing

3. Das A, Narayanam MK, Paul S, Mukherjee (ISNSCON-2018)”, 7-11 Jan 2019, New P, Ghosh S, Dastidar DG, Chakrabarty Delhi. S, Ganguli A, Basu B, Pal M, Chatterji U, Banerjee SK, Karmakar P, Kumar Other academic activities D, Chakrabarti G. A novel triazole, NMK- T-057, induces autophagic cell death in Conference/Symposium/Workshop breast cancer cells by inhibiting γ- attended secretase-mediated activation of Notch • Dr. Biswarup Basu attended the “East signaling. J Biol Chem. 26;294(17):6733- Zonal Oncology Symposium-2019” held 6750, 2019. form 19th January at Saroj Gupta Cancer Special achievement Center & Research Institute, Thakurpukur, Kolkata. • Dr. Biswarup Basu co-authored a conference proceeding on “Formulation • Dr. Biswarup Basu attended symposium nd development and Characterization of on “2 Annual Conference on Recent Chitosan Nanoparticles of an Antioxidant Trends in Cancer Research, Early Phytoconstituent for the management of Diagnosis, Prevention and Therapy” on cancer” with Harsheen Kaur, Misba World Cancer Day, 2019, held at CNCI, Majood, Kalpana Nagpal in “6th World Kolkata. Congress on Nanomedical Sciences

25

CNCI Annual Report 2018‐19 Research Wing

Oncogene Regulation

Head Dr. Chinmay Kumar Panda Senior Asst. Director Grade and Officer­in­Charge (Research)

Team Work done

Faculty Dr. Sankhadeep Dutta, Senior Scientific Officer II Projects running Dr. Santosh Kumar Guru, Senior Scientific Officer II Project 1 Woman Scientist Dr. Anindita Ghosh, Woman Scientist-A, DST Molecular analysis of some human Senior Research Fellow epithelial malignancies Md. Saimul Islam, CNCI 1. Analysis of Stem Cell Renewal Notch1 Mr. Anirban Roy Choudhary, CSIR Pathway Alterations During Ms. Rituparna Roy, CNCI Development of Head and Neck Ms. Mukta Basu, UGC-NET Squamous Cell Carcinoma (HNSCC) of Mr. Balarko Chakrobarty, UGC-NET Indian Patients Ms. Debalina Mukhopadhyay, Woman Scientist, DST HNSCC constitutes 4% of all malignancies Junior Research Fellow globally and is the sixth most common Ms. Priyanka Dutta, DST-INSPIRE cancer worldwide. Only 45-50% of HNSCC patients survive for 5 years. For this reason, early detection of HNSCC and Objectives in depth knowledge on its molecular The research focus of our group have been carcinogens is essential. Our lab presently understanding the molecular mechanism of focuses on identification of the candidate some epithelial malignancies most prevalent genes in Notch1 stem cell renewal in this part of Indian subcontinent, viz. Head pathway associated with HNSCC and Neck Squamous Cell Carcinoma development. To this attempt, mRNA (HNSCC), Uterine cervical carcinoma expression of a few key Notch1 pathway (CACX), Breast Carcinoma (CA-BR) and associated genes were analyzed in primary Bladder carcinoma (BlCa). To aid in early HNSCC samples (N=17), at first. Up- detection and prognosis of the disease and for regulation in mRNA expression was in the selection of appropriate therapeutic following order: Notch1 (71%)> Hes1, intervention of the tumors identification of Hey1, Hif1α (52-53%)>Jag2 (47%)> associated altered cellular pathways are ADAM10 (35%)>Jag1 (24%)> PSEN1 essential. Additionally, some phytochemicals (12%). In the HNSCC samples, infrequent of indigenous medicinal plants are also copy number variations (CNVs) in Notch1 evaluated through in vitro and in vivo models, (6.42%), Hif1α (7.33%) Jag1 (11.1%) and for their plausible chemopreventive and Jag2 (15.59%) loci were observed. Next, the 26 chemotherapeutic efficacies. protein expression of the frequently

CNCI Annual Report 2018‐19 Research Wing

altered genes (viz. NICD, HIf1α, Hes1) expression. were evaluated in normal oral epithelium 3. Association of Y654-p-beta-catenin (N=12), Hyperplastic (N=10), Dysplastic activation with EGFR protein over (N=10) and Invasive HNSCC samples expression and SH3GL2 down regulation (N=20) by immunohistochemistry (IHC). in TNBC irrespective of therapy: clinical All the proteins showed moderate/high and prognostic importance expression in the basal/parabasal layers of Triple Negative Breast Cancer (TNBC) is normal oral epithelium. The pattern was originated from less differentiated ductal also similar in hyperplastic, dysplastic and cell of breast having less sensitive to invasive samples. Thus, these findings radiotherapy/chemotherapy including indicate the expression profile of the neo-adjuvant chemotherapy (NACT) and frequently altered genes in Notch1 associated with poor prognosis. Over pathway in the basal/parabasal layers of expression of Y654-p-beta-catenin and normal oral epithelium is maintained EGFR has been reported in TNBC, but during Head and Neck carcinogenesis. their mechanism of activation and 2. Deregulation of IGF2 during the correlation, if any, have not yet been development of Uterine Cervical evaluated in both pre-therapeutic and Carcinoma NACT TNBC. Thus, in this study Uterine cervical carcinoma (CACX) is one molecular profiles (expression/ genetic/ of the leading causes of deaths in Indian epigenetic) of Y654-p-beta-catenin, EGFR women. Chromosomal alterations and SH3GL2 (the regulator of EGFR including 11p15.5 locus were reported in homeostasis) were analyzed in pre- CACX. Consequently, we strived for the therapeutic and NACT TNBC samples as first time to understand the molecular well as breast cancer (BC) cell lines. High status of the candidate gene Insulin-like nuclear expression (50-54%) of Y654-p- growth factor 2, IGF2 (11p15.5) in Indian beta-catenin protein, over expression (66- CACX patients (N = 128). DNA copy 84%) of EGFR protein and reduced number (CN) analysis using CGH-SNP expression (55-63.6%) of SH3GL2 protein analysis showed no genetic alteration and were seen in pre-therapeutic and NACT it was further validated by comparison TNBC samples. Unlike protein expression, with publicly available CN datasets. But low frequency of mRNA expression promoter hypo-methylation during the (3/15), gene amplification (10–32.5%) and progression of CACX was observed and mutation (1%) of EGFR were seen in the also found to be concordant with publicly TNBC samples. Low frequency (18-23%) of available DNA methylation datasets. deletion, high frequency (47-49%) of Interestingly, we found diverse expression promoter methylation and 47-52% overall of IGF2 transcript in both normal cervical alterations were seen in the TNBC epithelium (NCE) and CACX tumors. samples. The over expression of Y654-p- Similar heterogeneous expression pattern beta-catenin and EGFR proteins showed was seen in publicly available expression significant association in pre-therapeutic datasets as well. Finally, protein TNBC samples. The reduced expression of expression analysis in NCE showed SH3GL2 protein showed significant concordance with transcript expression association with over expression of EGFR, but tumors showed frequent low Y1045-p-EGFR and Y654-p-beta-catenin expression. Log-rank test showed a proteins in pre-therapeutic samples and difference (p-value = 0.057) in overall this has been validated by in-vitro using 5- survival between cases with and without Aza-2′-deoxycytidine. The inactivation of alteration for IGF2 in Indian CACX SH3GL2 and over expression of EGFR/ patients. Collectively, our study proposes Y654-p-beta-catenin proteins showed poor that regulation of IGF2 expression in NCE outcome of pre-therapeutic patients. Thus appeared to be multifaceted and our data indicates that inactivation deregulation during the development of SH3GL2 might increase the stability of CACX resulted in the differential EGFR protein resulting activation of beta- 27

CNCI Annual Report 2018‐19 Research Wing

catenin protein through phosphorylation signifying its probable role as a driver at Y654 residue. epigenetic phenomenon of the disease. 4. Alterations in chromosome 3 in urinary However, promoter hypermethylation of bladder cancer (BlCa) of Indian patients FANCD2 was significantly higher in BlCa samples with high arsenic accumulation. Bladder cancer (BlCa) ranks 9th worldwide, Upon validation, the alterations (deletion/ genomic instability due to environmental methylation) of the genes showed insults being one of the primary reasons of concordance with the mRNA/protein its development. Recently, arsenic in expression pattern as analyzed by qRT- drinking water has been associated with PCR/Immunohistochemistry, respectively. BlCa and arsenic has been found to be accumulated more in the tumor tissues. Project 2 Alterations in chromosome 3 were reported in several cancers, including Evaluation of anti-tumor activities of some BlCa. However, some ambiguity remains indigenous medicinal plant derived phytochemicals in its molecular role in the development of the disease. Amplifications in 1. Anticancer effects of Holarrhena chromosomal regions like 3p22-26, 3p24- antidysenterica derived triterpene 25, 3q25.1 and 3q26.32 regions were compounds reported in low grade non-muscle invasive This study is aimed to decipher the bladder carcinoma; whereas, Loss of anticancer efficacy of some natural Heterozygosity (LOH) at 3p24-25, 3p21-23, triterpene compounds from Holarrhena 3p12-14 were reported in invasive form of antidysenterica. For this purpose, isolation the carcinoma. In this study, we aimed to of chemical constituents by column explore the role of chromosome 3 in chromatography technique from seed development of BlCa among Indian pods of Holarrhena antidysenterica (Family: patients. At first, CGH-SNP microarray Apocynaceae) has been done. Compounds analysis was performed in 10 BlCa were purified, characterized and samples (Early stage samples = 5; Late structures assigned by 1D and 2D NMR stage samples = 5). Infrequent deletion has experiments. Three compounds have been been seen in the array analysis, i.e. only 1 isolated - one novel compound, late stage sample showed deletion at Holarol; along with two known 3p14.1. However, in allelotyping of compounds, dihydrocanaric acid and chromosome 3p, using some region betulin. specific microsatellite markers, frequent The compounds showed differential deletions has been seen in the following cytotoxcity against 4 tumor cell lines e.g. order: gtFANCD2 (3p25.3) (53.4%)> HeLa, Raji, EAC and T24. The T24 cell line D3S1317 (3p25.3) (47.8%)> D3S1611 was most sensitive to the compounds. In (3p22.1) (42.8%)> D3S1358 (3p21.31) addition, Holarol showed high (40.6%)> hmLIMD1 (3p21.31) (39.5%). effectiveness against EAC cell line. Since, genomic alteration is not the only Dihydrocanaric acid and betulin could factor effecting the expression of a gene, generate high ROS in T24 cell line and epigenetic modification plays an equal compared to Holarol. Dihydrocanaric acid and effective role too, we analysed the could induce high frequency of apoptosis promoter methylation of some of the in T24 cell line followed by Betulin and candidate Tumor-suppressor genes (TSGs) Holarol. Thus, it indicates that the located in chromosomal regions. Frequent triterpenoid compounds- Holarol, promoter methylation in the candidate dihydrocanaric acid and betulin isolated genes were found in the following order: from Holarrhena antidysenterica have FANCD2 (57%)> LIMD1 (53.26%)> VHL antitumor activity. The detail analysis of (49.25%) > MLH1 (34.78%)> RBSP3 the antiproliferative activity of the (28.26%). Importantly, promoter triterpenoids is under process. hypermethylation of Limd1 was more 2. Anti-proliferative effect of Pongapin, frequent among the early stage samples, 28 Karanjin and Plumbagin through

CNCI Annual Report 2018‐19 Research Wing

modulation of stem cell renewal of head and neck squamous cell pathways carcinoma (HNSCC) Previously our group has evaluated the Name of the Student: Mr. Balarko anti-proliferative effect of two Chakrobarty furanoflavanoid compounds - Pongapin P.I.: Dr. Chinmay Kumar Panda and Karanjin, isolated from Pongamia Funding agency: UGC-NET pinnata and a naphtoquinone compound Plumbagin, isolated from Plumbago 3. Analysis of stem cell renewal Notch1 zeylanica, on different cancer cell lines. pathway alterations during development The analyses revealed the underlying of head and neck squamous cell molecular mechanism leading to apoptosis carcinoma of Indian patients induction by differential ROS modulation Name of the Student: Ms. Debalina and G2/M arrest in HeLa cell. Presently, Mukhopadhyay we evaluated the effect of these P.I.: Dr. Chinmay Kumar Panda compounds on stem cell renewal pathway Funding agency: DST- Women scientist in HeLa cell. The compounds could scheme (A) significantly reduce the prevalence of 4. Analysis of DNA modifying and DDR CD44 positive cancer stem cell population. (DNA damage response) genes associated This restriction of CD44 prevalence by the with the development of uterine cervical compounds might be due to down carcinoma (CACX) regulation of its transcription regulator β- catenin, the effector protein of Wnt stem Name of the Student: Ms. Priyanka Dutta cell renewal pathway. It has been seen that P.I.: Dr. Chinmay Kumar Panda the compounds could reduce the Funding agency: DST-INSPIRE expression of Frizzled receptor of this 5. Anti-cancer effects of Holarrhena pathway leading to the down regulation antidysenterica derived triterpene expression of β-catenin/ activated β- compounds catenin expressions. The compounds could Name of the Student: Dr. Anindita Ghosh also modulate the Hedgehog stem cell renewal pathway by reducing expression Funding agency: DST- Women scientist of Gli1 in HeLa cells. Thus, the anti- scheme (A) proliferative effect of the polyphenols might be due to modulation of the stem Publications cell renewal pathways. 1. Bhattacharya R, Panda C. K., Nandi S, Mukhopadhyay A. An insight into Extramural Projects metastasis: Random or evolving 1. Identification of novel candidate gene(s) paradigms? Pathol Res Pract. 214(8):1064- associated with the development of 1073, 2018. uterine cervical carcinoma 2. Pal D, Sur S, Roy R, Mandal S, Panda C. P.I.: Dr. Chinmay Kumar Panda K.: Epigallocatechin gallate in combination Funding agency: CSIR with eugenol or amarogentin shows synergistic chemotherapeutic potential in Students’ Projects running cervical cancer cell line. J Cell Physiol. doi: 1. Molecular analysis of alterations in 10.1002/jcp.26900, 2018. chromosome 3 in Bladder carcinoma of 3. Sultana Z, Bankura B, Pattanayak AK, Indian patients Sengupta D, Sengupta M, Saha ML, Panda Name of the Student: Ms. Mukta Basu C. K, Das M. Association of Interleukin-1 P.I.: Dr. Chinmay Kumar Panda beta and tumor necrosis factor-alpha Funding agency: UGC-NET genetic polymorphisms with gastric cancer in India. Environ Mol Mutagen. 59(7):653- 2. Analysis of alterations of Wnt and 667, 2018. hedgehog pathways during development 29

CNCI Annual Report 2018‐19 Research Wing

4. Dasgupta H., Islam Md. S., Alam N., Roy Science Congress Association, Kanpur A., Roychoudhury S., Panda C. K.: Chapter meeting on “Future India: Science Induction of HRR genes and inhibition of and Technology” held in Kanpur during DNMT1 are associated with Anthracycline November 23-25, 2018. antitumor antibiotic tolerant Breast 2. Dr. Chinmay Kumar Panda has delivered Carcinoma cells. Molecular and Cellular his presidential lecture on “Emergence of Biochemistry, (2018 Sep 3). doi: precision medicine through systems 10.1007/s11010-018-3442-5. biology in oncology: a step forward in 5. Dasgupta H., Islam Md. S., Neyaz N., Roy modern biology” in 106th meeting of A., Roychoudhury S., Panda C. K.: Indian Science Congress, during held in Hypomethylation of Mismatch Repair Jalandhar, Punjab during January 3-7, genes MLH1 and MSH2 is associated with 2019. chemotolerance of breast carcinoma: 3. Dr. Chinmay Kumar Panda has delivered Clinical significance. J. Surg. Oncol. (2019 a lecture on “Analysis of molecular Jan) ;119(1):88-100. doi: 10.1002/jso.25304. signature during Uterine Cervical 6. Roy R., Pal D., Sur S., Mondal S., Saha P., Carcinogenesis: Clinical and Prognostic Panda C. K.: Pongapin and Karanjin, implications” in 38th Annual convention furanoflavanoids of Pongamia pinnata, of Indian Association for Cancer Research, induce G2/M arrest and apoptosis in at Chandigarh, on March 1-3, 2019. cervical cancer cells by differential ROS 4. Dr. Chinmay Kumar Panda has delivered modulation, DNA damage and NF-κB a lecture on “Development of Precision signalling. Phytotherapy Research (2019 Cancer Medicine: Future Perspectives” in March); https://doi.org/10.1002/ptr.6302. the conference on Drug Discovery & Gene Bank Submission Translational Medicine (DDTM-2019) held in Annamalai University, Tamilnadu 1. GenBank entry: Microsatellite repeat during March 14-16, 2019. Intron 4 of UIMC1, namely UIMC1_(GT) 17- Other oral presentation 23 (Accession Number MK163357- MK163359). 1. Mr. Balarko Chakraborty delivered a lecture titled “Role of Wnt-Beta Catenin 2. Global expression profile of uterine Stem Cell Renewal Pathway in the cervical carcinoma in Indian patients. development of Head and neck squamous Contributor(s): Roychowdhury cell carcinoma” 2nd Annual Conference A., Samadder S., Chatterjee A., On “Recent trends in cancer Research, Roychoudhury S., Panda C.K. Submission Early Diagnosis, Prevention and Therapy” Date: Nov 19,2018; NCBI GEO with held on 5th February (World Cancer Day), accession number GSE122697. 2019 at CNCI, Kolkata. 3. Landscape of genomic alterations in Poster presentation Indian Urinary Bladder cancer patients. Basu M., Ghosh A., Panda C. K.: NCBI 1. Dr. Anindita Ghosh presented poster titled GEO with accession number GSE122514 “Biological Investigations of Holarrhena antidysenterica derived triterpene- 3, 4- Other academic activities seco-lup-20(29)-en-3-oic acid for evaluating its anticancer activity” at the Paper presented 106th Indian Science Congress on Future Invited talk India: Science & Technology" (New Biology Section) held at Jalandhar, India 1. Dr. Chinmay Kumar Panda has delivered from 3-7 January 2019. a lecture on “Molecular pathogenesis of Triple Negative Breast Carcinoma: 2. Dr. Anindita Ghosh presented poster titled “Experimental and theoretical studies of 30 Strategy for future therapeutics” in Indian

CNCI Annual Report 2018‐19 Research Wing

1,3-dipolar cycloadditions of C-(1- in urinary bladder carcinoma” at the 38th naphthyl)-N-Methyl nitrone” at the 106th Indian Association for Cancer Research Indian Science Congress on Future India: held in Chandigarh, India from March1-3, Science & Technology" (Chemical Sciences 2019. Section) held at Jalandhar, India from 3-7 9. Ms. Priyanka Dutta presented poster titled January 2019. “Analysis of the changes in profile of Mismatch Repair Genes from Normal 3. Mrs. Rituparna Roy presented poster titled Cervical Epithelium to Invasive Cervical “Reactive oxygen species production Carcinoma (CACX)” at 1st annual meeting triggers Plumbagin induced anti- of Kolkata Gynecological Oncology proliferation and induces apoptosis in conference held at Biswa Bangla human cervical cancer” at the 106th Indian Convention Centre, Kolkata from March 2- Science Congress on 'Future India: Science 4, 2019. and Technology' held in Jalandhar, Punjab from 3-7 January 2019. PhD awarded

4. Mr. Balarko Chakraborty presented poster 1. Dr. Srabani Mittal was awarded PhD titled “Analysis of Molecular Profile of degree in the year 2018 from West Bengal Wnt-Beta Catenin Stem Cell Renewal University of Health Sciences for her thesis Pathway during development of Head and titled "Cumulative risk of high grade cervical neck squamous cell carcinoma” at the 10th intraepithelial neoplasia among high-risk human papilloma virus positive women East Zonal Oncology Symposium held on detected by hybrid capture ii assay: a 19th January, 2019 at SGCCRI, Kolkata. population based prospective study" under the 5. Mr. Balarko Chakraborty presented poster supervision of Dr. C K Panda. titled “Comparative Analysis of Wnt 2. Md. Saimul Islam was awarded PhD Pathway Receptors/ Co-receptors and (Science) degree in the year 2018 from Their Antagonists In Normal Oral University of Calcutta for his thesis titled Epithelium and Head and Neck Squamous "Analysis of HPV profile and molecular Cell Carcinoma (HNSCC) at Different mechanism of beta-catenin activation in Triple Clinical Stages” at 38th Annual convention Negative Breast Cancer in Indian patients" of Indian Association for Cancer Research under the supervision of Dr. C K Panda. held in Chandigarh, India from March 1-3, 2019. 3. Mr. Sudip Samadder was awarded PhD (Science) degree in the year 2018 from 6. Ms. Debalina Mukhopadhyay presented University of Calcutta for his thesis titled poster titled “NOTCH1 signalling "Analysis of regulation of self renewal pathway associated gene expression pathways and EGFR expression in uterine pattern in primary tumors of head and cervical carcinoma of Indian patients" under neck squamous cell carcinoma in Indian the supervision of Dr. C K Panda. patients” at 10th East Zone Oncology Symposium held on 19th January 2019 at Training Program Saroj Gupta Cancer Centre and Research Institute, Kolkata. Fifteen students from different colleges and universities from various parts of India 7. Ms. Debalina Mukhopadhyay presented completed their short term projects in this poster titled “Role of NOTCH1- HIF1α department. pathway in development of head and neck squamous cell carcinoma” at 38th Annual Miscellaneous convention of Indian Association for • Dr. Chinmay Kumar Panda acted as Cancer Research held in Chandigarh, member of the editorial board in the India from March1-3, 2019. "International Journal of Human Genetics". 8. Ms. Mukta Basu presented poster titled • Dr. Chinmay Kumar Panda acted as “High resolution genomic analysis Academic Editor in the journal "Scientific revealed alterations in FA-BRCA pathway 31

CNCI Annual Report 2018‐19 Research Wing

Reports”. Report, Scientific Report, Plos One, Experimental and Therapeutic Medicine, • Dr. Chinmay Kumar Panda was President, Clinical Epigenetics, Oncology Reports, New Biology Section, 106th Indian Science Frontiers in Oncology, Oncotarget, Congress Association Meeting held in Fundamental & Clinical Pharmacology, Jalandhar, Punjab during January 3-7, Histology and Histopathology, IUBMB 2019. Life, CMPB_2019_243, World Journal of • Dr. Chinmay Kumar Panda reviewed 31 Clinical Cases. scientific papers of different peer-reviewed • Dr. Chinmay Kumar Panda reviewed journals like Journal of Cancer Science and extramural grants submitted to different Clinical Oncology (JCS), 3 Biotech Journal, funding agencies like DBT (WB), Kerala CDD, European Journal Of Cancer, Journal State Council for Science, Technology and of Cellular Physiology, Journal of Environment Hematology & Oncology, Journal of Cellular Immunotherapy, Endocrinology • Dr, Chinmay Kumar Panda acted as & Metabolism International Journal, Treasurer in the Indian Association for Oncology Letters, Cellular and Molecular Cancer Research for the period of 2016- Life Sciences, BIOPHA_2018_1130_R1, 2018. IJCR, BMC Cancer, NMJI, Molecular • Dr, Chinmay Kumar Panda acted as Medicine Reports, Plos One, TCR, Cancer External examiner of Ph.D thesis under Management and Research, Indian University of Kalyani, Periyar University Journal of Medical Research, Bioscience and Calcutta University.

32

CNCI Annual Report 2018‐19 Research Wing

Pathology and Cancer Screening

Head Dr. Partha Nath Chief Medical Officer Grade

Team Work done

Faculty Dr. Vilas D. Nasare, Senior Scientific Officer Gr.II Projects running (Extramural)

Women Scientist 1. Study on MAD and BUB1 genes of Dr. Sutapa Mahata, DHR Woman Scientist Spindle Assembly Checkpoint with Ms. Ranita Pal, DST Woman Scientist response to primary adjuvant chemotherapy in advanced ovarian Young Scientist cancer patients Ms. Sinjini Sarkar, DHR Young Scientist P.I.: Ms. Sinjini Sarkar Senior Research Fellow Ms. Dipanwita Ghosh Mentor: Dr. Vilas D. Nasare Mr. Pranab Kumar Sahoo Joint P.I.: Dr. Madhumita Roy Supporting Staff Funding agency: Department of Health Ms. Debpriya Banerjee, Field Worker Research Ms. Piu Das, Field Worker

Mr. Avishek Kundu, Field Worker 2. MicroRNAs as prognostic biomarkers of Mrs. Sangita Bhaduri, Female attendant chemoresistance and chemosensitivity in Mrs. Shyamali Dhara, GDA ovarian cancer patients undergoing combinational therapy P.I.: Ms. Ranita Pal

Mentor: Dr. Vilas D. Nasare Funding agency: DST Objectives 3. A pharmacogenetics study on cytochrome P450 enzyme and transporter gene The department of Pathology and Cancer implicated in response to paclitaxel, Screening is catering to comprehensive cancer cisplatin, and 5-fluorouracil in oral cancer screening and awareness programs for the patients last 35 years. The program covers both rural and urban areas of West Bengal and adjoining P.I.: Dr. Vilas D. Nasare states. In addition, this department is also Funding agency: ICMR engaged in basic cancer research program for 4. Investigation of PIM1/STAT3 association the last 25 years and has published many as a regulator of EMT in triple negative fundamental research papers in international breast cancer journals. P.I.: Dr. Sutapa Mahata Mentor: Dr. Vilas D. Nasare Funding agency: Department of Health Research 33

CNCI Annual Report 2018‐19 Research Wing

Projects running (Internal) February 2019 at Chittaranjan National Cancer Institute, Kolkata 1. Identification of the causal involvement of HPV through assessment of oncogenic 4. Ranita Pal, Sinjini Sarkar, Dipanwita and proliferative markers, apoptosis Ghosh, Pranab K. Sahoo, Sutapa Mahata, and content assay in cervical pre- Kalyan K. Mukherjee, Partha Nath, Vilas neoplastic lesions for risk categorization D. Nasare. MicroRNAs as prognostic P.I.: Dr. Vilas D. Nasare biomarkers of chemoresistance and chemosensitivity in ovarian cancer Publications patients undergoing combinational therapy. Ist Annual Meeting of Kolkata 1. Ghosh D, Mahata S, Sahoo P K, Sarkar S, Gynecological Oncology Trials and Roy A, Datta K, Mandal S, Nasare V D. translational Research group ( KolGrTrg) on 2019, Socio-Demographic characteristics 2nd-4th March 2019 and use of PAP smear screening among women of Eastern part of India. Indian J of Students undergoing PhD Gynec Oncol 17:58. Two students are undergoing their PhD curriculum in the department. Other academic activities Students undergoing DNB Paper presented • Dr Gourav Singh has submitted DNB Poster presentation degree thesis in pathology in the year 2019 1. Panchali Saha, Sinjini Sarkar, Dipanwita entitled "Clinicopathological Evaluation of Ghosh, Pranab Kumar Sahoo, Sutapa malignant spindle cell neoplasm Mahata, Vilas D. Nasare. Study of the observational study in a tertiary cancer expression levels of CEA, ki67 and p53 in hospital" under the co-supervision of Dr. lung cancer at National Conference on Vilas D Nasare. “Emerging Trends in Non-Communicable • Dr. Afreen, DNB First Year (2019-2022). Diseases: Road to Prevention and Cure Clinicopathological correlation of November 17, 2018 at Institute of epithelial ovarian carcinoma with Estrogen Management studies,campus, NH-24, and progesterone receptors in Tertiary Adhyatmik Nagar, Ghaziabad-201015 (U.P) Care Hospital 2. Dipanwita Ghosh, Sutapa Mahata, Pranab Conference/Symposium/Workshop Kumar Sahoo, Sinjini Sarkar, Dr. Asoke Roy, Partha Nath, Karabi Datta , attended Syamsundar Mandal , Vilas D. Nasare 1. Annual meeting and Mini symposium Socio-demographic characteristics and use theme, Cancer Research and Treatment of Pap smear for Cervical Cancer screening organized by Indian association for Cancer among women of Eastern part of India on Research, West Bengal Chapter September 2nd Annual Conference on Recent Treands in 14, 2018 at Chittaranjan National Cancer Cancer Research, Early Diagnosis, Prevention Institute, Kolkata and Therapy on 4th and 5th February 2019 at th Chittaranjan National Cancer Institute, 2. 37 IACR Convention ‘From Cancer Kolkata Biology to Precision Oncology: Challenges and considerations’ date 23-25 February 3. Pranab Kumar Sahoo, Sinjini Sarkar, 2018 Venue Bose Institute, Unified Dipanwita Ghosh, Sutapa Mahata, Asoke Academic campus, Salt Lake, Kolkata Roy, Partha Nath, Karabi Datta, Syamsundar Mandal, Vilas D. Nasare Training Program Premalignant and malignant lesions oral Twelve students from different colleges and cavity in eastern India: A hospital based universities from various parts of India nd study 2 Annual Conference on Recent completed their short term projects in this Treands in Cancer Research, Early Diagnosis, department. Prevention and Therapy on 4th and 5th 34

CNCI Annual Report 2018‐19 Research Wing

Receptor Biology & Tumor Metastasis

Head Dr. Dona Sinha Senior Scientific Officer Grade‐I

erythroid-245 (NF-E2) related factor Nrf2 in lung cancer by green and black tea polyphenols: Implication in cancer Team therapeutics Faculty P.I.: Dr. Dona Sinha Dr. Nabanita Chatterjee, Senior Scientific Officer II Funding agency: ICMR Post Doctoral Fellow 2. Exploration of the role of diallyl Ms. Bornita Das, SERB-PDF disulphide on EMT in A549 lung cancer Anupama Mallick Trust Fellow cells Ms. Priyanka Prasad P.I.: Dr. Dona Sinha Junior Research Fellow Funding agency: SERB, DST Ms. Suchisnigdha Datta, ICMR Ms. Payel Das, CSIR Projects running (Internal) Supporting Staff Mr. Srikanta Barua, Lab Helper 1. Impact of low level arsenic on airways of exposed population: study on cell survival and proliferative signaling Objectives P.I.: Dr. Dona Sinha • Health impact of chronic arsenic exposure Students’ Projects running on rural population of West Bengal and 1. Exploration of the role of diallyl assessment of risk of arsenic-induced disulphide on EMT in A549 lung cancer carcinogenesis in asymptomatic cells individuals Name of the Student: Dr. Bornita Das • Assessment of anti-metastatic properties of Mentor: Dr. Dona Sinha phytochemicals and synthetic compounds Funding agency: SERB, DST in in vitro and in vivo tumor models • Redox regulation of cancer cells by Publications phytochemicals 1. Prasad P, Vasas A, Hohmann J, Bishayee • Altered mechanism of cancer metabolism. A, Sinha D*. Cirsiliol suppressed epithelial to mesenchymal transition in B16F10 malignant melanoma cells through alteration of PI3K/AKT/NF-κB Work done signaling pathway. Int J Mol Sc. 2019; 20

(3):608. [IF: 3.687] Projects running (Extramural) 2. Das B, Sarkar N, Bishayee A, Sinha D*. 1. Redox regulation of nuclear factor Dietary phytochemicals in the regulation 35

CNCI Annual Report 2018‐19 Research Wing

of epithelial to mesenchymal transition “Cellular and molecular alterations and associated enzymes: A promising associated with differential arsenic anticancer therapeutic approach.Semin exposure” at Golden Jubilee International Cancer Biol.(accepted) doi: Conference on Trends in Zoology; Jan 3-4; 10.1016/j.semcancer.2018.11.007. [Epub University of Burdwan; 2019. ahead of print] 2018. [IF: 10.198] PhD Awarded 3. Das B and Sinha D*. Diallyl disulphide

suppresses the canonical Wnt signaling 1. Mr. Kaustav Dutta was awarded PhD pathway and reverses the fibronectin- (Science) degree in the year 2018 from induced epithelial mesenchymal University of Calcutta for his thesis titled transition of A549 lung cancer cells. Food "Arsenic and the risk of carcinogenesis: A study among the rural population of West Funct. 2019; 10(1):191-202.[IF: 3.289] Bengal" under the supervision of Dr. Dona 4. Sarkar N and Sinha D. EGCG partially Sinha. restored redox homeostasis in arsenite stressed keratinocytes. J Appl Toxicol. Students undergoing PhD 2018; 38: 1071-1080. [IF: 3.159] 2. PhD thesis submitted by Ms. Priyanka 5. Das S, Chatterjee N, Mishra A, Ahiwar S, Prasad to University of Calcutta in Nov, Anne S, Satoskar A, Ganju R. Macrophage 2018 (Ph.D Regd. No. 6547PhD migration inhibitory factor (MIF): A novel (Sc)/Proceed/13) therapeutic target against aggressive 3. PhD thesis submitted by Ms. Nivedita breast cancer. The FASEB Journal. Sarkar to Jadavpur University in Mar, 2019 2019;33(1):(1 Supple) [conference (PhD Regd. No. 224/15/Life Sc./24) proceedings]. [IF : 5.5] Other awards or special achievements 6. Bose D, Banerjee S, Chatterjee N, Das S, Saha M, Saha KD. Inhibition of TGF-β 1. Ms. Suchisnigdha Datta was awarded the induced lipid droplets switches M2 2nd prize for her oral presentation “Redox macrophages to M1 phenotype. Toxicol In regulation of Nrf2 in lung cancer cells by Vitro. 2019 Mar 28;58:207-214. doi: EGCG: Implication in cancer therapeutics” 10.1016/j.tiv.2019.03.037. [Epub ahead of at 2nd Annual conference on recent trends print] PMID: 30930231[I.F : 3.12] in cancer research, early diagnosis, prevention and therapy. Feb 4-5, 2019. 7. Chatterjee N, Das S,Mishra D, AhiwarS, GanjuR, Croce R. Cannabinoid receptor Conference/Symposium/Workshop agonist JWH-015 inhibits growth and attended metastasis of triple negative breast 1. Dr. Dona Sinha attended the Golden cancers through regulation of autophagy Jubilee International Conference on Trends mechanism. AACR; Cancer Res. 2019. in Zoology; Jan 3-4; University of 77(13 Supple) [conference proceedings].[IF: Burdwan; 2019. 9.130] 2. Ms. Suchisnigdha Datta attended the 2nd 8. Ahiwar S, Chatterjee N, Mishra D, Ganju Annual conference on recent trends in R, Croce R.Slit inhibits breast cancer cancer research, early diagnosis, growth and metastasis by activating anti- prevention and therapy. Feb 4-5, 2019. tumor immune response. AACR; Cancer Res. 2019. 77(13 Supple) [conference Interesting observations proceedings].[IF : 9.130] • In order to elucidate the effect of low level Other academic activities arsenic (As) on key signaling pathways affecting cell cycle, cell proliferation and Paper presented growth we enrolled a total of 16 adult women aged 20-70 yrswere enrolled from Invited talk low level As-exposed areas- Langalberia, 36 1. Dr. Dona Sinha presented a paper entitled south 24PGNS where groundwater As is

CNCI Annual Report 2018‐19 Research Wing

in between 11 to 50 μg/L. Another 27 age- 0.04 Vs Control,0.65±0.02; p=0.0178]. matched womenwere enrolled from Arsenic exposure led to increased protein control area-Kushberia, south PGNS with levels of pAKTser473 by 2.3 fold [As- groundwater As<10 μg/L (Fig.1). The low exposed, 0.9± 0.07 Vs Control,0.4±0.11; level As exposed area had significant high p=0.0007] . Therefore, it may be indicated As content water in groundwater that upregulation of Raf /ERK/Akt and compared to control area [As-exposed area downregulation of PTEN by low level As 1.57 ±2.39 Vs control area 15.71 ±3.81; may orchestrate together to enhance p<0.001]. The low As exposed women did cellular proliferation. not have any significant difference in forced vital capacity (FVC) in comparison to control women. However, the sputa of these exposed women exhibited increase in number of multinucleated cells by 3.8 fold [As-exposed,10.66 ±2.05 Vs Control, 2.8±1.93; p=0.0016] and increased number of alveolar macrophages by 22.27 fold [As- exposed,2.2 ± 1.83 Vs Control, 49.0± 22.37; p=0.0026] in comparison to control women. The increased number of multinucleated cells indicated towards chromosomal instability. The leucocytes Fig.1: Health camp at Kushberia of low As-exposed women had reduced • Arsenite (AsIII) is known for inducing expression of p53ser15 by 2.4 fold[As- severe oxidative stress and skin exposed,0.34±0.05 Vs Control, 0.81±0.06; carcinogenesis. Contrastingly, p=0.0135] in comparison control women. phytochemical, epigallocatechin -3-gallate This was further validated by (EGCG) combats toxic insults. Our study immunocytochemistry of sputa where it focused on the effect of EGCG on redox was observed that average no. of lung status of AsIII-stressed normal human epithelial cells as well as inflammatory keratinocytes, HaCaT cells. EGCG (50µM) cells with high expression of p53ser15 increased the cell viability by 29% in AsIII decreased by 7.6 fold and that of low (50µM) insulted HaCaT cells but exhibited expression increased by 3.56 fold in low pro oxidant activity by elevated expression As-exposed women. p21, a downstream of the oxidative stress markers. EGCG target of p53, was reduced by 1.6 fold in was effective not only in reducing AsIII- exposed population[As-exposed, 0.6± 0.02 induced nuclear expression of Nrf2 and Vs Control,0.96 ±0.04; p=0.0008]. However, Nrf2Ser40 but also in increasing nuclear the expression of pRbser807/811 was expression of Keap1 both at protein and augmented by 2.49 fold in the leucocytes mRNA level (Fig.2).EGCG did not have of low As exposed group than control [As- similar effects on all Nrf2 downstream exposed, 0.87± 0.13 Vs Control,0.35 ±0.35; targets. EGCG elevated expression of HO- p=0.0095]. Therefore, deregulation of cell 1 and γ-GCL, showed no change in MRP1 cycle pivotal proteins like p53, p21and pRb but decreased SOD, NQO1 and GST by chronic low As exposure further activity in AsIII treated HaCaT cells. indicated towards aberrant cell cycle EGCG along with AsIII caused decreased progression.Key signaling molecules of phosphorylation of Nrf2 at ser40 residue cell proliferative pathway like Raf [As- which might have facilitated Keap1 exposed, 0.63± 0.02 Vs Control,0.52±0.01; mediated nuclear export and degradation p=0.0061] was upregulated by 1.21fold and of Nrf2 and paved the pro survival signal pERKThr202 expression by 1.28 fold [As- for As III-insulted HaCaT cells. In exposed, 1.19± 0.04 Vs Control,0.93±0.05; conclusion, it might be indicated that p=0.0073] but PTEN decreased by 1.3 fold EGCG in spite of inducing pro oxidant in comparison to control [As-exposed, 0.5± effect was effective in increasing the 37

CNCI Annual Report 2018‐19 Research Wing

viability of AsIII treated HaCaT cells by mediated signaling axis. partially restoring the Nrf2/Keap1

Fig.2: Regulation of Keap1 by EGCG in As-III stressed cells

• Globally non small cell lung cancer is a attributed to the reduced activity of leading cause of cancer mortality and geelatinases. DADS suppressed FN- about 40% of these cancers are detected in agggravated EMT of A549 cells by up metastatic stage. Epithelial mesenchymal reegulation of epithelial markers -E- transition (EMT), plays a critical role cadherin and cytokeratin-18; down during malignant transformation and reegulation of mesenchymal markers- N- extra cellular matrix component, cadherin, vimentin and transcription fibronectin (FN) is a known inducer of factors- snail, slug and twist. DADS was invasion and metastasis. Diallyl disulphide effective in inhibiting the nuclear (DADS), a bioactive component of garlic translocation of β-catenin, exhibits wide spectrum of biological phosphorylation of glycoogen synthase activities including inhibition of cancer cell kinase -3β and in suppressing activity of migration and invasion. The present study disheveled homolog 2 and T-cell-factor was aimed to decipher the effect of DADS /llymphoid enhancer factor in FN–induced on regulation of FN–induced EMT in A549 A549 cells. Cumulatively, this studdy lung cancer cells. DADS suppressed the indicated that DADS might be able to FN-induced invasion and migration reverse FN-induced EMT in A549 cells via 38 potential of A549 cells which may be suppression of Wnt signalinng (Fig.3).

CNCI Annual Report 2018‐19 Research Wing

Fig.3: DADS suppressed EMT in A549 cells by inhibiting Wnt pathway

39

CNCI Annual Report 2018‐19 Research Wing

Fig.4: Regulation of Cadherin switch by cirsiliol in B16F10 melanoma cells

down streams but in NCI-H23[low basal • Malignant melanoma is a highly Nrf2] EGCG (50µM/48H) upregulated aggressive form of skin cancer which has a Nrf2 and its targets. This effect of EGCG propensity for metastasis. Epithelial was achieved at low doses which further mesenchymal transition (EMT) plays a eliminated the issue of poor bioavailability primordial role in the progression of and high dose side effects. Regarding metastatic disease. Metastatic melanoma is regulation of Nrf2 by tea, it was observed resistant to conventional therapies. Hence, that p53, a negative regulator of Nrf2 was researchers have been exploring increased and p21, a Keap-1 competitive alternative approaches, including the inhibitor was downregulated in A549 but utility of bioactive phytochemicals to again in NCI-H23 a strikingly opposite manage metastatic disease. In the present phenomenon was observed reflecting the study, we investigated the potential of mutational status. Nrf2 plays a dominant cirsiliol, a flavonoid isolated from role in imparting chemoresistance in Centaurea jacea L., in modulating the cancer cells. Though the direction of Nrf-2 aggressive behaviour of B16F10 metastatic regulation was just opposite in two cell melanoma cells, including EMT, and lines but the aim was same, maintaining associated molecular mechanisms of the threshold level of Nrf-2 and increase action. Cirsiliol was found to be effective the responsiveness towards in restraining the colony formation and chemotherapeutic drugs - doxorubicin, migration of fibronectin-induced B16F10 etoposide and cisplatin. EGCG was metastatic melanoma cells. Cirsiliol observed to sensitize/potentiate lung inhibited the activity and expression of cancer cells towards chemotherapy at a matrix metalloproteinase-9 (MMP-9). much lower dose than the individual Cirsiliol also suppressed the drugs. Thus, EGCG might have a novel phosphatidylinositol-3-kinase (PI3K) / implication in chemotherapeutic protein kinase B (also known as management of lung cancer cells Akt)/nuclear factor-κB (NF-κB) signaling depending on the genetic make-up. pathway which, in turn, caused upregulation of E-cadherin and Training Program downregulation of N-cadherin (Fig.4), Integrative Course Work Taught to Ph. D Snail and Twist. Based on these results, students: cirsiliol may be considered a promising compound against EMT in the therapeutic • Cell cycle management of malignant melanoma. • Epithelial Mesenchymal Transition • The transcription factor Nrf2, controls • Cancer Stem Cells cellular adaptation during electrophilic and xenobiotic stress sensed by its physical Nine students from different universities and inhibitor Keap-1. A number of lung institutions were trained in the department tumors harbor somatic mutations in for short term duration. Keap1, enabling constitutive activation of Nrf2. Tea is extensively studied for its Patient care service anticancer effects. In this study, we tried to Pulmonary function test performed for CNCI modulate the Nrf-2 signaling by hospital patients epigallocatechin-3-gallate (EGCG) in two human adenocarcinoma cell lines Miscellaneous A549(G333C loss of function in Keap-1) • Dr. Dona Sinha was the external examiner and NCI-H23(Q193H gain of mutation in for M.Phil and Ph.D Course work of Keap-1) in order to manage University of Burdwan on three occasions chemoresistance. In A549[constitutively dated 13.04.2018, 30.11.2018 and 15.02. activated Nrf2] EGCG(0.5µM/12H) 2018. 40 effectively downregulated Nrf-2 and all its

CNCI Annual Report 2018‐19 Research Wing

Dr. Dona Sinha acted as a reviewer of • Toxicology, Elsevier Publications research projects submitted to Science and • Toxicological Sciences, Oxford Engineering Board, New Delhi. University Press Dr. Dona Sinha acted as a reviewer of the following peer reviewed journals/book Membership chapters: Dr. Dona Sinha was the Life Member of All • Metallomics, Royal Society of India Congress of Cytology and Genetics; Chemistry Indian Association of Cancer Research; Zoological Society of India; and

• Pytomedicine, Elsevier Publications Environmental Mutagen Society of India.

41

CNCI Annual Report 2018‐19 Research Wing

Signal Transduction and Biogenic Amines

Head Dr. Nabendu Mrmu Senior Scientific Officer Grade­I

factor for proliferative oral leukoplakia. vi) To investigate the complex role of protein- Team protein and protein-RNA interactions during viral as well as non-viral cancer Faculty Dr. Avik Biswas, Senior Scientific Officer Gr.II development and progression. Senior Research Fellow Mr. Sayantan Bhattacharyya, DST INSPIRE Ms. Sudipta Ray, UGC Work done

Ms. Paramita Ghosh, UGC Ms. Sreyashi Mitra, CNCI Junior Research Fellow Projects running (Extramural) Mr. Debarpan Mitra, CNCI 1. Molecular signaling mechanism in oral Ms. Depanwita Saha, SERB cancer: Effect of Lupeol in oral squamous Ms. Moumita Sil, CNCI cell carcinoma at transcription and post- Ms. Naazneen Khan, DST INSPIRE transcription level Supporting Staff P.I.: Dr.Nabendu Murmu Samir Banerjee, Tech. Officer (Scientific) Prem Chand Das, Lab Helper Funding agency: SERB Jitendra Kr. Shukla, Lab Helper Projects running (Internal) 1. Study on Wnt Pathways as the Signaling Objectives Hallmarks of Progressive OralSquamous Cell Carcinoma in Tobacco and Betel i) To decipher the correlation between Quid users vasculogenic mimicry, angiogenesis and P.I.: Dr.Nabendu Murmu tumour invasiveness in the light of 2. Study to decipher the molecular basis for molecular signaling in different cancers. protein-protein interactive (PPI) network ii) To examine the role of Ephrin pathway in in Hepatitis B virus (HBV) induced vasculogenic mimicry in breast and oral hepatocellular carcinoma (HCC) with cancer progression. special emphasis on the role of HBV x protein iii) To determine the molecular mechanism of P.I.: Dr. Avik Biswas cancer therapeutic and chemopreventive agents in signaling pathways, mRNA Students’ Projects running transcription and post transcription. 1. Molecular Signalling Mechanism of Risk iv) Establishment of RNA binding proteins as Factor Induced Carcinogenesis in Head therapeutic agents against cancer. and Neck Cancer: Synergistic Effect of Lupeol and Ionizing Radiation at Post- 42 v) To establish chewing tobacco as a risk

CNCI Annual Report 2018‐19 Research Wing

Transcription Level in Head and Neck Collaborative Project Cancer Cells 1. ACCEPT- Accelerated CANScript® - Name of the Student: Mr. Sayantan Enabled Personalized Treatment Study to Bhattacharyya measure predictive power of Funding agency: DST-INSPIRE CANScript®for chemotherapeutics in 2. HGF/cMet and EGFR Signaling in Oral Breast cancer Squamous Cell Carcinoma and Lymph This collaborative project is running with Node Metastasis: Effect of Lupeol on Mitra Biotech, Bangalore. these Signaling Pathways in vitro Name of the Student: Ms. Sudipta Ray Publications Funding agency: UGC International Publication 3. Study of mTOR and its downstream 1. Sayantan Bhattacharyya, Debarpan Mitra, target molecules in Gastric cancer Sudipta Ray, Nirjhar Biswas, Samir patients sample; the effect of Banerjee, Biswanath Majumder, Saunak chemopreventive agents in Gastric Mitra Mustafi, Nabendu Murmu. January carcinoma cell line and In-vivo model 2019. Reversing effect of Lupeol on Name of the Student: Ms. Paramita Ghosh vasculogenic mimicry in murine Funding agency: UGC melanoma progression. Microvascular 4. The role of environmental cxarcinogens Research. Volume 121, Pages 52-62. in male infertility and testicular cancer: 2. Saswati Gharami, Krishnendu Aich, The phytochemicals, targeting the Deblina Sarkar, Paramita Ghosh, therapeutic machinery of pre-cancerous Nabendu Murmu and Tapan Kumar cellular conditions Mondal. 2019. An ESIPT based Name of the Student: Ms. Sreyashi Mitra chromogenic and fluorescent ratiometric Funding agency: CNCI probe for Zn2+ with imaging in live cells 5. The role of Ephrin and HGF/cMet and tissues. New Journal of Chemistry. 43, pathway in regulating vasculogenic 1857-1863. mimicry in Breast cancer and possible http://dx.doi.org/10.1039/C8NJ04695F effects of phytochemicals 3. Ghosh P, Mitra D, Mitra S, Ray S, Banerjee Name of the Student: Mr. Debarpan Mitra S, Murmu N. Madhucaindica inhibits Funding agency: CNCI breast cancer cell proliferation by 6. Molecular signaling mechanism in oral modulating COX-2 expression. 2018 cancer: Effect of Lupeol in oral squamous December.CurrMol Med. doi: cell carcinoma at transcription and post- 10.2174/1566524019666181212100808. transcription level 4. Naveen Kumar, Peeyush Prasad Eshna, Name of the Student: Ms. Depanwita Saha Jash Smruthi, Jayasundar Itender Singh, Funding agency: SERB Neyaz Alam, Nabendu Murmu, S P Somashekhar, Aaron Goldman, Seema 7. Study on Wnt Pathways as the Signaling Sehrawat. 2018. cAMP regulated EPAC1 Hallmarks of Progressive Oral Squamous supports microvascular density, Cell Carcinoma in Tobacco and Betel Quid users angiogenic and metastatic properties in a model of triple negative breast cancer. Name of the Student: Ms. Moumita Sil Carcinogenesis, Volume 39, Issue 10, 8. Funding agency: CNCI Pages 1245–1253

8. Regulatory roles of RNA Binding 5. Saha, Rinku, Roychoudhury Shubhadeep; Proteins in Human Breast Carcinoma Kar Kushal Kumar, Varghese Alex C., Name of the Student: Ms. Naazneen Khan Nandi Parag, Mitra Sreyashi, Murmu Funding agency: DST-INSPIRE Nabendu, Massanyi Peter, Kolesarova Adriana. Aug/Sep 2018. A comparative assessment of semen quality in smokers 43

CNCI Annual Report 2018‐19 Research Wing

and non-smokers including sperm bpde- 3. Sayantan Bhattacharyya delivered an oral dna adduct formation and acrosome presentation on “Detection of nuclear p53 status. Journal of Microbiology, in tumor tissues using a novel differential Biotechnology & Food Sciences. Vol. 8 staining technique.” at 2nd Annual Issue 1, p741-744. 4p. Conference on “Recent trends in Cancer research, early diagnosis, prevention and 6. Feudjio Ndemanou Yolande, therapy” on 5th February, 2019 at Bhattacharyya Sayantan, Ghosh Paramita, Chittaranjan National Cancer Institute, Sarkar Deblina, Mouokeu Raymond Kolkata. S,Tume B. christopher, Murmu Nabendu. 2018. Cytotoxic effect of Spondiascytherea Poster presentation fruit extract in murine melanoma model in

vivo and in vitro. Journal of 1. Depanwita Saha presented a poster on Environmental Pathology, Toxicology and “Vasculogenic Mimicry in oral cancer: the Oncology. 37 (3), 231- 240 (2018). role of EphrinA2 signalingpathway”in 38th Annual Convention of Indian 7. Tapas Patra, Syamsundar Mandal, Neyaz Association for Cancer Research at Alam, Nabendu Murmu. 2018. PGIMER, Chandigarh on 1st- 3rd Clinicopathological trends of colorectal February, 2019. carcinoma patients in a tertiary cancer

centre in Eastern India. Clinical 2. Debarpan Mitra presented a poster on “In Epidemiology and Global Health. 6 (1)- 39- vitro and Ex vivo modelling delineates the 43. combinatorial effects of Lupeol and 5- Fluorouracil on breast cancer” at 2nd Book chapter Annual Conference on “Recent trends in Cancer research, early diagnosis, 1. Sreyashi Mitra, Nabendu Murmu, SM prevention and therapy” on 5th February, Rahman, Parag Nandi. Environmental 2019 at Chittaranjan National Cancer effect on Male Infertility: Preventive Institute, Kolkata. Therapeutic Approach. In: Gargi Ganguly Mukherjee, Gautam Khastagir, Ratna 3. Paramita Ghosh presented a poster on Chattopadhyay, editors. Practical Guide in “Madhucaindica inhibits breast cancer cell Andrology & Embryology. 23rd ISAR, proliferation by modulating COX-2 Kolkata; 2018. pp: 117-127. expression” at 2nd Annual Conference on “Recent trends in Cancer research, early Other academic activities diagnosis, prevention and therapy”on 5th February, 2019 at Chittaranjan National Oral presentation Cancer Institute, Kolkata.

1. Dr. Nabendu Murmu delivered a lecture 4. Sudipta Ray presented a poster on on “Molecular signalling mechanism on “Synergistic effect of Lupeol& Paclitaxel vasculogenic mimicry and effects of on HGF/c-Met Pathway in Oral Squamous Lupeol on the tumor microenvironment in Cell Carcinoma” at 2nd Annual aggressive cancers” in 38th Annual Conference on “Recent trends in Cancer Convention of Indian Association for research, early diagnosis, prevention and Cancer Research at PGIMER, Chandigarh therapy” on 5th February, 2019 at on 1st- 3rd February, 2019. Chittaranjan National Cancer Institute, 2. Dr. Avik Biswas presented paper Kolkata. on“RBMX: a double-edged sword against 5. Depanwita Saha presented a poster on Hepatitis C virus and hepatocellular “The expression of cMET, Gab1 and carcinoma” at International Symposium pERK1/2 in Oral Squamous Cell on “Frontiers in development and Carcinoma tissue and their association molecular medicine:models to insights” with Vasculogenic Mimicry.” at 2nd held at Biswa Bangla Convention Centre, Annual Conference on “Recent trends in Kolkata on March 1st – 3rd, 2019. Cancer research, early diagnosis, 44

CNCI Annual Report 2018‐19 Research Wing

prevention and therapy” on 5th February, by apoptosis 2019 at Chittaranjan National Cancer Our study revealed that in comparison to Institute, Kolkata. control and other treatments, combination Students undergoing PhD treatment of lupeol and docetaxel induced appreciable percentages of cells in early Six students are undergoing their PhD and late apoptosis stages. The number of curriculum in the department. apoptotic cells was significantly increased Conference/Symposium/Workshop from control to highest combination dose (lupeol 50µM/l and docetaxel 30nM/ml). attended The total apoptotic rates considering both • “Annual Meeting & Mini symposium” for early apoptosis and late apoptosis were IACR- West Bengal chapter found to be 14 % in AGS cell line. Members of caspase family of cysteine • East Zonal Oncology Symposium-2019 proteases play a significant role in (under banner of IASO) at Saroj Gupta apoptosis. The major executioner Cancer Centre & Research Institute, caspases, caspase-3 and caspase-7 are both th Kolkata on 19 January 2019. activated universally during diverse cell • 38th Annual Convention of Indian death stimuli. We further confirmed Association for Cancer Research at apoptosis induction in AGS cell line by PGIMER, Chandigarh on 1st- 3rd western blot analysis of caspase 3 protein. February, 2019. All the results concluded that the expression of caspase 3 increases • 2nd Annual Conference on “Recent trends significantly in highest dose of lupeol in Cancer research, early diagnosis, (50µM) and docetaxel treated sets as prevention and therapy” on 5th February, compared to untreated, lupeol and 2019 at Chittaranjan National Cancer docetaxel alone. Institute, Kolkata. III. Modulation of survival and apoptotic Interesting observations pathways by lupeol and paclitaxel in Oral Squamous Cell Carcinoma Cells I. Lupeol inhibits breast cancer cell growth in synergy with 5-FU In this current study, we investigated the synergistic effect of lupeol and paclitaxel This study provides substantial evidence on the HGF/cMet signaling cascade and that the anti-cancerous potential of 5-FU is apoptosis in OSCC cell lines UPCI: SCC131 enhanced by the addition of Lupeol even and UPCI: SCC084 in presence of growth at lower doses both in case of MCF-7 and factors EGF and HGF. The apoptotic MDA-MB 231 breast cancer cell lines. It activity of lupeol along with the showed significant decrease in colony chemotherapeutic drug paclitaxel on formation capability and wound healing OSCC cells was determined using Caspase capacity of the cancer cells. Apoptosis was 3/7 assay and Annexin V/PI apoptosis induced as evidenced by the induction of assay. The results demonstrated that expression of pro-apoptotic protein Bax, lupeol along with paclitaxel has a greater detected by immunofluorescence staining. activity on apoptosis in comparison to In all the experiments, the combination either agent alone in both the cell lines. treatment of 5-FU or Lupeol proved to be Further, the combinatorial treatment of more effective rather than individual Lupeol and Paclitaxel down-regulated the treatment. This opens up a plethora of expression of pMet, Gab1, pAkt, NF-κB opportunities that might ultimately aid in and COX-2 proteins of the HGF/cMet reducing the toxic load and their pathway even in presence of EGF and associated side effects of the HGF. chemotherapeutic drugs and at the same Evaluation of chewing tobacco induced time improve their efficacy drastically. IV. incidence of oral leukoplakia II. Combination treatment of Lupeol and Docetaxel induces gastric cancer cell death 89 fresh patients with oral leukoplakia (OL) were selected. The samples were 45

CNCI Annual Report 2018‐19 Research Wing

classified based on the individual’s potential risk factor. tobacco chewing habit. The samples were V. Effect of Lupeol on the molecules of EphA2 immunostained with antibodies for both of pathway expression in oral suqamous cell the EGFR as well as Wnt pathway carcinoma (OSCC) in vitro proteins. The samples were further Through the in-vitro model we aim to classified based on their proliferation establish the role of lupeol (a novel status and the expression of these phytochemical in modulating the oncoproteins on the proliferative expressional status of different signalling population was also observed. Results molecules of EphA2 pathway, involved in showed overexpressing EGFR and Wnt VM formation. The treatment with pathway proteins in all OL samples. different doses of lupeol on human tongue Structurally atypic cells had a tendency to cancer cell line SCC154 exhibited the overexpress these oncoproteins. However significant decrease in cell viability, the immunocytochemistry data could not inhibition of colony formation of cancer confirm any positive effect of chewing cells. The western blot analysis further tobacco on the OL’s proliferative state. revealed relatively lower level of Statistical data from the expression of pEphA2 and pERK1/2 in immunfluorescence staining finally lupeol treated cells which may indicate its revealed the overexpression of both the important effect in regulating the EGFR and Wnt pathway proteins on the expressional status of the EphA2 signaling proliferative population establishing axis. chewing tobacco as a positive risk factor VI. Detection of Nuclear Accumulation of p53 in for the onset of OL. In conclusion, this is Tumor Tissues using a Novel Differential the first time report showing the effect of Staining Technique chewing tobacco on the EGFR and Wnt

pathway in OL and its possible role as a

46

CNCI Annual Report 2018‐19 Research Wing

The guardian of genome- p53 plays the expression of COX-2 and its mRNA most critical role in carcinogenesis, tumour binding protein CUGBP2, western blot proliferation, progression and metastasis. analysis was performed and the Hence, pathological detection of p53 in the expression status of COX-2 and CUGBP2 histological sections has been the bull’s eye with tumour grade was assessed. Results for scientists as well as clinicians for a long showed relatively higher expression of time. Not only the expression status, but CUGBP2 in the patients with higher the localization of p53 (nuclear or tumour grade. The expression pattern of cytoplasmic) also differs from sample to its target protein COX2 will be further sample with different indication. Nuclear investigated in order to establish the role accumulation of p53 is thought to mark of COX2- CUGBP2 signaling in the poor prognosis with high aggressive status progression of Breast cancer. of the tumor in various cancer model VIII. Lead and Cadmium alters the p53-AKT including cancer of the breast and oral balance in the sperm cells of tea garden cavity. The gold standard process to detect workers causing infertility with a risk the accumulation in a given histological of pre-malignancy section is time consuming and costly. In this project, we designed a simple protocol using the coulombic charge competition incidence to detect nuclear accumulation of p53 in any histological sample. 3μ thin tissue sections were stained with three different dyes- one basic dye (haematoxylin) and two acidic dyes (eosin and light green SF yellowish). Results showed tumor (breast, oral, laryngeal, cervical, gastric, melanoma and lymphoma) sections with nuclear

accumulation p53 had pink colored nuclei The study aimed at evaluating the impact while the novel protocol was applied of Lead (Pb) and Cadmium (Cd) exposure whereas sections with cytoplasmic or no at molecular level on the reproductive p53 expression had blue nuclei. Statistical status of tea garden workers from North- analysis showed almost 100% accuracy of East India. The profiling of the semen our protocol with the gold standard parameters and oxidative stress was immunohistochemistry indicating the obtained in all samples followed by the accuracy of the protocol. evaluation of cell survival and apoptotic VII. Regulatory roles of RNA Binding Proteins proteins' [p53, phospho-Akt, nuclear in Human Breast Carcinoma factor-κB (NF-κB, p50 subunit) and B cell RBPs are highly versatile factors that can lymphoma 2 (Bcl2)] expressions. Results bind to multiple targets and regulate their revealed significant (P<0.0001) difference fate by a variety of mechanisms. Post in seminal heavy metal levels and various transcriptional gene regulation is a central semen parameters of patients' compared to mechanism of emerging importance in the donors'. High seminal Pb and Cd cancer research which is expected to concentrations showed positive (P<0.0001) provide novel targets for prognostic and association with the percentage of sperm therapeutic design.To identify Tumor multiple defects and level of seminal zones in Human Breast tumor samples: oxidative stress marker. In the samples of The human breast cancer tissue samples high Pb and Cd concentration groups, were obtained from Chittaranjan National seminal heavy metal concentrations Cancer Institute All samples were showed positive correlations with average thoroughly screened for tumour positive p53 expressions and negative correlations samples via hematoxylin and eosin with mean p-Akt and its downstream staining. In order to check the protein protein expressions on sperms. In low Pb, 47

CNCI Annual Report 2018‐19 Research Wing

Cd concentration groups, the reverse mean completed their short term projects in this range and correlation patterns were department. observed. It may be therefore inferred that the relative fluctuation of p53 and Akt and Miscellaneous its downstream proteins on heavy metal • Dr. Nabendu Murmu acted as reviewer for exposed patients was the determining various international peer reviewed factor of sperm cell fate which, in turn, journals. determined the fertility status of men • Dr. Nabendu Murmu reviewed several working in the tea gardens. Alteration in extramural projects submitted to Science the p53- Akt network also indicates the and Engineering Research Board, New probability of mutated spermatogenesis Delhi. which, in turn, can be established as a marker for pre-malignant germ cell • Dr. Avik Biswas has reviewed several population. papers for international journals (Journal Training Program of Medical Virology, Virus Research and International Journal of Infectious Thirteen students from different colleges and diseases). universities from various parts of India

48

CNCI Annual Report 2018‐19 Research Wing

Viral Associated Human Cancer

Head Dr. Chinmay Kumar Panda Senior Asst. Director Grade and Officer­in­Charge (Research)

HPV16 and 6.2% (2/32) HPV16/18. During post-therapy follow-up visit (N=16), 43.7% Team (7/16) have cleared HPV16, whereas, 12.5% (2/16) showed persistent HPV16/18 presence Faculty in their swabs. In parallel, HPV16 was absent Dr. Sankhadeep Dutta, Senior Scientific Officer Gr.II in plasma of 25.0% (4/16) CACX patients, Research Associate whereas, in 6.2% (1/16) the virus persisted. Dr. Gangotree Mohanty, CSIR Students’ Projects running 1. Studies on tumor induced thymic Work done atrophy in mice in relation to T cell

differentiation and death: Critical modulation by Neem Leaf Glycoprotein Projects running (Extramural) Name of the Student: Dr. Gangotree Project 1 Mohanty P.I.: Dr. Chinmay Kumar Panda Comparative evaluation of prevalence and clearance of HPV in uterine cervix of Funding agency: CSIR (Research asymptomatic Indian population and Associateship) cervical carcinoma patients In this study, we evaluated the prevalence Publications and clearance of HPV infection in cervix of 1. Islam S, Dasgupta H, Roy A, Alam N, asymptomatic Indian population and cervical Mandal G K, Roychoudhury S, Panda C carcinoma patients. The 156 asymptomatic K.: Skin mediates Human Papilloma Virus hrHPV infected women were selected based (HPV) infection in breast: A report of four on Hybrid Capture-II (HC-II) screening where cases. Indian Journal of Case Reports, 4(2), 143 samples were found to be HPV+ve in 98-102, 2018. PCR-based screening with 6.3% (9/143) HPV16 and 1.4% (2/143) HPV16/18 infection. Other academic activities During Follow-up (N=62), 9.8% (5/51) have cleared HPV infection, whereas, in 36.3% Poster presentation (4/11) individuals HPV16/18 persisted. From 1. Dr. Gangotree Mohanty presented a poster 32 paired swab and plasma samples collected entitled “Comparative evaluation of from Cervical Carcinoma (CACX) patients, all prevalence and clearance of HPV in cervix swabs were found to be HPV+ve with 84.3% of asymptomatic Indian population and (27/32) HPV16 and 15.6% (5/32) HPV16/18 cervical carcinoma patients” organized by infection. In the plasma, 43.7% (14/32) were 106th Indian science congress, held in found to be HPV+ve with 37.5% (12/32) Jalandhar, Punjab from January 3-7, 2019. 49

CNCI Annual Report 2018‐19 Research Wing

2. Dr. Gangotree Mohanty presented poster 3. Dr. Gangotree Mohanty presented poster entitled “Prevalance of high risk HPVs in titled “HPV Prevalance and clearance in cervical intraepithelial neoplasia (CIN) cervix of asymptomatic population and patients of Indian population” in the 10th cervical lesions” at 1st annual meeting of East Zonal Oncology Symposium held at Kolkata Gynecological Oncology Saroj Gupta Cancer and Research Institute, conference held at Biswa Bangla Thakurpukhur, Kolkata on 19 th January, Convention Centre, Kolkata from March 2- 2019. 4, 2019.

50

CNCI Annual Report 2018‐19 Research Wing

Academic Cell

Academic Coordinator Dr. Sutapa Mukherjee Senior Scientific Officer I

Dissertation Programme This year about 90 students from different Team Institutions and Universities throughout India Faculty have come to CNCI for training programme. Dr. Ugir Hossain Sk, Senior Scientific Officer Gr.II Students from abroad also came here for Dr Subhadip Hajra, Senior Scientific Officer Gr.II training programme. Dr Subhadip Hajra (SSO-II) is taking the responsibility in coordinating internship programme of Objectives undergraduate and postgraduate students coming from different colleges and Improvement of research in oncology using universities and their placement in various cutting edge technology is the most important research laboratories. priority zone of CNCI. Academic Cell being an integral part of CNCI research is actively This year around 4-5 students have submitted engaged with the academic affairs of research. their PhD thesis to different Universities. Some major noteworthy activities going on in CNCI furthermore gave consent to visit its Academic Cell at regular basis are: research laboratories and Dept of Animal Care and Maintenance among various i) Conducting and coordinating PhD undergraduate and post-graduate students of course work classes different colleges. ii) Placement of students (coming from different institutions and universities) to PhD Programme different departments of CNCI for their PhD Course work classes are going on at training programme. regular basis covering basic and advanced courses as per norms of University Grant iii) Conducting weekly seminar series Commission (UGC). The syllabus of the between faculties and students which is course work has been accepted and approved indeed a scientific platform for exchange by both the University of Calcutta and of views related to cancer research. Jadavpur University. Students are entitled for iv) Evaluation of project proposals by the PhD registration under either a) University of committee members of the Academic Calcutta, b) Jadavpur University, c) West Committee (Research) before submitting Bengal University of Health Sciences. the same to extramural funding agencies.

51

CNCI Annual Report 2018‐19 Research Wing

Total number of research fellows exchange knowledge through the working at CNCI, Kolkata presentation, followed by discussion. This in- house seminar is giving our researchers a JRF SRF Reseach Others platform to skill-up their data-presentation. In Associate (Young addition to in-house seminars, eminent (RA) Scientist/ Women scientists from various parts of India and Scientist/ abroad are also visiting CNCI and sharing Faculty their scientific experiences by delivering Scientist etc) lectures. Dr. Ugir Hossain Sk is coordinating Institute 8 4 ‐ ‐ the entire seminar series. Funded Extramural Academic Committee (Research) Funded 14 8 3 6 Project The purpose of the committee is to evaluate the project proposals and giving some Weekly Scientific Seminar Series valuable inputs for strengthening the project scientifically, before final submission to the Academic Cell of CNCI is organizing funding agencies (DST, DBT, CSIR, DRDO “Weekly Scientific Seminar Series" on etc). Interview / Assessment of individual regular basis, involving scientists and research fellows (CSIR-UGC, DST-INSPIRE, research fellows (JRF, SRF, RA, and Young DBT, ICMR etc) are taken by Academic Scientists, Emeritus Scientists). The objective Committee (Research). Meeting of the of this seminar series is to create a scientific committee is held in the 2nd week of every platform where scientists and fellows can month depending on the pending issues. freely share their scientific ideas and

52

CNCI Annual Report 2018‐19 Research Wing

Animal Care and Maintenance

Head Dr. Abhijit Rakshit Technical Officer­Animal House

Prevention of Cruelty to Animals Act 1960. The objective of CPCSEA is to ensure that Team animals are not subjected to unnecessary pains or suffering before, during or after Laboratory Helper performance of experiments on them. For this Mr. Shri Shibashis Das purpose, under the delegated powers, the Committee formulated the ‘Breeding of and Experiments on Animals (Control and Objectives Supervision) Rules, 1998’ which were amended in 2001 and then in 2006, to regulate

• To maintain laboratory animals in a clean the experimentation on animals. and hygienic environment According to the provisions of the said Rule, • To produce good quality, healthy animals the Animal Care and Maintenance by adopting scientific breeding techniques Department has its own ‘Institutional Animal • To provide healthy, disease-free animals to Ethics Committee (IAEC)’ comprising of five various departments of this Institute for internal members and four CPCSEA their research work Nominees. The CPCSEA Registration of the Animal • To provide technical support in animal House has been renewed for 5 years w.e.f. 25th experiments June 2018 and the IAEC has been • To organize the Institutional Animal Ethics reconstructed with the following members: Committee (IAEC) meetings to scrutinize Name Designation and guide the animal experimentation Dr. Chinmay Kumar Chairman & Biological projects conducted by different research Panda, CNCI Scientist departments of this Institute Dr. Sukumar Manna CPCSEA Main Nominee • To supervise ethical aspect of animal Dr. Pratip Chakraborty CPCSEA Link Nominee experimentation Dr. Amit Pal CPCSEA Scientist Nominee This Animal Care and Maintenance Dr. Soma Banerjee CPCSEA Socially Aware Department is registered with the CPCSEA Nominee (Committee for the Purpose of Control and Dr. Abhijit Rakshit, CNCI Member Secretary & Supervision of Experiments on Animals), Veterinarian Member, Department of Animal Husbandry and In‐Charge of Animal Dairying, Ministry of Agriculture and Facility Farmers Welfare, Government of India, Dr. Prosenjit Saha, CNCI Biological Scientist having its Registration No. Member Dr. Nabendu Murmu, Biological Scientist 1774/GO/RBi/S/14/CPCSEA. The CPCSEA CNCI Member is a statutory Committee, which is established Dr. Sutapa Mukherjee, Biological Scientist under Chapter 4, Section 15(1) of the CNCI Member 53

CNCI Annual Report 2018‐19 Research Wing

The functions of the IAEC are: Work done

• To scrutinize and approve proposed animal experimentation projects following The Animal Care and Maintenance the SOP formulated byb CPCSEA Department is the central animal facility of • To review periodically the animal house the Institute, where Swiss albino and facility, give suggestions for its betterment C57BL/6J mice are maintained. Random and submit report to the CPCSEA outbreeding is practised for animal production. Different scientific departments • To ensure that all persons involved in of this Institute carry out animal animal care and use are appropriately experimentation in this facility and their qualified to perform their duties and experimental animals are maintained in the conduct proposed activities. Animal House. Durinng the year two IAEC meetings were conducted on 26th July 2018 and 24th

December 2018, to scrutinize and review the animal experimentation projects those were proposed and run by the scientists of CNCI.

The following chart shows the details of the animal experimentation projects approved in the two IAEC meetings.

IAEC dated 26th July 2018 Project Title P.I. Funding Source Duration Animals approved

1. A way to overcome chemoresistance Dr. Prosenjit DBT Research 24 months; Swiss Albino mice: in colorectal cancer stem cells: Saha Associate Program Sept. 2018 260 therapeutic targeting by natural in Biotechnology to Sept. BALB/c mice: 390 flavonoid Orientin and Life Sciences, 2020 Department of Biotechnology, GOI, New Delhi 2. Studies on Tumor‐Induced Homing of Dr. CNCI, Kolkata and 12 months; C57BL/6J mice: 228 Mesenchymal Stem Cells in Tumor‐ Rathindranath Dept. of Science August Draining Lymph Nodes and Its Baral and Technology, 2018 to Consequences on Tumor Progression: Govt. of India July 2019 Modulation by Neem Leaf Glycoprotein 3. Understanding the influence of Dr. CNCI and CSIR, 36 months; C57BL/6J mice: 30 Cardiovascular disease‐linked Statin(s) Rathindranath Govt. of India, New Aug.2018 out of a total of 408 treatment on Cancer Immuno‐editing Baral Delhi to Aug. C57BL/6J mice were process: Modulatory role of Neem 2021 approved for Leaf Glycoprotein initiation of the project 4. Intervention of neem leaf glycoprotein Dr. CNCI, Kolkata and Extension Swiss Albino mice: on 4 nitoquinoline 1 oxide mediated Rathindranath DBT, Govt. of India, for 3 yrs; 315 for 3rd, 4th & 5th oral carcinogenesis: Special emphasis Baral New Delhi Nov.16 to year on epithelial mesenchymal transition May21 (ongoing project)

54

CNCI Annual Report 2018‐19 Research Wing

IAEC dated 24th December 2018 5. Anticarcinogenic efficacy of nano‐ Dr. Prosenjit ICMR 5 Years; Animals required for eugenol by targeting EMT pathway Saha Jan 2019 to the 1st year: Dec 2024 C57BL/6 mice ‐ 93 6. Evaluation of chemopreventive and Dr. Subhadip SERB 3 Years; Animals required for therapeutic efficacy of PLGA nano‐ Hajra March the 1st year: encapsulated phenolic compounds 2019 to Swiss albino mice ‐ used in combination with carboplatin: March 108, Sprague‐Dawley an in vivo experimental study 2022 rats: 60 7. Isothiocyanate: Role in enhancing Dr. Sutapa CNCI Extension Swiss albino mice ‐ platinum accumulation in cervical Mukherjee for 2 Years 96 cancer 8. Identification of intra‐thymic Dr. Subhasis CNCI 3 Years; Animals required for mechanisms associated with T‐cell Barik March the 1st year: commitment from T stem/progenitor 2019 to C57BL/6 mice ‐ 135, cells and robust T‐cell proliferation in March Balb/c mice ‐ 135 T‐cell leukemia/lymphoma 2022 9. Study on dynamic regulation of insulin Dr. Biswarup CNCI 3 Years; Animals required for and Dopamine in dermal wound Basu Jan 2019 to the 1st year: healing and bone tissue regeneration Jan2022 Swiss albino ‐ 84 in normal and diabetic condition 10. Development of dual‐drug‐dendrimer Dr. Ugir ICMR 3 Years; Animals required for multifunctional nanodevices for Hossain Dec 2019 the 1st year: therapy against breast cancer: A novel to Dec Balb/c mice ‐ 60 drug delivery approach 2022 11. Role of COX‐2 RNA Binding Proteins in Dr. Nabendu SERB 3 Years; NSG mice female ‐ 50 Human Breast Carcinoma; An in vitro / Murmu April 2019 in vivo Study Towards Better to March Treatment Modalities 2022 12. Role of VEGF‐VEGFR(s) axis in Dr. CNCI 2 Years; Animals required for polarizing Regulatory T cells (Treg) and Rathindranath Jan 2019 to the 1st year: Th17 cells under the influence of Baral Dec 2020 C57BL/6 mice ‐ 92 tumor hypoxia: Modulation by Neem Leaf Glycoprotein

Besides the above new projects, fourteen animal Production experimentation projects of different P.I.s were Species Strain Male Female Total running in the Animal House during the year. Swiss 804 888 1692 Mouse C57BL/6J 276 264 540 Following is the chart of animals produced and supplied to various departments of the institute Supply in the year 2018-19: Species Strain Male Female Total Swiss 372 682 1054 Mouse C57BL/6J 112 421 533

55

CNCI Annual Report 2018‐19 Research Wing

Central Research Instrumentation Facility

In‐Charge Dr. Chinmay Kumar Panda Senior Asst. Director Grade and Officer­in­Charge (Research)

9. Genetic Analyzer Team 10. GS 800 Densitometer 11. Heraeus brand non-refrigerated Micro Supporting Staff centrifuge Mr. Netai Chandra Mondal, Technical Officer Mr. SourinMaity, SSA 12. HERMLE Refrigerated High Speed Mr. Ganga Routh, GDA Centrifuge Contractual Staff 13. Hidex 300 SL TCDR Beta Counter Mr. Rathindranath Das, Jr. Consultant 14. Icycler, Base Onl For advanced research on cancer, the department has following facilities like : i) Microbiology, ii) 15. KALTIS Ultra Low Vertical -86 degree Molecular and cell biology, iii) DNA sequencing, Freezer iv) Cold room, v) Flow cytometry, vi) Liquid 16. Lab Balance nitrogen plant, vii) Quantitative RT PCR, viii) Laser capture microdissection and ix) Radio 17. Laminar Air Flow Hood (incl. 2nos.Fume isotope. Hood) This department has large number of small and 18. Leica brand Histology Equipments sophisticated instruments for experimental 19. Leica Microscope Model : DMIL works. The researchers can make unrestricted and unhindered use of these instruments. The 20. Leica Microtome instruments were well maintained by trained 21. Liquid Nitrogen Plant staffs. 22. Mycycler Thermal The following is a list of scientific instruments of the department: 23. Nikon ECLIPSE E600F 1 Microscope 1. -86 degree Deep Freezer 24. Real Time PCR System 2. Atomic Absorption System 25. Savant Speed Vac. System 3. Blue Star Her Con Unit 26. System, Chemidoc 4. ESCO -80 degree Freezer 27. Tecan ELISA Multimode Reader 5. Flow Cytometer - FACS Calibur 3 CS 28. Ultra WX 100 Centrifuge 6. Fluorescence Carry Eclipse System 29. UV-VIS Cary 100 7. Gel Doc XR System 30. UV-VIS Cary 100/300 Spectrometer 8. GENEAMP PCR SYS 2700.96 WELL 31. Water Purification System 56

CNCI Annual Report 2018‐19 Research Wing

Library

Assistant Library & Information Officers Mr. Sanmoy Chakraborty Mr. Ganesh Gorai

web OPAC. • For help to better research work for Team Scientist and to better treatment for Doctor. Supporting Staff Gita Khatua, GDA • In addition it also extended its facilities to other institutions and universities. Objectives The library service is the pivot of all the Work done academic and clinical activities of the Institute. In one-hand there are Research work 1. Library has subscribed to 61 Print & E- carried on in the Research section by the Journals for the period January 2018 to Scientist and Ph. D Fellows and on the other March 2018 and 61 Print & E-Journals for hand there are many academic courses and the period April 2018 to December 2019. clinical Researches are conducted in the 2. Library has procured 89 books for period Hospital site. To cater the needs of all of the of 2018-2019. above mentioned areas library plays a vital role. The readers and consumers from the 3. Library automation software KOHA, and above mentioned sectors prefer to get the institutional repository software library service available in all working days. DSPACE are running successfully. • To collect, organize & disseminate printed 4. Total 2450 old books are scanned for & digital information digitized and 650 old books are uploaded on repository software DSPACE. This • To provide information to the users will be helpful to the end users i.e. • To develop knowledge house doctors, scientist, research scholar etc. • To create and update a comprehensive 5. Library is well equipped with sufficient database of cancer literature number of computers with internet connectivity through LAN and wireless • To provide online and print journals networking facility for laptop users. • To provide print and e-books Library is having access to plenty of • Library offers Online Public Access electronic journals, e-books, archives at Catalogue (OPAC) which allows user to institutional level. Online journals are browse library collection by author, title, also accessible within the campus subject, classification number, etc. through through campus LAN. 57

CNCI Annual Report 2018‐19 Research Wing

6. The CNCI library also facilities to access Resources to NML ERMED Consortium. Research Library 7. The library provided the photocopying services to the users. • No. of Books: 3492 8. Library provides the newspaper clipping • Journals (Online & Print) - 40 service on news related to cancer. • No. of Bound Journals: 13824 9. Library also provides e-mail service to • E Books: 54 the users. • Electronic Resources: 212 10. The library shares its resources with all important academic / research Hospital Library institutions in India. • Total no. of Books: 6439

• Journals (Online & Print) - 21

• No. of Bound Journals: 2100

• E books: 119 • Electronic Resources: 25

58

CNCI Annual Report 2018‐19 Research Wing

Clinical and Translational Research

Head Dr. Kalyan Kusum Mukherjee Specialist Grade I

• New drug development • Biomarker development Team • New target and molecules identification Faculty and study of elaboration of activity Dr. Ugir Hossain Sk, Senior Scientific Officer Gr.II Facility of the Department Supporting Staff Mr. Subhabrata Dey, Technical Officer, In‐Charge ‐ The translation research department is well Technical Facility equipped with the modern instrument like Mr. Jyotirmoy Adhikari, Junior Scientific Assistant atomic absorption spectroscopy, LC-Mass Mr. Sumanta Adhikari, Junior Scientific Assistant Spectrometry (UPLC), Elisa Reader Tecan Austria GmbH, and HPLC (waters) which will be accessible to patient sample analysis, Objectives research molecules pharmacokinetics validation, bioavailability determination. The • The clinical and translation research laboratory has highly equipped with department aims at highly chemistry facility like Rotary Evaporator, interdisciplinary research focused on the chillier, vacuum pump for the synthesis of pre-clinical development of novel organic small molecules and polymer-drug molecules/therapeutic devices against the conjugates. Furthermore, the department will different type of cancer, which exclusively also be aiming to undertake facility for covers Organic chemistry, analyzing metabolites in biological samples nanotechnology-based drug delivery, using mass spectrometry (LCMS). molecular biology, and animal studies techniques. Herein, our objective is to Our present works are in the development create a pathway which bridge between stage scientist and clinician aiming to translate 1. Development of drug-dendrimer basic research outcome to the clinic for the multifunctional nanodevices against cancer patient health benefit. The mission cancer: Our ongoing research interests of this department is to initiate Clinical include polymer-based targeted delivery Trials based on the finding on the basic of clinical drugs. To minimize toxicity research team. The work will be carried and enhance the efficiency of treatment out with biologist and drug discovery and imaging; synthesis of nano- scientist for the development of novel conjugate, characterization, and testing; targeted cancer therapeutics. Our team is preclinical in vitro and in vivo evaluation highly interdisciplinary and efficient of anticancer therapeutics; sustained researcher consists of organic chemistry release characteristic of the drugs from and clinician from medical oncology nanodevices in physiological condition expert. and determined Pharmacokinetics. One 59

CNCI Annual Report 2018‐19 Research Wing

of the goals is to develop single P.I.: Dr. Kalyan Kusum Mukherjee nanodevices of combination drugs 3. A global, multicentre, three arms, open- therapy to increase efficacy against label randomized study to evaluate the disease. efficacy and safety of Nanosomal 2. Modification of existing cancer Docetaxel Lipid Suspension compared to therapeutic small molecules by using Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast various linker attached bioactive-motif cancer patients with locally advanced or and their anticancer activity followed by metastatic breast cancer after failure to pharmacokinetics through LCMS in vivo. prior chemotherapy. (Ongoing- Indian) 3. Development of the natural glycoside P.I.: Dr. Kalyan Kusum Mukherjee based drug delivery system for cancer 4. A Phase 1 Study to Determine Safety, therapeutics. Tolerability, Pharmacokinetics, and 4. Heavy metals (Cd, Cu, As and Pb) Activity of K0706, a Novel Tyrosine analysis in blood samples from cancer Kinase Inhibitor (TKI), in Subjects with patient: Correlation cause of cancer with Chronic Myeloid Leukemia (CML) or heavy metal through occupational Philadelphia Chromosome Positive exposure. Acute Lymphoblastic Leukemia (Ph+ ALL). (Global-Ongoing) P.I.: Dr. Kalyan Kusum Mukherjee Work done 5. A Randomized, Double-blind, Multi-

center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity Clinical Trial of SAIT101 Versus Rituximab as a First- Clinical data process team is also delivering line Immunotherapy Treatment in output through the following project. The Patients with Low Tumor Burden project consist of following manpower: Mr. Follicular Lymphoma.(Global-Ongoing) Somnath Chakraborty (Study Coordinator), P.I.: Dr. Kalyan Kusum Mukherjee Mr. Suryakanta Ray (Phlebotomist) and Mrs. 6. Multicentre, Double-Blind, Randomized, Mili Das (Study Coordinator) Parallel-Group Study to Assess the 1. A Randomized, Multiple-dose, Efficacy and Safety of MYL-1402O Multicenter, and Comparative Parallel Compared With Avastin®, in the First - Study to Evaluate the Efficacy, Safety and line treatment of Patient with Stage IV Pharmacokinetic Characteristics of Non-Squamous Non-Small Cell Lung Intravenous Infusion of Trastuzumab Cancer. (Ongoing- Global) (Hetero) and Reference Medicinal P.I.: Dr. Kalyan Kusum Mukherjee Product (HERCEPTIN® - Trastuzumab, 7. A Multi-Centre, Randomized, Double Genentech, Inc.) in combination with Blind, Parallel-Group, Comparative standard chemotherapy in Patients of Clinical Trial to evaluate the Safety and HER2-positive Metastatic breast cancer. Clinical Equivalence of Generic (Ongoing- Indian) Clotrimazole Troche/Lozenges USP, P.I.: Dr. Kalyan Kusum Mukherjee 10mg (Unique Pharmaceutical 2. Randomized, Assessor-Blind, Laboratories, India) to Clotrimazole Multicentre, Parallel Group, Two Arms, Troche/Lozenges ® 10mg (Roxane Clinical Study to Assess the Efficacy, Laboratories Inc., USA) in subjects with Pharmacokinetics, Pharmacodynamics, Oropharyngeal Candidiasis”. (Ongoing- Immunogenicity and Safety of Rituximab Global) (Test Product, Zydus) in comparison with P.I.: Dr. Kalyan Kusum Mukherjee Rituximab (Reference Product, Roche/Genentech) in Patients with Publications Diffuse Large B Cell Lymphoma (DLBCL). (Ongoing- Indian) 1. Mukherjee A, Mukherjee KK, Mukherjee S 60 and Roy M. Curcumin May Enhance the

CNCI Annual Report 2018‐19 Research Wing

Efficacy of Anti-Leukemia Drugs in mice". 8th Annual Conference of Indian Myeloid Leukemia, Int. J.Curr.Microbiol. Academy of Biomedical sciences (IABS) App.Sci (2018) 7 (5): 3274-3283 held at CSIR-NIIST, Thiruvananthapuram, Kerala 25th- 2. Sharma S; Mishra, Chhimwal J; Patial V, 27th February, 2019. Sk U. H., Dendrimer conjugated podophyllotoxin supresses DENA induced Other awards or special achievements HCC progression by modulation of inflammatory and fibrogenic factors. 1. Dr. Kalyan Kusum Mukherjee was Toxicology Research, 2019, 8, 560-567 awarded for “Outstanding Scientist Award” by International Organization of Other academic activities Scientific Research and Development (IOSRD) on 29th September 2018 at Poster presentation Chennai, India. 1. Patial V, Sharma S, Chhimwal J and Sk Miscellaneous UH. "Inhibition of hepatocellular carcinoma by dendrimer conjugated Dr. Ugir Hossain Sk, Editorial Board Member, podophyllotoxin through modulation of ‘Nature Scientific Reports’ since 2015-present. inflammatory and fibrogenic factors in

61

CNCI Annual Report 2018‐19 Research Wing

62

CNCI Annual Report 2018‐19 Research Wing

63

CNCI Annual Report 2018‐19 Research Wing

64

CNCI Annual Report 2018‐19 Hospital Wing

Anaesthesia and ITU

Head Dr. Shubhra ray Specialist Grade I

Others 9 GI & 40 Team genitourinary Surgery Breast and soft 67 11 5 227 Faculty Unit III tissue Dr. Deepa Chakrabarti, Specialist GradeII(SG) Head and neck 83 Dr.Sripurna Mondal, Specialist GradeII Others 21 Dr.Deepanwita Das, Specialist GradeII Gynaecol Dr.Debasish Jatua, SMO 201 10 2 213 ogy Junior Doctors ENT and Dr. Chayan Khan, Junior Resident head‐ 154 4 158 Dr. Suchandra Majumder, Junior Resident neck Dr. Pathik Shit, Junior Resident Total 1120 Pre­anaesthetic check up Work done OPD (Wednesday and Friday) Major surgeries under general ± Total no cases: 2965 regional anaesthesia New: 1506

Old: 1459

Male: 1367 Major

Total Female: 1598 Palliative

/ Inoperable Emergency ITU GI & 88 No. of cases No. of deaths genitourinary Surgery 600 17 Surgery Breast and soft 81 19 13 281 Unit I tissue ENT 139 01 Head and neck 66 Gynae 203 02 Others 14 Medical Oncology 56 13 GI & 24 Radiotherapy 02 00 genitourinary Surgery Breast and soft 7 3 241 Total no. of cases 1000 Unit II 117 tissue Total no. of deaths 33 Head and neck 81

63

CNCI Annual Report 2018‐19 Hospital Wing

ENT‐Head & Neck Oncology

Head Dr. Aniruddha Dam Specialist Grade­I

the psychological and social rehabilitation of cancer patients continued to be part of the Team treatment goal. Effort was made to work in conjunction with the departments of Faculty Radiotherapy and Chemotherapy so that a Dr. Anup Kr. Bhowmick, Specialist Grade I multidisciplinary treatment option could be Dr. Aniruddha Sarkar, Specialist Grade II offered. A significant part of the departmental Dr. Rup Kumar Saha, Chief Medical Officer-NFSG activity involved training and teaching the Junior Doctors DNB Surgical Oncologists doing their rotation Dr. Shomes Mozumder, Sr. Resident duties in the Head & Neck sub-specialty. The Dr. Kinshuk Chatterjee, Sr. Resident department continued with the head & Neck Dr. Samyadipta Dey, Sr. Resident Dr. Rupam Mitra, Jr. Resident fellowship program as part of its mandate for Dr. Priyadarshan Kumar, Jr. Resident training of manpower in oncology. The Dr Ankit Khandelwal, Clinical Fellow department actively participated in the Dr. Monika Gupta, Clinical Fellow Virtual Tumor Boards of the National Cancer Grid (NCG) of Government of India along with the other cancer institute across the Objectives country. During the above period ENT-Head & Neck Oncology Department continued to provide quality care to all the patients, both in the Work done OPD and the Indoors. There was significant (I) Analysis of patients reviewed by the modification of the treatment protocols with department during this period greater emphasis being placed in combining chemotherapy with radiotherapy as well as Total number of cases (old + new) reviewed 5825 surgery. Internationally accepted treatment by the department combination such as induction chemotherapy Total number of new cases attending the 1129 and concomitant chemo-radiotherapy were department offered to patients attending the Tumor Total number of old cases followed up in the 4696 Board. Even though major ablative and department reconstructive surgeries continued to be Total number of patients attending Tumor 923 necessary, a greater portion of the surgical Board Total number of planned minor surgical load handled by the department during this 47 period were with ’salvage surgery’ as an procedures Total number of planned major surgical definitive treatment option for residual or 143 recurrent head & neck tumors. There was a procedures Total number of flexible endoscopies sharp decline in the overall number of 187 surgical treatment as the first line option. (Therapeutic/Diagnostic) 64 Adequate patient counseling and assistance in Total number of emergency Tracheostomy 29

CNCI Annual Report 2018‐19 Hospital Wing

(II) Analysis of treatment offered by the Conference/Symposium/Workshop department during this period attended Dr. Aniruddha Dam: Percentage Type of Treatment (Approx.) 1. Panelist for the CME on Surgical Radiotherapy (with/without surgery) 24.6% Approaches to Thyroid(CURE 2018) at Concomitant Chemo‐Radiotherapy 6th 7th 18.5% TMC Kolkata on - April 2018. (CCRT) Surgery (with/without RT) 20.4% 2. External Examiner for the Head & Neck Induction Chemotherapy 8.5% Fellowship Program at B. Booroah Cancer Palliative Care 12.2% Institute, (BBCI) Guwahati, Assam, 23rd June 2018. (III) Analysis of the tissue diagnostic technique followed during this period 3. Chairperson to the Workshop on TOUSS in Head & Neck Cancer at AIIMS, New Cytology Diagnosis (FNAC from Delhi, 16th -17th August 2018. 32.3% regional Nodes)

Histopathology Diagnosis (Biopsy 4. Panelist for the CME (ENT Enclave)on th from Primary and incisional biopsy 52.3% Thyroid (ENT) at Novotel 15 September, from neck nodes) 2018. Immunohistochemistry 2% 5. Proctor for Cadaveric Dissection (IV) Analysis of distribution of Head & Workshop at IPGMER & SSKM Hospital Kolkata as part of FHNO 2018 and Neck Regions affected IFHNOS World Tour on 25th October 2018. Anatomical Region Percentage 6. Chairperson for the LH Hiranandani Larynx(Supraglottis, Glottis, 11.16% Oration during the Annual National Meet Transgltiic) of the Foundation for Head and Neck Thyroid 13.87% Oncology (FHNO) and the International Tonsil 3.57% Federation of Head and Neck Oncologic Base‐of –tongue (BOT) (including 5.4% Societies (IFHNOS WORLD TOUR) held Vallecula) in Kolkata 26th October 2018. Pyriform Fossa 5.4% 7. Faculty for the Global Oncology Nose 0.75% Leadership Fellowship Examinations of Buccal Mucosa 8.9% the International Federation of Head & Parotid 3.14% Neck Oncologic Societies on 28th October Sinonasal carcinoma 0.98% 2018, Kolkata. Oral Tongue 11% Nasopharynx 2.1% Dr. Anup Kr Bhowmick: Unknown Primary 2.1% Esophagus 0.1% 1. Participated as delegate in the Annual Mastoid/External Auditory Canal 0.4% National Meet of the Foundation for Head and Neck Oncology (FHNO) and the Publications/Monographs/Patents International Federation of Head and Neck Oncologic Societies (IFHNOS WORLD etc. TOUR)held in Kolkata from October 25th- 1. Shomes Mozumder, Shirish Dubey, 28th 2018. Kinshuk Chatterjee, Priyadarshan Kumar, Dr. Rup Kr Saha: Ankit Khandelwal, Aniruddha Dam, Anup Kr Bhowmick. Reconstruction of Head 1. Participated as delegate in the Annual and Neck Defects with Lower Trapezius National Meet of the Foundation for Head Myocutaneous Flap. Bengal Journal of and Neck Oncology (FHNO) and the Otolaryngology and Head and Neck International Federation of Head and Neck Surgery Vol 26, August 2018. Oncologic Societies (IFHNOS WORLD TOUR)held in Kolkata from October 25th- 65

CNCI Annual Report 2018‐19 Hospital Wing

28th 2018 Hospital Kolkata during FHNO 2018 and IFHNOS World Tour Conference on 25th Dr. Shomes Mozumder: October 2018. 1. Proctor for Cadaveric Dissection 5. Attended 5th laser surgery course and Workshop at IPGMER & SSKM Hospital hands on cadaver dissection workshop at Kolkata as part of FHNO 2018 and Tata Memorial Hospital Mumbai from IFHNOS World Tour on 25th October 2018. 14th-15th December 2018. 2. Poster presentation at the Annual National 6. Awarded 1st prize for oral presentation for Meet of the Foundation for Head and original article entitled “Incidence of level Neck Oncology (FHNO) and the IV metastases in early node negative oral International Federation of Head and Neck tongue cancer—is routine level IV Oncologic Societies (IFHNOS WORLD clearance justified” at World Cancer Day TOUR) held in Kolkata from October 25th- CME held on 4th-5th February 2019 at 28th 2018. CNCI. Dr. Kinshuk Chatterjee: Dr. Priyadarshan Kumar: 1. CME on Surgical Approaches to 1. Poster presentation at the Annual National Thyroid(CURE 2018) at TMC Kolkata on Meet of the Foundation for Head and 6th-7th April 2018. Neck Oncology (FHNO) and the 2. Attended a CME (ENT Enclave) on International Federation of Head and Neck Thyroid (ENT) at Novotel 15th September, Oncologic Societies (IFHNOS WORLD 2018. TOUR) held in Kolkata from October 25th- 28th 2018. 3. Poster presentation at the Annual National Meet of the Foundation for Head and Dr. Ankit Khandelwal: Neck Oncology (FHNO) and the 1. Poster presentation at the Annual National International Federation of Head and Neck Meet of the Foundation for Head and Oncologic Societies (IFHNOS WORLD Neck Oncology (FHNO) and the TOUR) held in Kolkata from October 25th- International Federation of Head and Neck 28th 2018. Oncologic Societies (IFHNOS WORLD 4. Attended hands on live surgical workshop TOUR) held in Kolkata from October 25th- on TORS/TOUSS at Apollo Gleneagles 28th 2018.

66

CNCI Annual Report 2018‐19 Hospital Wing

Gynecological Oncology

Head Dr. Ranajit Kumar Mandal Specialist Grade­I

Clinical activities Team During the period between 1st April 2018 and 31st March 2019 a total of 1246 new cases were Faculty registered in the Department. During the same Dr. Manisha Vernekar, Specialist Grade-II period a total of 2052 patients attended the OPD Dr. Dipanwita Banerjee, Specialist Grade-II for follow up visits. Junior Doctors The diagnoses of patients according to the site Dr. Amit Mandal, Sr. Resident are given in Table 1. Dr. Puja Chatterjee, Sr. Resident Dr. Debilina Roy, Sr. Resident Table 1: The number of new cancer Dr. Parmita Sinha, Jr. Resident cases attended OPD during 2018­2019

Type of cancer Number of new cases Percentage Objectives Cervix 472 48.5% • Diagnostic work up of women with Ovary 391 40.2% suspected gynaecological cancers Uterus 74 7.6% • Appropriate management through Vulva 25 2.6% surgery, chemotherapy and radiation Vagina 7 0.7% therapy and their combinations GTD 4 0.4% • Screening and early detection of Total 973 100.00% Gynecological cancers Distribution of new cases in OPD • Palliative treatment for gynecological 0.7% cancer patients 2.6% 0.4% • Generate trained human resources in early detection and effective management of 7.6% Cervix Gynecological cancers Ovary • To conduct research and training workshops in the field of Gynecological Uterus 48.5% Oncology Vulva

40.2% Vagina Work done GTD

67

CNCI Annual Report 2018‐19 Hospital Wing

The total number of patients admitted under the D/C Endometrial Biopsy 45 Department for treatment was 227. Vulval Biopsy 12 During 2018-19 a total 203 major surgical Wound debridement ± Secondary suturing 2 procedures were performed in the Department. The details of the procedures are given in Table Pleural Tapping 4 2. Vulval lipoma excision 1 Table 2: List of major surgeries in the Chest drain 3 Department during 2018­19 Cervical Pap Smear 19

Surgical Procedure Number Vaginal biopsy 2 Ca cervix 26 Urethral dilatation 1 Ca ovary 107 Vulval wart excision 2 Ca endometrium 26 Colposcopy 246 Ca vagina 2 Total 936 Uterine sarcoma 7 Virtual Tumour Board Ca Vulva 12 Actively participated and presented 5 cases for Debulking surgery in pseudomyxoma 1 virtual tumour board organized by National peritonei Cancer Grid. Emergency TAH for choriocarcinoma 1 Hernioplasty 3 Community Based Programs of the Department Burst Abdomen Repair 3 1. Integrated project on Non communicable Colostomy / ileostomy for intestinal 3 diseases (IPNCD) obstruction PI: Dr. Ranajit Mandal Colostomy reversal 1 The project started in May, 2017 to assess Oophorectomy in a case of Ca Breast 1 the feasibility of a comprehensive non Benign / pre‐cancerous lesion 10 communicable diseases screening Total 203 approach for women in collaboration with International Agency for Research on Cancer, WHO that includes cervical The total number of minor surgical procedures screening on self-collected vaginal carried out in the department was 936. The samples. Between April, 2018 to March, details are given in Table 3. 2019, total 5977 women aged between 30- Table 3: The list of minor surgeries in 60 years have been recruited in this project. Random capillary blood glucose, the Department during 2018­2019 Blood pressure monitoring, oral Surgical Procedure Number examination for tobacco habitués, awareness on breast cancer and self breast Cystoscopy 36 examination and lastly human Hysteroscopy + D/C Endometrial Biopsy 6 papillomavirus DNA (HPV DNA) Pyometra Drainage 16 detection test from self collected cervico vaginal samples were done in all women Cervical Biopsy 395 participated in the project. LEEP (Loop Electro‐surgical Excision 29 Procedure) 2. Feasibility and Acceptability of two dose Cryotherapy 6 quadrivalent Human papillomavirus Thermo Coagulation 106 vaccine for adolescent girls in rural parts Polypectomy + D/C Biopsy 5 of West Bengal- A pilot study 68 PI: Dr. Dipanwita Banerjee

CNCI Annual Report 2018‐19 Hospital Wing

The HPV screening and early diagnosis in low and vaccination middle income countries- Current project started Situation and future perspective. in July, 2017 is Bundessgesundheitsbl 2018 61: 1505-1512 a community (23rd October,2018) based HPV vaccine Book Chapter project. The 1. Dipanwita Banerjeee. Tumours of the project is the Cervix uteri: Jeffcoat’s Principle of first Gynaecology; Page 553-72,9th Edition, community 2018. ISBN: 9789352704774, Jaypee based demonstration project in eastern publishers India to assess the feasibility and acceptability of two dose HPV vaccination Other academic activities in rural population of West Bengal. Total 555 girls between 9-14 years were Paper presented recruited in this project and received their Dr. Puja Chatterjee: two dose vaccination till June, 2018. No serious adverse effects were reported. 1. Presented a paper entitled “Feasibility and compliance of Self-sampling for HPV The second phase of the study has been DNA detection in a cervical cancer started in association with Rotary screening project ” at 2nd Annual International Initiative, where a total 1000 conference on recent trends in Cancer girls between 9-14 years age will be Research, Early diagnosis , Prevention and vaccinated in next 9 months. The project Therappy on 4th February, 2019 held at started on 17th March, 2019 at the District CNCI and received the Second Prize for of South 24 Parganas, West Bengal. the same. Publications 2. Presented free communication (oral) titled “Association of Endometriosis with 1. Mittal Srabani Basu, P, Mandal Ranajit, Mullerian Anomalies- A Retrospective Ghosh Ishita, Banerjee Dipanwita & Panda Observational Study” in ICE 2019 Chinmay & Biswas J. Enablers and Barriers organised by “Endometriosis Society of Follow-Up Care: An Experience from an India”, endorsed by“ World Endometriosis HPV DNA Detection–Based Cervical Society ” & supported by Jaipur Obstetrics Cancer Screening Program in Rural India. & Gynnaecological Society from 8th to 10th Journal of Global Oncology. 00-00. March 2019 at B M Birla Auditorium, 10.1200/jgo.18.24200 (2018) Jaipur and stood Third in this Category. 2. Banerjee Dipanwita, Mandal Amit & Conference/Symposium/Workshop Chakraborty Rashmi. Bevacizumab in Gynaecological Malignancies: New Drugs attended in Obstetrics and Gynnaecology. April, Dr. Ranajit Kumar Mandal was: 2018. FOGSI Focus; April,2018 1. Invited Faculty for colposcopic training in 3. Banerjee Dipanwita Taghavi Katayoun, collaboration with IARC, Lyon, France at Mandal Ranajit, Maji Tapas et al. Nargis Dutt Memorial Cancer Hospital, Gynocular™ as a Field Colposcope: Real- Barsi, Maharashtra, 18-22nd February, life Experiences from a VIA and HPV 2019. DNA-based Cervical Cancer Screening Program in Rural India. Accepted in The 2. Organizing secretarry for the first meeting Journal of South Asian Federation of of Kolkata Gynaecological oncology-Trial Menopause Societies. 6. 52-56. 10.5005/jp- and Translational Research Group 2019 journals-10032-1136.2018 3. Invited Faculty in various national 4. Ranajit Mandal, Partha Basu. Cancer Conferences and workshops 2018-2019 including “BOGSCON 44”, “CME on 69

CNCI Annual Report 2018‐19 Hospital Wing

Preventive aspects of Gynaecology 3. DNB trainees of broad and super Oncology”, “2nd Annual conference on specialties of Gynaecology, Radiotherapy recent trends in Cancer Research, Early and Surgical Oncology are trained by diagnosis, Prevention and Therapy” and means of regular seminars, bedside “Updates in cervical cancer” lectures and demonstrations during surgical procedures, every year. Dr. Dipanwita Banerjee was: 1. Invited Faculty in various national Miscellaneous Conferences and workshops 2018-2019 Dr. Dipanwita Banerjee was: including “East zone Yuva FOGSI”,

“Updates in cervical cancer”, “KOLGO- 1. Member of FOGSI team of experts on TRG” ,All India ESIC Speciality developing good clinical practice Conference” and “BOGSCON-44” recommendations (GCPR) guidelines on cervical cancer screening relevant to 2. Organizing Secretary for “Preventive Indian women. aspects of Gynaecological Oncology”

CME under the aegis of AOGIN India in 2. Completed Cervical Cancer Prevention February,2019. and Colposcopy Training from The International Federation of Cervical Dr. Manisha Vernekar was: Pathology and Colposcopy(IFCPC) in 1. Faculty in various workshops and CME’s November,2018. in the field of Gynaecological Oncology, 2018-19 2. Attended the “9th Annual conference of AOGIN India September 2018” Dr. Puja Chatterjee was: 1. Part of organizing team of International Congress on Endometriosis(ICE), 2019. Training workshops 1. On Cervical pre cancer detection and management in collaboration with West Bengal Government, and IARC (International Agency for Research on Cancer) 27/6/18 and 28/6/2018 at CSS 2. Colposcopy workshop at CNCI on 21/4/2018 and 22/4/18.

70

CNCI Annual Report 2018‐19 Hospital Wing

Medical Oncology

Head Dr. Kalyan Kusum Mukherjee Specialist grade I

ward. Different non Govt. organization attended the paediatric patients in the ward through Team Counseling, Play therapy and with different self activities within the child. Faculty No. of paediatric patient admitted in Dr. Partha Nath, CMO Grade 203 paediatric ward Contractual Doctors Dr. Rajib Bhattacharjee, Consultant Total No. of new patient admitted 72 Dr. Shuvam Halder, Medical Officer No. of Total Paediatric Patient (OPD + IPD) 383 Junior Doctors Dr. Subhadeep Das, Sr. Resident Leukemia Dr. Sayani Bhanja, Sr. Resident Acute Lymphoblastic Leukemia 112 Dr. Avinandan Paul Chowdhary, Jr. Resident Dr. Azmal T, Jr. Resident Acute Myeloid Leukemia 02 Dr. Amaresh Roy, Jr. Resident Chronic Myeloid Leukemia 01 Lymphoma Work done Hodgkin’s disease 85 Treatment Report Non Hodgkin’s diseases 42 Paediatric Solid Tumor Patient Status Rabdomyosarcoma 7 Total no. patient attending the OPD in 1 Retinoblastoma 1 year (including new patients, Follow up and 16391 patients receiving chemotherapy) Ewing’s sarcoma 11 No. of new patient registered in the dept. 812 Osteosarcoma 17 Patient referred from other dept. for Wilm’s tumor 5 2001 chemotherapy Neuroblastoma 1 Total no. of patient in indoor 1781 Status of Total (Adult & Paediatric) No. of patient received treatment in day 6964 care services patients underwent treatment Leukemia Paediatric Oncology Acute Lymphoblastic 195 A new 9 bedded Paediatric Ward opened on 04- Myeloid 59 Feb-2013. Arrangement of modern treatment facilities with isolation care has been made in this Total 271 71

CNCI Annual Report 2018‐19 Hospital Wing

Other academic activities Chronic CML 209 Paper presented CLL 28 Total 251 1. Invited talk on “Immunology and Cancer” at “UGC-CPE sponsored International Lymphoma Conference on Facets of Basic Sciences & Hodgkin’s disease 221 Applications (FBSA)” organized by IQAC & Departments of Botany, Chemistry, Non Hodgkin’s diseases 329 Computer Science, Electronics and Zoology of Bijoy Krishna Girls College , Multiple Myeloma 121 Howrah.

Adult Solid Tumors Conference/Symposium/Workshop attended Gynecological Tumor Ovary 246 1. Participated as Chairperson on Annual Vulva 7 National Conference of FHNO at Hotel Cervix 26 Novotel, in 2018. GTT 16 2. Participated as Co-Ordinator for Workshop on Neoadjuvant Chemotherapy Other Primary site Head and neck tumor 403 in “Head & Neck Cancer” organized by Breast 637 FHNO in 2018 at CNCI. Lung 340 3. Participated as Course Co-Ordinator in the workshop on “Good Clinical Practice” Stomach 81 organized by “Novartis Healthcare Pvt. Esophagus 39 Ltd. and CNCI, at Chittaranjan National th Colorectum 107 Cancer Institute, dated 04 August 2018 in Kolkata. Anal canal 31 Training Program Gall bladder 221 DNB students of Radiotherapy attended Urinary Bladder 32 Medical Oncology Department Clinical Work Testis 59 on rotational basis in each year. Kidney 25

72

CNCI Annual Report 2018‐19 Hospital Wing

Medical Physics

Head Dr. Dilip Kumar Ray Physicist, Radiological Safety Officer

Brachytherapy machines, procurement and disposal of radioactive sources and Team finally ensuring radiation safety for the patient, staff and public and Physicists implementation of radiation protection Mr. Dillip Kumar Misra rules as per Atomic Energy Regulatory Mr. Atanu Kumar, Radiological Safety officer Board guidelines are some of the Mr. Rajib Das Mr. Bijan Kumar Mohanta important functions of the department. The department actively involves in Medical Physics Interns medical physics research, education and Ms. Poonam Ray training of medical and paramedical Mr. Chandan Bhattacharya Ms. Jayita Ghosh courses. International standards of Mr. Tarani Mondal dosimetry are maintained by participating Mr. Santanu Maity in international IAEA/BARC dose inter- comparison Programme. Medical Physics Students Mr. Manoj Mahato • This department is equipped with one Mr. Subhankar Sinha state of the art Dual Energy Linear Mr. Amit Mandal accelerator (ELEKTA Synergy) and one Ir- Mr. Santanu Bag Mr. Mehedi Hasan 192 HDR after-loading brachytherapy Ms. Sinjini Sengupta machine (Integrated brachytherapy unit). Mr. Avishek Adhikari The department is equipped with many Mr. Suman Joardar sophisticated equipments like treatment Mr. Sandip Goala planning systems TPS (CMS-XIO, Monaco, DRT Tech Students Oncentra), dosimeters and calibration Ms. Shrayashi Das instruments like Unidos E electrometers,3- Ms. Bipasha Ghosh D RFA water phantom(MP3-M,PTW), Mr. Pradip Mondal fluence analysis dosimetry system (2D Mr. Sourav Mondal array), Film dosimetry system etc. Ms. Swarnali Ray Ms. Fatema Khatun • The department is actively involved in Mr. Dhrubojyoti Ghosh dosimetry, data acquisition of various teletherapy machines like Telecobalt and linear accelerators. Treatment Planning Objectives and dosimetry verification of state of the art radiotherapy treatment techniques like • Radiation Treatment planning, accurate 3D conformal treatment with Multileaf and precise dose delivery to patient, collimator (MLC), Intensity Modulated radiation dosimetry, dose calculation, Radiation therapy (IMRT), Image guided Calibration, Quality Assurance, Radiation therapy (IGRT), Volumetric maintenance of the teletherapy and Modulated Arc therapy (VMAT) and SBRT 73

CNCI Annual Report 2018‐19 Hospital Wing

treatments. We also involve in e. Teaching faculty of Diploma in Radio Brachytherapy planning like ICRT, ILRT, therapeutic Technology (DRT-Tech) and Surface Mould and Interstitial Implants Diploma in Radio-diagnosis Technology (Head and Neck, Breast etc). This (DRD-Tech). department is responsible for calibration f. Internship in Medical Physics. and Quality assurance of the radiation g. Internship in DRT(Tech.) therapy machines. We are also involved in radiation protection and QA of X-Ray, h. Clinical training of DRT (Tech) students Mammography and CT-Scan of Radio- from other institutes. diagnosis department. Publications/Monographs/Patents • Our department runs Post M.Sc. Diploma etc. course in Medical Physics and actively involved in teaching of other courses like Thesis/ Publication DNB Radiotherapy, paramedical courses like DRT (Tech) and DRD (Tech) courses. 1. A thesis titled “A prospective This department is actively involved in observational study on image guidance research in Medical Physics. with cone beam CT for Intensity modulated radiotherapy for head and neck cancer “ was submitted by Dr. Priyanka Biswas (Guide: Dr. Debarshi Work done Lahiri Co-Guide: Dr. Sanjoy Roy, Dr. Dilip Kumar Ray) to National Board No. of External Beam Radiotherapy treatment 146 Examinations (NBE), New Delhi and was planning accepted by the NBE. No. of manual treatment calculation 1100 2. A thesis titled “A prospective comparative No. of Brachytherapy treatment plan 201 study on the three different dose No. of Brachytherapy treatment fractions 543 fractionation schedules of intracavitary No. of CT‐ simulation 93 high dose rate brachytherapy in the Quality Assurance tests, Radiation protection treatment of locally advanced cervical and e-LORA compliance as per AERB Guidelines carcinoma.” was submitted by Dr. Pinakin of the following machines: Thakorbhai Tandel (Guide: Dr. Kalyan Kusum Mukherjee Co-Guide: Dr. Tapas • One Linear Accelerator Maji, Dr.Dilip Kumar Ray) to National • Four 3D Treatment Planning System Board Examinations (NBE), New Delhi. • One Brachy therapy Machine 3. A thesis titled “A randomized comparative study of outcome of • One CT Simulator treatment for locally advanced head and • One Mammography neck squamous cell carcinoma treated by concurrent chemoradiation with • One X-ray machine. conventional fractionation vs accelerated Academic Activities: fractionation of External beam radiotherapy“ was submitted by Dr. a. Post M.Sc. Diploma course in Medical Srikanya Chavitipalli (Guide: Dr Tapas Physics in collaboration with Jadavpur Maji Co-Guide: Dr. Debarshi Lahiri, University. Dr. D. K. Ray is the Course Dr.Dilip Kumar Ray) to National Board Coordinator. Examinations (NBE), New Delhi. b. Ph.D Programme in Medical Physics 4. A thesis titled “Daily Low dose cisplatin under affiliation of West Bengal concurrent with Intensity Modulated university of Health Sciences. Radiotherapy in Ca cervix” is currently c. Teaching faculty of DNB Radiotherapy. being done by Dr Nitesh Anand (Guide : d. Teaching faculty of Ph.D course. Dr Tapas Maji Co-Guide: Dr. Debarshi 74 Lahiri, Dr.Dilip Kumar Ray).

CNCI Annual Report 2018‐19 Hospital Wing

5. A thesis titled “A study on high grade presented two Poster presentations in 39th glioma using Intensity Modulated Annual National Conference of Radiotherapy by Simultaneous Intensity Association of Medical Physicists of India Boost vs Sequential boost” is currently (AMPICON- 2018) held at Chennai Trade being done by Dr Patibandla Srikanth Center, Chennai from 02nd -4th November (Guide : Dr Tapas Maji, Co-Guide: Dr. 2018. Debarshi Lahiri ,Dr. Dilip Kumar Ray ). 4. Dr Dilip Kumar Ray acted as Chairperson 6. A thesis protocol “A prospective study on of scientific session in Annual Conference Image guidance with cone beam CT for on International day of Medical Physics 3DCRT of Cancer Cervix“ has been (IDMP) held at Medical College, Kolkata submitted by Dr Arya R M (Guide: Dr on November 07, 2018. Debarshi Lahiri Co-Guide : Dr.Kallol 5. Dr Dilip Kumar Ray & Shri Atanu Kumar Bhadra, Dr. Sanjoy Roy, Dr.Dilip Kumar Attended the KOLGOTRG Conference Ray, Mr. Dillip Kumar Mishra) to National (Kolkata Gynecological Oncology Trials & Board Examinations (NBE), New Delhi Translational Research group) held at and was accepted by the NBE. The study is Kolkata from 02nd March to 04th March being done. 2019. 7. A thesis protocol “Dose escalation in 6. Dr Dilip K.Ray & Shri Rajib Das attended a esophageal cancer by Simultaneous workshop ON Implementation & Quality Integrated Boost Intensity Modulated Assurance of Stareotaxy (WIQAS) held at Radiotherapy technique“ has been Narayana Super Specialty Hospitals, submitted by Dr Christine J Nongram Kolkata on 25th August, 2018. (Guide: Dr Tapas Maji Co-Guide : Dr. Debarshi Lahiri, Dr. Sanjoy Roy, Dr.Dilip 7. Shri Dillip Ku.Misra, Shri Atanu Kumar, Kumar Ray, Mr, Atanu Kumar ) to Shri Rajib Das & Shri Bijan Ku. Mohanta National Board Examinations (NBE), New attended the CME on Indian Society of Delhi Neuro-Oncology (ISNO),West Bengal Chapter followed by Proton Therapy Other academic activities Symposium held at Park Hotel, Kolkata on 02nd March ,2019. Poster presented 8. Dr Dilip Kumar Ray, Shri Dillip Kr. Misra,

1. Shri Bijan Kumar Mohanta attended & Shri Atanu Kumar, Shri Rajib Das & Shri th presented two Poster presentations in 39 Bijan Kumar Mohanta attended the Annual National Conference of Annual Conference on International day of Association of Medical Physicists of India Medical Physics (IDMP) held at Medical (AMPICON- 2018) held at Chennai Trade College, Kolkata on November 07,2018. Center, Chennai from 02nd -4th November 2018. 9. Dr Dilip Kumar Ray, Shri Dillip Kr. Misra, Shri Atanu Kumar, Shri Rajib Das & Shri Other awards or special achievements Bijan Kumar Mohanta participated in Installation and commissioning of 16 Slice 4D various Scientific Seminars & workshops CT Simulator (GE, OPTIMA 580W). Conducted by CNCI, Kolkata throughout the year. Conference/Symposium/Workshop attended Training Program 2. Dr. Dilip Kumar Ray, Participated in “1st • No. of candidates admitted in Post M.Sc. International Proton Therapy Educational Diploma Course in Medical Physics: 9 Programme” held on 2nd- 3rd November • No. of candidates passed Post M.Sc. 2018 at Chennai organised jointly by- Diploma Course in Medical Physics: 9 PTCOG and APCC. • No. of Ph.D Scholar: 1 3. Shri Bijan Kumar Mohanta attended & 75

CNCI Annual Report 2018‐19 Hospital Wing

• No. of Medical Physics Interns admitted: 5 B.K.Mohanta acted as examiner and paper setter of Post M.Sc. Diploma in Medical • No. of candidates admitted DRT-Tech Physics Course at Jadavpur University. course: 4 • Dr. Ray, Shri Kumar and Shri Das acted as • No. of candidates passed DRT-Tech internal Examiner for DRT (Tech) and course: 3 DRD (Tech) course. • No. of DRT (Tech) students admitted for • Dr. Ray also acted as External Examiner internship: 3 for Diploma in Radiotherapy Technology • Imparted clinical training to 10 DRT (DRT, Tech) course at R. G. Kar Medical (Tech.) trainees from various Govt. College, IPGMER Medical College and Medical Colleges of West Bengal. N.R.S. Medical College and hospital. He is guide of PhD scholar in Medical Physics Miscellaneous and co-guide of DNB Radiotherapy theses. • Shri Dillip Ku. Misra Appointed as an He also acted as Nodal Officer of CNCI at External Expert to meeting of Standing West Bengal University of Health Sciences Selection Committee for the post of for All India Survey on Higher Education Radiological Safety Officer on 17th January (AISHE), Ministry of Human Resource 2019 held at IGMS, Patna, Govt .Of Bihar. Development, Department of Higher Education, Govt. of India. • Dr. D. K. Ray, Shri D.K.Misra, Shri Atanu Kumar, Shri Rajib Das and Shri

76

CNCI Annual Report 2018‐19 Hospital Wing

Pathology

Head Dr. Saunak Mitra Mustafi Specialist Grade II(SG)

Mr. Samaresh Acharyya, Lab Technician Mr. Chirantan Pal, Lab Technician Team Mr. Swarnav Kundu, Lab Technician Faculty Dr. Srabanti Hajra, Specialist(GR II) Objectives Dr. Smita Gupta, Chief Medical Officer & In charge of Blood Bank • To provide precise histopathological/ Dr. Smarajit Pal, Biochemist & In charge of Clinical cytopathological / haematological Biochemistry Unit diagnoses for different tumours and to Junior Doctors provide correct pathological staging. Dr. Atreyo Roy Chowdhury, Senior Resident Dr Atreya Sarkar, Junior Resident, Blood Bank • To provide biochemical, haematological & clinicopathological diagnosis / follow up DNB-PGT in tumour and non-tumour cases. Dr. Susmitha Potti Dr. Komati Poornima • To provide safe blood (around 3000 units) Dr. Deepika Pandey for hospital in-patients (i.e., CNCI), Dr. Gaurav Singh Chittaranjan Seba Sadan & Sishu Sadan Dr. Hitesh Bucha Hospitals. Dr. Cheryl Mazumder Dr. Jebaunnesa Khatun • To run DNB Pathology Program (broad Dr. Swapnika Golla speciality) of Govt. of India. Supporting Staff • To pursue clinical research work in the Mr. Gobinda Baidya, Lab Technician Mr. Raja Ray, Lab Technician field of tumour pathology. Mr. Bhagwan Mishra, Lab Technician Mr. Indrajit Ghosh, Lab Technician Mr. Somnath Mondal, Lab Technician Mr. Tapas Dutta, Technician ‘A’ Work done Mrs. Purnima Panja, JSA Mr. Prodip Bala, JSA Clinical Biochemistry Unit Mr. Jagadish Mandal, JSA The unit of Clinical Biochemistry plays a very Mr. Tapas Debnath, JSA Mr. Krishnanu Seth, JSA important role in providing facilities of Mrs. Rakhi Das Majumder, JSA instrumental, technological and scientific. The Mr. Dinadandhu Das, SSA unit has been functioning with automated Mr. Debasish Roy Chowdhury, SSA sophisticated instruments to perform routine Mr. Purnendu Ray, GDA biochemical and electrolytes tests of patients Mr. Bhola Paul, Lab Helper attending indoor, outdoor and various clinics in Contractual this institute. Besides these activities this unit Dr. Subhasis Basu, Specialist also engaged in research work in collaboration Mr. Sougata Ghosh, Lab Technician with different departments/units. Clinical 77

CNCI Annual Report 2018‐19 Hospital Wing

Biochemistry unit is performing daily internal 10. Sternal Region 15 03 quality control as well as external quality control 11. Thyroid 21 15 (EQAS) collaboration with CMC Vellore. 12. Urogenital (Male) 20 11 Routine Investigations 13. Urogenital (Female) 75 42 14. Lung 20 03 Sl. Type of investigation Total No. 15. Lymph Node 165 62 No. 1. Sugar (Glucose) 8984 2. Urea 16013 Clinical Pathology 3. Creatinine 16023 4. Bilirubin (total) 14222 1. CBC 20425 5. Bilirubin (direct) 14222 2. Hb%, Total Count 1511 6. Alkaline phosphatase 14222 3. BT, CT 338 7. Alanine aminotransferase 14222 8. Aspartate aminotransferase 14222 4. Bone Marrow 08 9. Protein (total) 14230 5. Malaria Parasite 24 10. Albumin 14230 Total Number of Case 22306 11. Electrolytes (Sodium, Potassium & 9812 Chloride) Total No. of tests 150402 Blood Bank Total No. of patient attended 16967 Blood bank CNCI attended the outdoor voluntary blood donation camps for collecting Cytology blood units for the hospital. Collected blood units are processed as per drug control rule before FNAC Slide Review issuing the blood to the patients. Outdoor voluntary blood donation Malignant Benign 1. 49 camp attended 1. Breast 140 22 2. Voluntary blood collection 2734 units 2. ENT 76 11 3. Fluid 59 06 3. Indoor blood collection 20 units 4. Gallbladder 72 04 4. Blood supplied 2551 units 5. G.I. Tract 35 02 Supplied blood units which received 5. 50 units 6. Liver 59 03 from CBB 7. Oral / Mouth 49 04 6. Requisition served 1747 8. Pancreas 15 03 9. Sternal Region 09 02 Histopathology 10. Thyroid 33 06 11. Urogenital Male 16 07 Malignant Benign 12. Lung 147 05 Breast 837 75 13. Lymph Node 122 17 14. Urogenital Female 60 17 Uterus 351 59 15. Omentum 01 ‐ Cervix 545 83 16. Scalp 01 ‐ ENT 215 26 17. Limb 24 05 Lung 188 15 Lymph Node 379 119 FNAC slides of CNCI Oral& Mouth 884 73 GI Tract 703 53 Malignant Benign Ovary 196 48 1. Breast 115 70 Thyroid 89 21 2. ENT 55 20 Vault & Vagina 86 19 3. Fluid 102 68 Head & Neck 120 26 4. Gallbladder 81 15 Genito Urinary 225 27 5. G.I. Tract 22 03 Gynaecology 88 19 6. Liver 85 04 Bone & Connective Tissue 195 21 7. Oral / Mouth 61 15 Eye 16 01 78 8. Pancreas 16 ‐ Skin 22 07

CNCI Annual Report 2018‐19 Hospital Wing

Gallbladder 120 14 Conference on Renal Pathology held from Others 0 0 17th - 19th June 2018, at Kolkata. Brain 32 02 3. Dr. Srabanti Hajra attended the Pathology Liver 36 03 Conference on Frozen Section-, held from Kidney 09 0 5th – 7th October 2018.at Sir H. Reliance Pancreas 16 04 Hospital Mumbai Pituitary Gland 0 03 Fluid 09 03 4. Dr. Srabanti Hajra attended the 3rd Total 5361 721 International Pediatric Pathology CME 2019 held from 18th - 20th January, 2019 at Publications/Monographs/Patents Tata Medical Center, Kolkata. etc. 5. Dr. Atreyo Roy Chowdhury attended the CAPPCON 2018 “Conference on Breast & 1. Mustafi SM, Murmu N, Biswas N, Ray S, Uropathology Update” held from 17th to Majumder B, Mitra D, Banerjee S, 18th Nov 2018 at Hotel Golden Tulip, Bhattacharya S. 2018. Reversing effect of Kolkata. Lupeol on Vasculogenic mimicry in murine melanoma progression. 6. Dr. Atreyo Roy Chowdhury attended the Microvascular Research, 1, 77. International Pediatric Pathology CME 2019 on Pediatric Pathology held from 18th 2. Mustafi SM, Ray S, Bhattacharya S, Sen S, - 20th January, 2019 at Tata Medical Center, Mandal S, Murmu N. 2019. Alterations in Kolkata. biomarkers associated with oral squamous cell carcinoma and lymph node metastasis Miscellaneous due to chronic exposure to chewing • National Board of Examinations inspected tobacco. Pathology and Oncology Research, the Department in 2017 and has renewed 19, 224. the accreditation from January 2017 to Other academic activities December 2020. • The Department of Pathology, CNCI Conference/Symposium/Workshop conducted Formative Assessment Test attended (Practical) on 05th March 2019 for Kolkata 1. Dr. Smarajit Pal attended the 45th National DNB Pathology institutes. Conference (ACBIOCON) of Indian • Two primary and two secondary seats Association of Clinical Biochemist as Chair have been allotted to this department per person in the Symposia of Clinical year. Biochemistry held from 24th to 27th November, 2018 at Kala Academy, Goa. 2. Dr. Srabanti Hajra attended the Pathology

79

CNCI Annual Report 2018‐19 Hospital Wing Radiation Oncology

Head Dr. Tapas Maji Specialist Grade I (SAG)

under department of Radiation Oncology including management during course of Team radiotherapy and chemotherapy, overseeing the treatment planning, Faculty evaluation, implementation and their Dr. Debarshi Lahiri, Specialist Grade II (SG) follow-up, decision making and Dr. Kallol Bhadra, Specialist Grade II implementation of treatment options Contractual Doctors regarding clinical management of cancer Dr. Sanjoy Roy, Specialist patients including comprehensive Junior Doctors multidisciplinary cancer care and Dr. Palas De, Senior Resident participation in the institutional joint Dr. Ashish Upadhyay, Senior Resident tumor boards. Dr. Mohammad Rizwan, Junior Resident • The department along with the medical Radiotherapy Technician physics team is actively involved in Mr. Barun Roy Chowdhury delivery of different radiation modalities Mr. Tapas Kar Mr. Manas Chakraborty including radical, palliative and Mr. Koushik Ghosh prophylactic treatments for various Mr. Prashanta Kumar Ray tumors. DNB Trainees • The department is equipped with one state Dr. Sri Kanya Chavitipalli of the art Dual Energy Linear accelerator Dr. Pinakin Thakorbhai Tandel (ELEKTA Synergy) with electron beam Dr. Priyanka Biswas treatment facility, one 16 slice CT Dr. Nitesh Anand Dr. Patibandla Srikanth simulator and one Ir-192 HDR after- Dr. Christine J Nongram loading brachytherapy machine Dr. Arya R M (Integrated brachytherapy unit). Besides these, there are two bunkers ready and DRT Tech Students Ms. Shrayashi Das, 2nd year acquisition of one low energy Linear Ms. Bipasha Ghosh, 2nd year accelerator and one Telecobalt machine is Mr. Pradip Mondal, 2nd year under process. Mr. Sourav Mondal, 2nd year Ms. Swarnali Ray, 1st year Ms. Fatema Khatun, 1st year Mr. Dhrubojyoti Ghosh, 1st year Work done Ms. Nasrin Khan, 1st year Total no. of Radiotherapy beds 37 General/Free 21 Objectives Subsidized 16 • Comprehensive management of patients 80

CNCI Annual Report 2018‐19 Hospital Wing

Total no. of Indoor admissions 359 Subsidized 3483 General/Free 240 Subsidized 119 New Cases Planned for External Beam 652 Radiotherapy (Computerized + Manual) OPD attendance 11619 Brachytherapy cases: ICRT for Cervix, 201 Vagina and Endometrial cancers General/Free 8136 No. of CT‐Simulation 93 Subsidized 3483 One new 16 slice 4D‐CT Simulator (GE, Optima 580w) installed in October, 2018 OPD attendance 11619 General/Free 8136 Details of category of new cases received for treatment by the department of Radiotherapy from the existing departments of the institute (Surgical Oncology, Medical Oncology, ENT H & N Oncology and Gynecological Oncology): Main site of cancer Sub sites/Cancer type/Organ‐wise Total number of Referred from the distribution (No. of cases) cases department Skin ‐ 4 Surgical Oncology Surgical Oncology & Head & Neck 128 ENT Surgical Oncology & Lung ‐ 30 Radiation Oncology Breast ‐ 169 Surgical Oncology Esophagus (9) Surgical Oncology Stomach (6) Surgical Oncology G.I System Colo rectal (24) 44 Surgical Oncology Anal Canal (5) Surgical Oncology Hepatobilliary & Gall B (0) Surgical Oncology Cervix uteri (156) Gynecological oncology Endometrium (22) Gynecological oncology Vulva (1) Gynecological oncology Vault (3) Gynecological oncology Gynae/Genitourinary Vagina (1) 205 Gynecological oncology System Kidney (2) Surgical Oncology Urinary bladder (3) Surgical Oncology Surgical Oncology & Prostate (18) Radiation Oncology Hodgkin’s Lymphoma (2) Medical Oncology Lymphoma & Hematological Non‐Hodgkin Lymph (6) Medical Oncology 31 Malignancies Myeloma / Plasmacytoma (2) Medical Oncology Leukemia (21) Medical Oncology Primary tumors of Central Radiation Oncology and Brain & Spinal Cord 21 Nervous System Surgical Oncology Soft Tissue Sarcoma ‐ 15 Surgical Oncology Unknown Primary ‐ 5 All departments

81

CNCI Annual Report 2018‐19 Hospital Wing

6. A thesis protocol “A prospective study on Publications/Monographs/Patents Image guidance with cone beam CT for etc. 3DCRT of Cancer Cervix“ has been submitted by Dr Arya R M (Guide: Dr Thesis publication Debarshi Lahiri Co-Guide : Dr.Kallol 1. A thesis titled “ A prospective Bhadra, Dr. Sanjoy Roy, Dr.Dilip Kumar observational study on image guidance Ray, Mr. Dillip Kumar Mishra) to National with cone beam CT for Intensity Board Examinations (NBE), New Delhi modulated radiotherapy for head and and was accepted by the NBE. The study is neck cancer “ was submitted by Dr. being done. Priyanka Biswas (Guide: Dr. Debarshi 7. A thesis protocol “ Dose escalation in Lahiri Co-Guide: Dr. Sanjoy Roy, Dr. Dilip esophageal cancer by Simultaneous Kumar Ray) to National Board Integrated Boost Intensity Modulated Examinations (NBE), New Delhi and was Radiotherapy technique“ has been accepted by the NBE. submitted by Dr Christine J Nongram 2. A thesis titled “A prospective comparative (Guide: Dr Tapas Maji Co-Guide : Dr. study on the three different dose Debarshi Lahiri, Dr. Sanjoy Roy, Dr.Dilip fractionation schedules of intracavitary Kumar Ray, Mr, Atanu Kumar ) to high dose rate brachytherapy in the National Board Examinations (NBE), New treatment of locally advanced cervical Delhi. carcinoma.” was submitted by Dr. Pinakin Thakorbhai Tandel (Guide: Dr. Kalyan Other academic activities Kusum Mukherjee Co-Guide: Dr. Tapas DNB/PhD/Other degrees, if any, Maji, Dr.Dilip Kumar Ray) to National awarded Board Examinations (NBE), New Delhi. 1. Dr. Sayoni Bhanja, Dr. Deepsikha Goyel A thesis titled “A randomized 3. and Dr. Srikrishnadevarayulu Rangineni comparative study of outcome of successfully passed DNB treatment for locally advanced head and Radiotherapy from this institute. neck squamous cell carcinoma treated by concurrent chemoradiation with Conference/Symposium/Workshop conventional fractionation vs accelerated attended fractionation of External beam radiotherapy “was submitted by Dr. 1. Dr. Tapas Maji participated as faculty and Srikanya Chavitipalli (Guide: Dr Tapas chaired various academic sessions in the Maji Co-Guide: Dr. Debarshi Lahiri, Dr. Foundation for Head and Neck Oncology Anup Kumar Bhowmick, Dr.Dilip Kumar Conference, 2018 and also in the Annual Ray) to National Board Examinations Conference of Indian Society of Neuro (NBE), New Delhi. Oncology Conference, 2019. 4. A thesis titled “Daily Low dose cisplatin 2. Dr Debarshi Lahiri and Dr Kallol Bhadra concurrent with Intensity Modulated attended “Controversies in Clinical Radiotherapy in Ca cervix” is currently Oncology “, organised by Tata Medical being done by Dr Nitesh Anand (Guide : Center, Kolkata held in July 2018 Dr Tapas Maji Co-Guide: Dr. Debarshi 3. Dr. Tapas Maji, Dr. Debarshi Lahiri, and Lahiri, Dr.Dilip Kumar Ray). Dr. Sanjoy Roy attended the FHNO & 5. A thesis titled “A study on high grade IFHNOS Head & Neck Oncology Summit glioma using Intensity Modulated Experts’ Evidence, Consensus Guidelines th th Radiotherapy by Simultaneous Intensity held in Kolkata from 26 to 28 October Boost vs Sequential boost” is currently 2018. being done by Dr Patibandla Srikanth 4. Dr. Sanjoy Roy attended the “Updates in (Guide : Dr Tapas Maji, Co-Guide: Dr. Lung Cancer” held in December, 2018 at 82 Debarshi Lahiri, Dr. Dilip Kumar Ray).

CNCI Annual Report 2018‐19 Hospital Wing

BKC, Mumbai. 6. Internship in Medical Physics. 5. Dr. Sanjoy Roy, Dr. Kallol Bhadra and Dr. Miscellaneous Palas De attended the “Apollo Cancer Conclave 2019” held from 25 to 27th 1. Dr. Tapas Maji attended as invited external January 2019 at ITC Grand Chola, examiner for MD Radiotherapy Chennai. examination at PGIMER, Chandigarh in December, 2018 6. Dr Kallol Bhadra attended a National Conference – “Young Radiation 2. Dr. Debarshi Lahiri was nominated as Oncologist Conference, 2019” as faculty member of the Academic Committee of the held at Siliguri, West Bengal research wing of the institute. Training Program 3. Dr Tapas Maji attended DNB FAT 2018 practical examination as Examiner held at 1. DNB Radiotherapy affiliated to National Chittaranjan National Cancer Institute. Board of Examinations (NBE), New Delhi. 4. Dr. Debarshi Lahiri attended DNB FAT 2. Diploma in Radio therapeutic Technology 2018 Practical Examination as Exam (DRT-Tech) and Diploma in Radio- Coordinator held at Chittaranjan National diagnosis Technology (DRD-Tech). Cancer Institute. 3. Internship in DRT(Tech.) 5. Dr. Sanjoy Roy and Dr. Kallol Bhadra attended DNB FAT 2018 Practical 4. Clinical training of DRT (Tech) students Examination as Examiner held at from other institutes. Chittaranjan National Cancer Institute. Teaching faculty of Post M.Sc. Diploma 5. course in Medical Physics.

83

CNCI Annual Report 2018‐19 Hospital Wing

Radiodiagnosis

Head Dr. Suparna Mazumder Specialist Grade­I

FNAC, biopsy, drainage. vi) Review reporting of imaging (CT/ MRI) Team done outside. Contractual Doctor vii) CT SCAN started from month of Dr. Srabanti Roychoudhury, Radiologist NOVEMBER 18. Junior Doctors Dr. Pooja Shaw, Junior Resident Supporting Staff Work done Mr. Alok Roy, Technician Mr. Kamal Ghosh, Technician Ultrasonography & Mammography Mr. Debapratim Das, Technician Month Number USG‐ USG‐ Other MMG USG of Abdomen Small Parts/ Guided Patient Parts Doppler FNAC Objectives Apr18 403 170 156 52 51 78 May18 429 146 60 142 50 59 • The department is a vital link providing Jun18 339 172 121 72 23 48 diagnostic support to all the departments in the hospital wing. It plays an important role Jul18 390 232 150 46 42 46 in patient care services and management – Aug18 352 164 132 82 30 80 both routine and emergency, of new cancer Sep18 373 192 140 82 39 61 cases as well as those on follow-up by helping Oct18 270 133 77 63 21 48 in early detection, diagnosis, intervention, Nov18 400 227 110 58 28 55 prognosis and follow-up. Dec18 387 201 123 55 19 55 • The current radiological facilities include the Jan19 259 140 88 37 18 32 following services: Feb19 383 208 129 75 28 64 Mar19 393 168 150 62 32 52 i) X-ray – Three units, one for general Grand radiography, one for fluoroscopy and 4378 2153 1436 826 381 678 Total special procedures and one mobile X-ray at ITU. ii) Computerisd Radiography system with laser camera for digital films.

iii) Ultrasonography- Two units: one B & W, one colour Doppler. iv) Mammography unit (analogue model). 84 v) Guided (USG) interventions such as USG Doppler Study Mammography

CNCI Annual Report 2018‐19 Hospital Wing

Computed Tomography Scans Conferences attended by Dr. Suparna Month No of Patient Brain Body Total Mazumder Days Case 1. One day CME 22.04.18 by IRIA (WB Nov 18 8 31 19 37 56 Branch, Kolkata). Dec 18 23 151 82 219 309 Jan 19 24 253 169 338 507 2. Peerless Breast Imaging Update, 05.05.18, Kolkata Feb 19 24 254 135 379 514 Mar 19 24 231 92 378 470 3. 73rd Annual State Conference of IRIA Total 920 497 1351 1856 (West Bengal Branch), Kolkata. On 6 and 7 October, 2018.

4. 72nd Annual Conference of IRIA, PGIMER, Chandigarh, 17 to 20 January, 2019.

5. 1st Annual Meeting of KolGOTrg, 2 to 4 March, 2019, Kolkata. Training Program 1. DNB faculty

2. PhD program faculty Computed Tomography Scan 3. DRD (Tech) & DRT (Tech)- these are two X Rays year Diploma courses for paramedical Month Chest X‐Ray Others Special training run under the aegis of West Investigations Bengal State Medical Faculty. All the Apr 18 363 76 7 members of the Department are actively May 18 384 80 9 involved in various capacities. Jun 18 328 58 6 4. Clinical Trials: CT imaging review for, Jul 18 364 90 9 breast, lung cancers, & colorectal cancers Aug 18 345 52 6 etc for departments like medical oncology, Sep 18 337 70 4 gynae oncology & others as per RECIST Oct 18 258 53 1 criteria are being done actively. Nov 18 347 65 1 Future Upgradation plans Dec 18 318 48 4 Jan 19 320 66 3 1. Digital mammography Feb 19 325 71 3 2. Digital radiography Mar 19 333 66 6 Total Case 4022 795 59

Fibular Osteosarcoma 85

CNCI Annual Report 2018‐19 Hospital Wing

Surgical Oncology

Head Dr. Jayanta Chakrabarti Director

also. We are conducting DNB Surgical Oncology Course to train future Team oncosurgeons. Faculty Various Types of Surgeries Dr. Neyaz Alam, Specialist Grade-I G.I. and G.U. Head and Neck Breast Others Dr. Sagar Sen, Specialist Grade-II Dr. Sandip Swarup Mandal, Specialist Grade-II Whipple’s Commando Modified Surgery for Dr. Souradip Gupta, Specialist Grade-II procedure operation for radical various Dr. Indranil Ghosh, CMO - NFSG various types mastectomy peripheral Dr. Durgaprasd Nanda, SMO of oral cancers soft tissue sarcomas Junior Doctors Radical Various Beast Lobectomy Dr. Soham Bhattacharjee, Senior Resident gastrectomy reconstructive conservation for lung Dr. Somdeep Ghosh, Senior Resident procedures surgeries cancers Dr. Atharva Pintu Thakur, Junior Resident Hemicolectomy, Thyroidectomy Various Dr. Pragati Singh, Junior Resident APR and LAR reconstructive Dr. Mizan Ahmed, Junior Resident procedures for Dr. Abhirup Ghose, Junior Resident breast Dr. Nashreen, Junior Resident reconstruction DNB PDT Radical Parotidectomy Amputation Dr. Arghya Basu cholecystectomy Dr. Suvendu Majhi Radical nephrectomy Transthoracic and Microvascular trans hiatal flaps for Objectives oesophagectomy advanced reconstruction • To provide the patients best possible after head and treatment with highest level of neck surgery professionalism and recent developments Radical in the field of oncology and protocol based cystectomy and management. many others • Surgical oncology is one of the most important departments in the treatment of cancer. We are dealing with surgery of Work done solid tumours. The department is striving to keep itself up-to-date with the recent Cases attended in OPD advances in the field of oncology for better New patients 5877 patient care. Follow‐up patients 21457 • The Department of Surgical Oncology is 86 maintaining high standards in academics

CNCI Annual Report 2018‐19 Hospital Wing

Surgeries done 7. Kumar N., Prasad P, Jash E, Jayasundar S, Singh I, Alam N, Murmu N, Somashekhar Total number of minor surgeries 1589 SP, Goldman A, Sehrawat S 2018, cAMP Total number of major surgeries 758 regulated EPAC1 supports microvascular density. Angiogenic and metastatic

properties in a model of triple negative Gastrointestinal & Genitourinary surgeries 275 breast cancer, CarcinogenesisOct Head and neck surgeries 257 2018,39(10):1245-1253 Breast cancer surgeries 208 Other academic activities Others 18 Paper presented Publications/Monographs/Patents 1. Dr. Souradip Gupta presented a paper on etc. Variation of Vascular Anatomy of ALT Flap in APSICON, 2018, Lucknow. 1. Sen. S, Gajagowni J.G. , Pandey J.K., Dasgupta P., Sahni A, Gupta S, MP S., Ravi Poster presented B. 2019, Effectiveness of pectoralis major 1. Dr. Sagar Sen presented a poster on myocutaneous flap in the surgical Spindle cell sarcoma of left ileum - a management of oral cancer: A diagnostic dilemma and a treatment retrospective studyJ Stomatol Oral challenge, at IMSOS (Indian MaxillofacSurg120(1):21-27 Musculoskeletal Oncology Society) 2. DasguptaP.,Sen S., Srikanth H.S., Kamath National Conference 8-10th March 2019, G. 2018 Sella Turcica Bridging As A Kolkata. Predictor Of Class II Malocclusion–An Investigative Study J Stomatol Oral Conference/Symposium/Workshop MaxillofacSurg119(6):482-485 attended 3. Maji, S., Ghosh, I. 2018 Ameloblastic 1. Dr. Jayanta Chakrabarti attended Workshop Fibrosarcoma in Pregnancy: an on Neo Adjuvant Chemotherapy in Head & Unreported Entity Indian J Neck Cancer conducted under FHNO th SurgOncol Volume 10, Issue 1, pp 180– &IFHNOS at CNCI-Kolkata, 25 Oct 2018. 183 2. Dr. Jayanta Chakrabarti attended 18th 4. MAJI, S.; GHOSH, I. 2018 Recurrent FHNO (Foundation for Head & Neck Neuroglycopenia: Do Not Forget Non-islet Oncology) National Conference at Kolkata th th Cell Induced Tumor 26 - 28 October 2018. Hypoglycemia. Middle East Journal of 3. Dr. Sagar Sen attended the Good Clinical Cancer, [S.l.], v. 9, n. 4, p. 344-347, Practice Training Workshop At 5. Bhattacharjee P.K., Nanda D.P. 2018 Chittaranjan National Cancer Institute, prospective observational Study on Kolkata on 4th Aug 2018. Cholelithiasis in Patients with Carcinoma 4. Dr. Sagar Sen attended Workshop On Neo Gall Bladder in a Tertiary referral Hospital Adjuvant Chemotherapy in Head & Neck in Eastern India Cancerjournal.net vol XX, Cancer conducted under FHNO issue XX. &IFHNOS at CNCI-Kolkata, 25th Oct 2018. 6. Sahu S.K., Nanda D.P., Mandal S.S., 5. Dr. Sagar Sen Invited as Faculty at Chakraborty J., 2019, A Prospective Study SASICME -2018 SEPT, Kolkata. of Early Postoperative Course and Pathological Outcome of Modified D2 6. Dr. Sagar Sen attended 18th FHNO Gastrectomy- A Single Institute (Foundation for Head & Neck Oncology) Experience, IOSR-JDMS, vol 18, issue 4 National Conference at Kolkata 26th- 28th ser.14, 47-58 October 2018. 87

CNCI Annual Report 2018‐19 Hospital Wing

7. Dr. Sagar Sen attended National Training FHNO &IFHNOS at CNCI-Kolkata, 25th Programme on - ‘Good Clinical Practice, Oct 2018. Current regulatory and ethical 10. Dr. Sandip Swarup Mandal attended 18th requirements for conducting clinical FHNO (Foundation for Head & Neck trials/research in India including Oncology) National Conference at Kolkata Schedule Y’ held at Clinical Development 26th- 28th October 2018. Services Agency (CDSA), THSTI on December 04-05, 2018. 11. Dr. Sandip Swarup Mandal attended DaVinci Xi Simulator Training - ROBO- Dr. Sagar Sen attended DaVinci Xi 8. Onco-Con, Max Institute of Cancer Simulator Training - ROBO-Onco-Con, Max Care,New Delhi. 03 Feb 2019. Institute of Cancer Care,New Delhi. 03 Feb 2019. 12. Dr. Suvendu Majhi Attended the symposium on “Passive Euthanasia & Dr. Sandip Swarup Mandal attended 9. Humane end Of Life care” by the West Workshop On Neo Adjuvant Chemotherapy in Bengal Society for The study of Pain, at Head & Neck Cancer conducted under Kolkata.

88

CNCI Annual Report 2018‐19 Hospital Wing

Pain and Palliative Care

Head Dr. Ranajit Kumar Mandal Specialist Grade­I

• Is applicable early in the course of illness, in conjunction with other therapies that Team are intended to prolong life, such as chemotherapy or radiation therapy, and Faculty includes those investigations needed to Dr. Debasish Jatua, Senior Medical Officer better understand and manage distressing Palliative Care Consultant clinical complications. Dr. Prabir Chaudhuri The patients experience pain often at presentation, sometimes during treatment and even during post treatments follow up as Objectives a sequential result of the treatment or as a result of treatment failure rather with the • Palliative care improves the quality of life further progress of the disease. The efficient of patients and families who face life- and judicious management of pain at any threatening illness, by providing pain and stage thus helps to reduce the pain and symptom relief, spiritual and psychosocial improves the QOL of the sufferer. With a well support to from diagnosis to the end of life designed target, the functioning of this unit is and bereavement. Palliative care: continued with the regular supply and • Provides relief from pain and other distribution of Morphine tablets at free of cost distressing symptoms and with all the supportive care (wound care, lymphedema care, psychosocial counseling, • Affirms life and regards dying as a normal music therapy and home based care) as process applicable in individual cases at this institute. • Intends neither to hasten or postpone death • Integrates the psychological and spiritual Work done aspects of patient care The number of new patients attending this unit is • Offers a support system to help patients gradually increasing. In house patients are also live as actively as possible until death attended on their needs. Approximately 85075 tablets of Morphine [10 mg (SR & IR) & 30 mg- • Offers a support system to help the family SR] have been supplied to the patients of this cope during the patients illness and in institute during the last one year to meet the their own bereavement challenge of pain management effectively and • Uses a team approach to address the needs adequately. The Fentanyl patches of 25 and 50 of patients and their families, including mcg and Buprenorphine patches (10mcg) are also bereavement counseling, if indicated. distributed to the needy patients free of cost. • Will enhance quality of life, and may also The unit OPD is functional thrice in a week, on positively influence the course of illness Mondays, Wednesday and Saturdays and also in 89

CNCI Annual Report 2018‐19 Hospital Wing

the other working days of a week when specially The total home based Palliative care services required. A full Counseling only clinic is provided to the needy and deserving patients operated on Thursday of every week with the free of cost are 150 including Bereavement care assistance of an NGO. A total number of 520 for 23 families from the period of April 2018 to patients have been newly registered in the unit March 2019 around Kolkata and adjacent area. during the period between April’ 2018 and Approximately 119 patients received March’ 2019.The unit also have treated 1425 of Lymphedema Care between April’ 2018 and old/follow up cases during the year. Total March’ 2019 number of cases during the year is 1945. Among We are getting the active support of this NGO at these the total number of patients, who were this institute OPD thrice in a week as a routine. provided psychosocial counseling, is 710. The They are also providing the medicines to the patients are tabulated according to the site of poor patients free of cost. Around 103 patients malignancy as below: were benefitted from such initiative. Thus Distribution of Total cases improving the QOL of the patients concerned. A more pragmatic approach has been started in Disease Site Total cases the way of Music Therapy with the help of Ruma Head & Neck 887 Abedona Hospice to the terminally ill patients Thorax 287 and till date total13 patients are included in this Abdomen 290 approach between April’ 2018 and March’ 2019 Gynaecological sites 285 with satisfactory result in most of the cases. Genito Urinary 75 Misc. malignancies 121 Seminars/Workshops Total 1945 One Work shop on “Right to natural Death and Passive Euthanasia” was held at the auditorium Ruma Abedona Hospice of the Chittaranjan National Cancer Institute in Ruma Abedona Hospice, a city based NGO has collaboration with ‘West Bengal Society for study started functioning in this institute since of Pain’ on Saturday the 23rd June, 2018, with June’13.This NGO helps the patients of this Padma Shree Dr M R Rajagopal as the Chief hospital and their care givers with careful and Guest Speaker. effective counseling as and when required. With The workshop had an attendance of more than the help of this NGO, we have started with home 120 eminent physicians, nurses, social workers & based Palliative care services to the needy and Psychologists and was covered by the leading deserving patients free of cost. This organization press media of Kolkata. offers healthy dressings of the wounds of the patients under care of the Palliative care unit effectively under close supervision of the doctors.

90

CNCI Annual Report 2018‐19 Hospital Wing

Medical Records

Head Dr. Syamsundar Mandal Statistical Officer

1. Number of new cancer patients registered for treatment during 2018-19 Team Male Female Total In-Charge 4482 (48.6%) 4738 (51.4%) 9220 Sanmoy Chakraborty, ALIO Supporting Staff 2. Number of cancer patients admitted for Dr. Kausik Ray, Junior Scientific Assistant treatment during 2018-19

Male Female Total Objectives 3033 (50.9%) 2923 (49.1%) 5956 • To maintain the medical records of the 3. Number of new & old cases attended at patients who come for their treatments to OPD during 2018-19 the hospital of this institute. Male Female Total • To provide medical records of the patients 30891 (51.2%) 29443 (48.8%) 60334 to the departments related to patients’ services and research. 4. Total number of hospital deaths during 2018-19: 313 Projects running (Extramural)

1. “Hospital Based Cancer Registries and Pattern of Care and Survival Studies on Cancer Breast, Cancer Cervix and Head & Work done Neck Cancers” supported by National The statistical information related to the Centre For Disease Informatics and patient-services provided by the Medical Research, National Cancer Registry Records Unit during the period 2018-19 are as Programme, Indian Council of Medical follows:- Research (ICMR).

91

CNCI Annual Report 2018‐19 Hospital Wing

Dietetics

Head Ms. Paromita Das Dutta Dietitian

Special Food is arranged for all festivals for the indoor patients admitted in CNCI (in addition to Objectives the usual food supplied) like Durga Puja, Id, 23rd & 26th January, 15th August, Christmas etc. • Diet Therapy has an immense evidenced role in treatment as well as prevention of Management Activities cancer. The Department of Dietetics was • meal planning started in the year 1997 to make Diet Therapy an integral part of treatment in • training new workers this hospital. This Dept. is run • Supervising workers to plan, prepare and singlehandedly by Ms. Paromita Das serve meals Dutta, Dietitian, since its inception. • Inspection of the prepared meals • Assessment of meals in terms of quality Work done and quantity At present 11 types of diet are supplied to the • Inspection of Kitchen (outside Hospital patients to cater to the different requirements. Premises) at regular intervals The details are as follows: Sl. Type of Diet Total Quantity of Administrative Activities No. Diet supplied per day (average) • Preparation of Tender Papers. 1. Normal Non‐ vegetarian 106 • Convener of Diet Committee. 2. Normal vegetarian 1 3. Diabetic Non‐ vegetarian 12 • Maintaining records and preparation of 4. Diabetic vegetarian ‐ reports and everything pertaining to 5. Normal Liquid 21 patients’ diet. Normal High Protein 6. 5 Non‐ vegetarian • Checking safety and cleanliness rules are Normal High Protein 7. ‐ being strictly followed. vegetarian 8. Liquid High Protein 2 • Checking, verification and certifying 9. Liquid Diabetic 1 Monthly Diet Bills. 10. Pediatric Diet 9 11. Pre‐op/ light diet ‐ Clinical Activities

• Providing foods that provide the correct Apart from the above 11 types of diet supplied nutrients for patients, in close coordination from hospital scale, special therapeutic diets are with doctors and health care workers. planned for patients with special dietary needs and are supplied accordingly. • Based on patients' health and nutritional 92 information, developing diets.

CNCI Annual Report 2018‐19 Hospital Wing

• Changing the diet according to the since 2008. patients’ need. Ms. Paromita Das Dutta has delivered lectures • Doing Nutritional Assessment, Nutrition and radio talks on various occasions at different Prescriptions, daily Ward Rounds and forums. She is a regular speaker for different OPD clinics. electronic media on nutrition and health related issues. She has been registered as a Reviewer of • Issuing Home Diet Charts to discharged “Food & Nutrition Research”, a peer-reviewed patients and preparing Special Therapeutic journal that presents the latest scientific research Diet Charts. in various fields focusing on human nutrition. The journal publishes both quantitative and Other Activities qualitative research papers. Ms. Paromita Das Dutta is the founder Secretary Ms. Paromita Das Dutta is a regular Guest of a voluntary nonprofit professional association Faculty for P.G. Diploma in Dietetics and Master “Society for Nutrition & Dietetics” founded in Degree Courses at All India Institute of Hygiene 2012. She was the Organizing Secretary of the 5th and Public Health under West Bengal University Annual Conference on of Health Sciences and PG Diploma Course in “Recent Perception in Nutrition and Dietetics for Gerontology & Age Management recognized by Combating Chronic Diseases” organized by University of Calcutta. She acts as the External Society for Nutrition and Dietetics. Ms. Das Examiner of P.G. Diploma in Dietetics and Dutta is the Honorary Secretary of International Master Degree Courses under West Bengal College of Nutrition, Calcutta Chapter, a University of Health Sciences. voluntary nonprofit professional association

93

CNCI Annual Report 2018‐19 Hospital Wing

Division of Preventive Oncology

Head Dr. Ranajit Kumar Mandal Specialist Grade­I

1746 (35%) and 1106 (18%) women were recruited respectively. Work done Preventive Oncology Services at The Ruplal Distribution of Age Nandy Memorial Cancer Research Centre (RNMCRC), Hooghly has been temporarily suspended during the year 2018-19 due to major 19% 30‐39 civil work. However, Preventive Oncology 40‐49 services were rendered from CNCI, Kolkata 29% 52% 50‐60 campus as follows. Community Based Programs of the Department Figure 1: Age distribution of women recruited 1. Integrated project on Non communicable diseases (IPNCD) Marital Status PI: Dr. Ranajit Mandal Married Widowed Separated The project started in May, 2017 to assess the feasibility of a comprehensive non 5% communicable diseases screening approach for women in collaboration with International Agency for Research on Cancer, WHO that 28% includes cervical screening on self-collected 67% vaginal samples. Between April, 2018 to March, 2019, total 5977 women aged between 30-60 years have been recruited in this project. Random capillary blood glucose, Blood pressure monitoring, oral examination for Figure 2: Marital Status of Women tobacco habitués, awareness on breast cancer and self breast examination and lastly human b. Out of 5977 women, 734 women (12.2%) had a papillomavirus DNA (HPV DNA) detection blood pressure out of reference range (> test from self collected cervico vaginal 140/90 mmHg) and were referred to the samples were done in all women participated nearest sub divisional hospital/ Medical in the project. Following were the key College for further management. Total findings of the project. number of high random blood sugar a. Majority of women participated are between (RBS>160 mg/dl) was 279 (4.66%). Majority 30 to 39 years age group (N=3125, 52%). of these women were known hypertensive 94 Between 40-49 years and 50-60 years of age and/diabetic but did not continue their

CNCI Annual Report 2018‐19 Hospital Wing

prescribed medications. All these women colposcoppy examination followed bby cervical were followed up after 1 month. The newly punch biopsy by trained doctors of the diaagnosed case of hypertension and diabetes department of Gynaecological Oncology, were 185 and 110 respectively. CNCI. Total 394 (6.6%) women are HPV Distribution of women detected with positive till date, out of which 261(66.2%) abnormal CBG and BP women had their colposcopy and biopsy followed by treatment. The histopathology distribution of the HPV DNA positive cases are described in Figure 5. The rate of detection 279 734 of Cervical intra epithelial neoplasia (CIN ) 1, 2 and 3 are 29, 11 and 5 respectivelly and also received treatment either by Thermocoagulation, Cryotherapy or loop RBS>160 BP> 140/90 mm Hg electrosurgical excision procedure (LEEP). 3 invasive cancer cervix cases were referred to c. Maintaining proper privacy, the women were CNCI and received appropriate treatment by encouraged to do self sampling of vaginal chemoradiation therapy. swabs in the outreach clinics. The samples Histopathology Distribution of HPV were brought back to CNCI and were tested DNA positive cases in the CNCI laboratory for high risk Normal CIN I CIN II CIN III INV. Ca oncogenic HPV DNA detecting 13 types of 2% 1% 5% HPV causing cervical cancer. Total 10 cases of breast lump and / nipple discharge and 5 cases of oral ulcer has been picked up and 14% were referred to CNCI for further evaluation Pending (Figure 4). Total 1 woman had squamous cell biopsy carcinoma of buccal mucosa and received report = 33 78% treatment from CNCI, whereas 2 breast lump cases received surgical management. Rest of

the women with abnormal breast/ oral Figure 5: Histopathology distribution of the HPV DNA findings were managed conservatively. The positive cases women attendingn these outreach clinics were provided with free iron, calcium, vitamin, Distribution of Treatment Received albendazole tablets and also received treatment of other reproductive tract 200 infections. 150 261 100

N= 50 Test Results for Cervix, Breast and Oral 0 Cancer Detection and Screening Therm Cryo LEEP RH RT o Coagu lation Series1 198 5 55 2 1 N=5977 Figure 6: Treatment received

HPV Breast Oral 2. Feasibility and Acceptability of two DNA lump/D Ulcer dose quadrivalent Human positive ischarg e papillomavirus vaccine for adolescent Series1 394 10 5 girls in rural parts of West Bengal­ A pilot study Figure 4: Number of HPV positive cases, symptomatic Breast lump/ discharge and Oral ulcers PI: Dr. Dipanwita Banerjee d. All HPV positive women were recalled to The HPV vaccination project started in July, these outreach clinics and undergone 2017 is a community based HPV vaccine 95

CNCI Annual Report 2018‐19 Hospital Wing

project. The project is the first community reported. based demonstration project in eastern India The second phase of the study has been to assess the feasibility and acceptability of started in association with Rotary two dose HPV vaccination in rural population International Initiative, where a total 1000 of West Bengal. Total 555 girls between 9-14 girls between 9-14 years age will be years were recruited in this project and vaccinated in next 9 months. The project received their two dose vaccination till June, started on 17th March, 2019 at the District of 2018. No serious adverse effects were South 24 Parganas, West Bengal.

96

CNCI Annual Report 2018‐19 ANNEXURE Running Projects

Extramural Projects structure-function relationship P.I.: Dr. Tapasi Das 1. Development of an advanced class of multi- Funding agency: DHR-ICMR modality nanoparticle for progressive cancer 9. Elucidation of the role of tumor residing therapy immune suppressor cells in generation of P.I.: Dr. Supratim Ghosh multi drug resistance in murine lymphoma Funding agency: DST with immune modulation by Neem Leaf Glycoprotein (Azadirachta indica) 2. A Way to Overcome Chemo-Resistance in P.I.: Dr. Rathindranath Baral Colorectal Cancer Stem Cells: Therapeutic Targeting By Natural Falvonoid Orientin Co-P.I.: Dr Swapan Kumar Ghosh P.I.: Dr. Prosenjit Saha Funding agency: DBT, Govt. of West Bengal Funding agency: DBT 10. Understanding of the intra/extra-tumoral trafficking of mesenchymal stem cells and 3. Evaluation of chemotherapeutic efficacy of modulation of its immunosuppressive rutin during metastasis by targeting EMT character by neem leaf glycoprotein and Anoikis P.I.: Dr. Rathindranath Baral P.I.: Dr. Prosenjit Saha Funding agency: ICMR Funding agency: ICMR 11. Targeting glycolytic pathway through redox- 4. Modulation of Therapeutic Targets Aurora active metal chelates to overcome multi-drug A and B by phytochemicals in breast cancer resistance (MDR) in cancer cells P.I.: Dr. Soumitra Kumar Choudhuri P.I.: Dr. Sutapa Mukherjee Funding agency: ICMR [74/10/2014-Pers. Joint P.I.: Dr. Madhumita Roy (EMS)] Funding agency: DST 12. Environmental regulation on T cell 5. A comparative study of the population development and autoimmunity chronically exposed to arsenic in two P.I.: Dr. Subhasis Barik different demographic regions of Eastern India: Identification of responsible genes Funding agency: DBT-Ramalingaswami Re- and susceptible population Entry Fellowship 2017-2018 (D.O. No. th P.I.: Dr. Madhumita Roy BT/HRD/35/02/2006 dated 19 November 2018) Funding agency: DBT-Twining 13. Identification of novel candidate gene(s) 6. Understanding the role of T cell subset(s) in associated with the development of uterine regulation of cancer initiating stem like cells cervical carcinoma P.I.: Dr. Anamika Bose P.I.: Dr. Chinmay Kumar Panda Funding agency: DST-WOS Funding agency: CSIR 7. Studies on the role of cancer-associated 14. Study on MAD and BUB1 genes of Spindle adipocytes in progression of mammary Assembly Checkpoint with response to carcinogenesis in relation to obesity: primary adjuvant chemotherapy in advanced Emphasis on Immune Evasion ovarian cancer patients P.I.: Dr. Sudeshna Mukherjee P.I.: Ms. Sinjini Sarkar Funding agency: DST-SERB Mentor: Dr. Vilas D. Nasare 8. An attempt to characterize the protein and Joint P.I.: Dr. Madhumita Roy carbohydrate moieties of Neem Leaf Funding agency: Department of Health Glycoprotein with special emphasis on Research i

ANNEXURE CNCI Annual Report 2018‐19

15. MicroRNAs as prognostic biomarkers of diseases (IPNCD) chemoresistance and chemosensitivity in PI: Dr. Ranajit Mandal ovarian cancer patients undergoing combinational therapy 26. Feasibility and Acceptability of two dose quadrivalent Human papillomavirus vaccine P.I.: Ms. Ranita Pal for adolescent girls in rural parts of West Mentor: Dr. Vilas D. Nasare Bengal- A pilot study Funding agency: DST PI: Dr. Dipanwita Banerjee 16. A pharmacogenetics study on cytochrome 27. “Hospital Based Cancer Registries and P450 enzyme and transporter gene Pattern of Care and Survival Studies on implicated in response to paclitaxel, Cancer Breast, Cancer Cervix and Head & cisplatin, and 5-fluorouracil in oral cancer Neck Cancers” patients Supported by National Centre For Disease P.I.: Dr. Vilas D. Nasare Informatics and Research, National Cancer Funding agency: ICMR Registry Programme, Indian Council of Medical Research (ICMR). 17. Investigation of PIM1/STAT3 association as a regulator of EMT in triple negative breast 28. Integrated project on Non communicable cancer diseases (IPNCD) P.I.: Dr. Sutapa Mahata PI: Dr. Ranajit Mandal Mentor: Dr. Vilas D. Nasare In collaboration with International Agency for Funding agency: Department of Health Research on Cancer, WHO Research 29. Feasibility and Acceptability of two dose 18. Redox regulation of nuclear factor erythroid- quadrivalent Human papillomavirus vaccine 245 (NF-E2) related factor Nrf2 in lung for adolescent girls in rural parts of West cancer by green and black tea polyphenols: Bengal- A pilot study Implication in cancer therapeutics PI: Dr. Dipanwita Banerjee P.I.: Dr. Dona Sinha Funding agency: ICMR Intramural Projects 19. Exploration of the role of diallyl disulphide on EMT in A549 lung cancer cells 1. Project Title: Development of novel organo- P.I.: Dr. Dona Sinha metallic complex for acute leukemia treatment Funding agency: SERB, DST P.I.: Dr. Supratim Ghosh 20. Molecular signaling mechanism in oral cancer: Effect of Lupeol in oral squamous 2. Therapeutic efficacy of eugenol thorough cell carcinoma at transcription and post- induction of apoptosis in Ehrlich Ascites transcription level Carcinoma (EAC) cell line P.I.: Dr. Nabendu Murmu P.I.: Dr. Prosenjit Saha Funding agency: SERB 3. Alteration of cancer stem cell self-renewal pathway by xanthone from ancient

21. Comparative evaluation of prevalence and medicinal plant Swertia Chirata clearance of HPV in uterine cervix of asymptomatic Indian population and P.I.: Dr. Prosenjit Saha cervical carcinoma patients 4. Prevention of Lung cancer by eugenol and P.I.: Dr. C K Panda its effect on modulation of Cancer Stem Cell 22. PBCR and PBCS, Kolkata P.I.: Dr. Prosenjit Saha 23. HBCR and POCSS, CNCI 5. Chemopreventive potential of xanthone isolated from Swertia chirata against DMBA 24. Rural PBCR, Daspur-II, Paschim Medinipur induced mouse skin carcinogenesis model ii 25. Integrated project on Non communicable P.I.: Dr. Prosenjit Saha

CNCI Annual Report 2018‐19 ANNEXURE

6. Evaluation of chemopreventive and This collaborative project is running with therapeutic efficacy of naturally occurring Mitra Biotech, Bangalore. phytochemicals by targeting stem cell self renewal pathways in vivo and in vitro experimental models Student Projects P.I.: Dr. Subhadip Hajra 1. Studies on tumor induced thymic atrophy in 7. Black tea in prevention of skin cancer: A mice in relation to T cell differentiation and mechanistic study death: Critical modulation by Neem Leaf P.I.: Dr. Madhumita Roy Glycoprotein 8. Phenethylisothiocyanate: Role in enhancing Name of the Student: Ipsita Guha platinum accumulation in cervical cancer Funding agency: CNCI P.I.: Dr. Sutapa Mukherjee 2. Analysis of tumor-induced regulator of G- 9. Prevention of arsenic induced renal protein Signaling 5 (RGS5) mediated carcinogenesis by black tea alterations in tumor pericytes: Therapeutic modulation by Neem Leaf Glycoprotein P.I.: Dr. Madhumita Roy Name of the Student: Shayani Dasgupta 10. Study on dynamic regulation of insulin and Funding agency: UGC Dopamine in dermal wound healing and bone tissue regeneration in normal and 3. Studies on the mechanism of Neem Leaf diabetic condition Glycoprotein (NLGP) mediated down- P.I.: Dr. Biswarup Basu regulation of VEGF in tumors: Special emphasis on HIF degrading pathway 11. Identification of the causal involvement of Name of the Student: Akata Saha HPV through assessment of oncogenic and proliferative markers, apoptosis and content Funding agency: CNCI/CSIR assay in cervical pre-neoplastic lesions for 4. Studies on tumor induced homing of risk categorization mesenchymal stem cells in tumor draining P.I.: Dr. Vilas D. Nasare lymph nodes and its consequences on tumor progression: Modulation by Neem Leaf 12. Impact of low level arsenic on airways of Glycoprotein exposed population: study on cell survival and proliferative signaling Name of the Student: Partha Nandi P.I.: Dr. Dona Sinha Funding agency: DST 13. Study on Wnt Pathways as the Signaling 5. Intervention by neem leaf glycoprotein on Hallmarks of Progressive OralSquamous the initiation-promotion protocol during 4- Cell Carcinoma in Tobacco and Betel Quid nitroquinoline-1-oxide mediated tongue users carcinogenesis: Special emphasis on epithelial mesenchymal transition P.I.: Dr.Nabendu Murmu Name of the Student: Juhina Das 14. Study to decipher the molecular basis for Funding agency: DBT protein-protein interactive (PPI) network in Hepatitis B virus (HBV) induced 6. Identification of signaling gateway of neem hepatocellular carcinoma (HCC) with special leaf glycoprotein on macrophages and emphasis on the role of HBV x protein dendritic cells P.I.: Dr. Avik Biswas Name of the Student: Nilanjan Ganguly Funding agency: CSIR Collaborative Project 7. Understanding the mechanism of cancer progression in tumor hosts with type I/type 1. ACCEPT- Accelerated CANScript® -Enabled II diabetes with reference to alteration in Personalized Treatment Study to measure cancer immune-surveillance: Correction by predictive power of CANScript®for NLGP chemotherapeutics in Breast cancer iii

ANNEXURE CNCI Annual Report 2018‐19

Name of the Student: Anirban Sarkar P.I.: Dr. Chinmay Kumar Panda Funding agency: UGC Funding agency: DST-INSPIRE 8. Understanding the role of T cells in 15. Anti-cancer effects of Holarrhena regulation of cancer stem cells: Influence of antidysenterica derived triterpene NLGP driven immunomodulation compounds Name of the Student: Mohona Chakrovarti Name of the Student: Dr. Anindita Ghosh Funding agency: UGC Funding agency: DST- Women scientist scheme (A) 9. Study of the role of tumor residing Immunosupressor cells of the generation of 16. Exploration of the role of diallyl disulphide multidrug resistance in murine lymphoma on EMT in A549 lung cancer cells with the immunomodulation by Neem Leaf Name of the Student: Dr. Bornita Das Glycoprotein Mentor: Dr. Dona Sinha Name of the Student: Sukanya Dhar Funding agency: SERB, DST Funding agency: DST 17. Molecular Signalling Mechanism of Risk 10. Understanding the influence of Factor Induced Carcinogenesis in Head and cardiovascular disease-linked statin(s) Neck Cancer: Synergistic Effect of Lupeol treatment on cancer immunoediting process: and Ionizing Radiation at Post-Transcription Modulatory role of Neem Leaf Glycoprotein Level in Head and Neck Cancer Cells Name of the Student: Aritra Gupta Name of the Student: Mr. Sayantan Funding agency: CSIR Bhattacharyya 11. Molecular analysis of alterations in Funding agency: DST-INSPIRE chromosome 3 in Bladder carcinoma of 18. HGF/cMet and EGFR Signaling in Oral Indian patients Squamous Cell Carcinoma and Lymph Node Name of the Student: Ms. Mukta Basu Metastasis: Effect of Lupeol on these P.I.: Dr. Chinmay Kumar Panda Signaling Pathways in vitro Funding agency: UGC-NET Name of the Student: Ms. Sudipta Ray 12. Analysis of alterations of Wnt and hedgehog Funding agency: UGC pathways during development of head and 19. Study of mTOR and its downstream target neck squamous cell carcinoma (HNSCC) molecules in Gastric cancer patients sample; Name of the Student: Mr. Balarko the effect of chemopreventive agents in Chakrobarty Gastric carcinoma cell line and In-vivo model P.I.: Dr. Chinmay Kumar Panda Name of the Student: Ms. Paramita Ghosh Funding agency: UGC-NET Funding agency: UGC 13. Analysis of stem cell renewal Notch1 pathway alterations during development of 20. The role of environmental cxarcinogens in head and neck squamous cell carcinoma of male infertility and testicular cancer: The Indian patients phytochemicals, targeting the therapeutic machinery of pre-cancerous cellular Name of the Student: Ms. Debalina conditions Mukhopadhyay Name of the Student: Ms. Sreyashi Mitra P.I.: Dr. Chinmay Kumar Panda Funding agency: CNCI Funding agency: DST- Women scientist scheme (A) 21. The role of Ephrin and HGF/cMet pathway in regulating vasculogenic mimicry in Breast 14. Analysis of DNA modifying and DDR cancer and possible effects of (DNA damage response) genes associated phytochemicals with the development of uterine cervical carcinoma (CACX) Name of the Student: Mr. Debarpan Mitra iv Name of the Student: Ms. Priyanka Dutta Funding agency: CNCI

CNCI Annual Report 2018‐19 ANNEXURE

22. Molecular signaling mechanism in oral P.I.: Dr. Kalyan Kusum Mukherjee cancer: Effect of Lupeol in oral squamous 3. A global, multicentre, three arms, open-label cell carcinoma at transcription and post- randomized study to evaluate the efficacy transcription level and safety of Nanosomal Docetaxel Lipid Name of the Student: Ms. Depanwita Saha Suspension compared to Taxotere® Funding agency: SERB (Docetaxel Injection Concentrate) in triple- negative breast cancer patients with locally 23. Study on Wnt Pathways as the Signaling advanced or metastatic breast cancer after Hallmarks of Progressive Oral Squamous failure to prior chemotherapy. (Ongoing- Cell Carcinoma in Tobacco and Betel Quid Indian) users P.I.: Dr. Kalyan Kusum Mukherjee Name of the Student: Ms. Moumita Sil Funding agency: CNCI 4. A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity 24. Regulatory roles of RNA Binding Proteins in of K0706, a Novel Tyrosine Kinase Inhibitor Human Breast Carcinoma (TKI), in Subjects with Chronic Myeloid Name of the Student: Ms. Naazneen Khan Leukemia (CML) or Philadelphia Funding agency: DST-INSPIRE Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (Global-Ongoing)

25. Studies on tumor induced thymic atrophy in P.I.: Dr. Kalyan Kusum Mukherjee mice in relation to T cell differentiation and death: Critical modulation by Neem Leaf 5. A Randomized, Double-blind, Multi-center, Glycoprotein Multi-national Trial to Evaluate the Efficacy, Name of the Student: Dr. Gangotree Mohanty Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line P.I.: Dr. Chinmay Kumar Panda Immunotherapy Treatment in Patients with Funding agency: CSIR (Research Low Tumor Burden Follicular Associateship) Lymphoma.(Global-Ongoing) P.I.: Dr. Kalyan Kusum Mukherjee Clinical Trials 6. Multicentre, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy 1. A Randomized, Multiple-dose, Multicenter, and Safety of MYL-1402O Compared With and Comparative Parallel Study to Evaluate Avastin®, in the First -line treatment of the Efficacy, Safety and Pharmacokinetic Patient with Stage IV Non-Squamous Non- Characteristics of Intravenous Infusion of Small Cell Lung Cancer. (Ongoing- Global) Trastuzumab (Hetero) and Reference P.I.: Dr. Kalyan Kusum Mukherjee Medicinal Product (HERCEPTIN® - Trastuzumab, Genentech, Inc.) in 7. A Multi-Centre, Randomized, Double Blind, combination with standard chemotherapy in Parallel-Group, Comparative Clinical Trial Patients of HER2-positive Metastatic breast to evaluate the Safety and Clinical cancer. (Ongoing- Indian) Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique P.I.: Dr. Kalyan Kusum Mukherjee Pharmaceutical Laboratories, India) to 2. Randomized, Assessor-Blind, Multicentre, Clotrimazole Troche/Lozenges ® 10mg Parallel Group, Two Arms, Clinical Study to (Roxane Laboratories Inc., USA) in subjects Assess the Efficacy, Pharmacokinetics, with Oropharyngeal Candidiasis”. Pharmacodynamics, Immunogenicity and (Ongoing- Global) Safety of Rituximab (Test Product, Zydus) in P.I.: Dr. Kalyan Kusum Mukherjee comparison with Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL). (Ongoing- Indian)

v

ANNEXURE CNCI Annual Report 2018‐19 Publications

1. Upasana Das1, Aditi Sahoo2, Subhas 8. Roy M, Sarkar R, Mukherjee A, Mukherjee S Haldar3, Shyam Sundar Mandal1, Sudin & Biswas J (2018) Phytochemicals as Bhattacharya1, William H. Gmeiner4, Chemosensitizers in Breast Cancer; Cancer Supratim Ghosh1* “Secondary Structure Cell Chemoresistance and Dependent Physicochemical Interaction of Chemosensitisation. Chapter 6, pg 129-162. Oligonucleotides With Gold Nanorod and Publisher: World Scientific Publishing, Photothermal Effect for Future Applications: Singapore, edited by Dr Ajaikumar B. A New Insight” ACS omega 3 (10), 14349- Kunnumakkara, Bordoloi Devivasha, 14360. Monisha Javadi. 2. Barua A, Choudhury P, Maity JK, Mandal 9. Mukherjee S, Mukherjee A, Biswas S, Roy M SB, Mandal S, Saha P. 2019. (2018). Apoptosis: A Regulatory Mechanism Chemotherapeutic potential of novel non- in Cancer: Rediscovering Cancer: From toxic nucleoside analogues on EAC ascitic Mechanism to Therapy, Part I, Chapter 3; pg tumour cells. Free Radic Res. 53(1):57-67. 201-222. ISBN No 978-1-77188-690-1 (Apple Academic Press). 3. Pattanayak R, Barua A, Das A, Chatterjee T, Pathak A, Choudhury P, Sen S, Saha P, 10. Roy M and Mukherjee S (2019) Black Tea Bhattacharyya M. 2018. Porphyrins to restrict Extract prevents 4-nitroquinoline 1-oxide progression of pancreatic cancer by induced oral tumorigenesis in mice by stabilizing KRAS G-quadruplex: In silico, in targeting Protein Tyrosine Kinases and vitro and in vivo validation of anticancer associated biological response, Available strategy. Eur J Pharm Sci. 125:39-53. online at www.sciencerepository.org, Clinical and Oncology Research, 2(1): 2-7. 4. Hajra S, Patra AR, Basu A, Saha P, Bhattacharya S. 2018. Indole-3-Carbinol (I3C) 11. Ghosh A, Mukherjee A, Mukherjee S and enhances the sensitivity of murine breast Roy M (2019) Role of Black Tea in prevention adenocarcinoma cells to doxorubicin (DOX) of Skin Carcinogenesis, LAP LAMBERT through inhibition of NF-κβ, blocking Academic Publishing. angiogenesis and regulation of mitochondrial 12. Mukherjee A, Mukherjee S and Roy M (2019) apoptotic pathway. Chem Biol Interact. Curcumin plays a dual role: in adjuvant 290:19-36. therapy and reversal of drug resistance in 5. Hajra S, Patra AR, Basu A, Bhattacharya S. Acute Myelogenous Leukemia, International 2018. Prevention of doxorubicin (DOX)- Journal of Current Medical and induced genotoxicity and cardiotoxicity: Pharmaceutical Research, 5(02A), 4078-4084. Effect of plant derived small molecule 13. Ghosh S, Choudhury S, Mukherjee S, Gupta indole-3-carbinol (I3C) on oxidative stress P, Chowdhury O, Baral R, Chattopadhyay S. and inflammation. Biomed Pharmacother. (2018) Fluoxetine triggers selective apoptosis 101:228-243. in inflammation-induced proliferating (Ki-67 6. Mukherjee A, Mukherjee K K, Mukherjee S high) thymocytes, Immunology & Cell and Roy M (2018) Curcumin may enhance Biology. Wiley Online Library. the efficacy of anti-leukemia drugs in doi.org/10.1111/imcb.12227 Myeloid Leukemia. Int. J. Curr. Microbiol. 14. Ghosh S, Jawed J, Halder K, Banerjee S, Paul App. Sci 7(5): 3274-3283. Chowdhury B, Saha A, Juin S, Bhattacharyya 7. Mukherjee S, Roy M, Biswas J (2018). Majumdar S, Bose A, Baral R, Majumdar S. Oncogenesis and Telomerase Activity in (2018) TNFα mediated ceramide generation Cancer: Rediscovering Cancer: From triggers cisplatin induced apoptosis in Mechanism to Therapy, Part I, Chapter 3; pg B16F10 melanoma in a PKCδ independent 21-58. ISBN No 978-1-77188-690-1 (Apple manner. Oncotarget, 9(102), p.37627. Academic Press). vi 15. Patra AR, Roy SS, Basu A, Bhuniya A,

CNCI Annual Report 2018‐19 ANNEXURE

Bhattacharjee A, Hajra S, Sk UH, Baral R, metastasis: Random or evolving paradigms? Bhattacharya S. (2018) Design and synthesis Pathol Res Pract. 214(8):1064-1073, 2018. of coumarin-based organoselenium as a new 23. Pal D, Sur S, Roy R, Mandal S, Panda C. K.: hit for myeloprotection and synergistic Epigallocatechin gallate in combination with therapeutic efficacy in adjuvant therapy. Sci eugenol or amarogentin shows synergistic Rep, 8, 2194. chemotherapeutic potential in cervical cancer 16. Maity P, Bepari M, Pradhan A, Baral R, Roy cell line. J Cell Physiol. doi: S, Maiti Choudhury S, (2018) Synthesis and 10.1002/jcp.26900, 2018. characterization of biogenic metal 24. Sultana Z, Bankura B, Pattanayak AK, nanoparticles and its cytotoxicity and anti- Sengupta D, Sengupta M, Saha ML, Panda C. neoplasticity through the induction of K, Das M. Association of Interleukin-1 beta oxidative stress, mitochondrial dysfunction and tumor necrosis factor-alpha genetic and apoptosis. Colloids Surf B Biointerfaces polymorphisms with gastric cancer in India. 161, 111-20. Environ Mol Mutagen. 59(7):653-667, 2018. 17. Miller MM, Barik S, Cattin-Roy AN, Ukah 25. Dasgupta H., Islam Md. S., Alam N., Roy A., TK, Hoeman CM and Zaghouani H. A new Roychoudhury S., Panda C. K.: Induction of IRF-1-driven apoptotic pathway triggered by HRR genes and inhibition of DNMT1 are IL-4/IL-13 kills neonatal Th1 cells and associated with Anthracycline antitumor weakens protection against viral infection. antibiotic tolerant Breast Carcinoma cells. Journal of Immunology. 2019 (In press). Molecular and Cellular Biochemistry, (2018 18. Barik S, Cattin-Roy AN, Miller MM, Ukah Sep 3). doi: 10.1007/s11010-018-3442-5. TK, Zaghouani H.IL-4 and IL-13 Guide Early 26. Dasgupta H., Islam Md. S., Neyaz N., Roy A., Thymic Progenitors To Mature toward Roychoudhury S., Panda C. K.: Dendritic Cells. Journal of Immunology. Hypomethylation of Mismatch Repair genes 2018, 201(10):2947-2958. MLH1 and MSH2 is associated with 19. Kaur P, Sharma AK, Nag D, Das A, Datta S, chemotolerance of breast carcinoma: Clinical Ganguli A, Goel V, Rajput S, Chakrabarti G, significance. J. Surg. Oncol. (2019 Jan); Basu B, Choudhury D. Novel nano-insulin 119(1):88-100. doi: 10.1002/jso.25304. formulation modulates cytokine secretion 27. Roy R., Pal D., Sur S., Mondal S., Saha P., and remodeling to accelerate diabetic wound Panda C. K.: Pongapin and Karanjin, healing. Nanomedicine 15(1):47-57, 2019. furanoflavanoids of Pongamia pinnata, 20. Muthuraman, S, Sinha S, Vasavi CS, Waidha induce G2/M arrest and apoptosis in cervical KM, Basu B, Munussami P, Balamurali cancer cells by differential ROS modulation, MM, Doble M, Saravana Kumar R. Design, DNA damage and NF-κB signalling. synthesis and identification of novel Phytotherapy Research (2019 March); coumaperine derivatives for inhibition of https://doi.org/10.1002/ptr.6302. human 5-LOX: Antioxidant, 28. Ghosh D, Mahata S, Sahoo P K, Sarkar S, pseudoperoxidase and docking studies. Roy A, Datta K, Mandal S, Nasare V D. 2019, Bioorg Med Chem. 15;27(4):604-619, 2019. Socio-Demographic characteristics and use of 21. Das A, Narayanam MK, Paul S, Mukherjee PAP smear screening among women of P, Ghosh S, Dastidar DG, Chakrabarty Eastern part of India. Indian J of Gynec S, Ganguli A, Basu B, Pal M, Chatterji Oncol 17:58. U, Banerjee SK, Karmakar P, Kumar 29. Prasad P, Vasas A, Hohmann J, Bishayee A, D, Chakrabarti G. A novel triazole, NMK-T- Sinha D*. Cirsiliol suppressed epithelial to 057, induces autophagic cell death in breast mesenchymal transition in B16F10 malignant cancer cells by inhibiting γ-secretase- melanoma cells through alteration of mediated activation of Notch signaling. J Biol PI3K/AKT/NF-κB signaling pathway. Int J Chem. 26;294(17):6733-6750, 2019. Mol Sc. 2019; 20 (3):608. [IF: 3.687] 22. Bhattacharya R, Panda C. K., Nandi S, 30. Das B, Sarkar N, Bishayee A, Sinha D*. Mukhopadhyay A. An insight into Dietary phytochemicals in the regulation of vii

ANNEXURE CNCI Annual Report 2018‐19

epithelial to mesenchymal transition and 38. Saswati Gharami, Krishnendu Aich, Deblina associated enzymes: A promising anticancer Sarkar, Paramita Ghosh, Nabendu Murmu therapeutic approach.Semin Cancer and Tapan Kumar Mondal. 2019. An ESIPT Biol.(accepted) doi: based chromogenic and fluorescent 10.1016/j.semcancer.2018.11.007. [Epub ratiometric probe for Zn2+ with imaging in ahead of print] 2018. [IF: 10.198] live cells and tissues. New Journal of Chemistry. 43, 1857-1863. 31. Das B and Sinha D*. Diallyl disulphide http://dx.doi.org/10.1039/C8NJ04695F suppresses the canonical Wnt signaling pathway and reverses the fibronectin- 39. Ghosh P, Mitra D, Mitra S, Ray S, Banerjee S, induced epithelial mesenchymal transition of Murmu N. Madhucaindica inhibits breast A549 lung cancer cells. Food Funct. 2019; cancer cell proliferation by modulating COX- 10(1):191-202.[IF: 3.289] 2 expression. 2018 December.CurrMol Med. doi: 10.2174/1566524019666181212100808. 32. Sarkar N and Sinha D. EGCG partially restored redox homeostasis in arsenite 40. Naveen Kumar, Peeyush Prasad Eshna, stressed keratinocytes. J Appl Toxicol. 2018; Jash Smruthi, Jayasundar Itender Singh, 38: 1071-1080. [IF: 3.159] Neyaz Alam, Nabendu Murmu, S P Somashekhar, Aaron Goldman, Seema 33. Das S, Chatterjee N, Mishra A, Ahiwar S, Sehrawat. 2018. cAMP regulated EPAC1 Anne S, Satoskar A, Ganju R. Macrophage supports microvascular density, angiogenic migration inhibitory factor (MIF): A novel and metastatic properties in a model of triple therapeutic target against aggressive breast negative breast cancer. Carcinogenesis, cancer. The FASEB Journal. 2019;33(1):(1 Volume 39, Issue 10, 8. Pages 1245–1253 Supple) [conference proceedings]. [IF : 5.5] 41. Saha, Rinku, Roychoudhury Shubhadeep; 34. Bose D, Banerjee S, Chatterjee N, Das S, Saha Kar Kushal Kumar, Varghese Alex C., Nandi M, Saha KD. Inhibition of TGF-β induced Parag, Mitra Sreyashi, Murmu Nabendu, lipid droplets switches M2 macrophages to Massanyi Peter, Kolesarova Adriana. M1 phenotype. Toxicol In Vitro. 2019 Mar 28; Aug/Sep 2018. A comparative assessment of 58:207-214. doi: 10.1016/j.tiv.2019.03.037. semen quality in smokers and non-smokers [Epub ahead of print] PMID: 30930231[I.F : including sperm bpde-dna adduct formation 3.12] and acrosome status. Journal of 35. Chatterjee N, Das S,Mishra D, AhiwarS, Microbiology, Biotechnology & Food GanjuR, Croce R. Cannabinoid receptor Sciences. Vol. 8 Issue 1, p741-744. 4p. agonist JWH-015 inhibits growth and 42. Feudjio Ndemanou Yolande, Bhattacharyya metastasis of triple negative breast cancers Sayantan, Ghosh Paramita, Sarkar Deblina, through regulation of autophagy mechanism. Mouokeu Raymond S,Tume B. christopher, AACR; Cancer Res. 2019. 77(13 Supple) Murmu Nabendu. 2018. Cytotoxic effect of [conference proceedings].[IF: 9.130] Spondiascytherea fruit extract in murine 36. Ahiwar S, Chatterjee N, Mishra D, Ganju R, melanoma model in vivo and in vitro. Croce R.Slit inhibits breast cancer growth Journal of Environmental Pathology, and metastasis by activating anti-tumor Toxicology and Oncology. 37 (3), 231- 240 immune response. AACR; Cancer Res. 2019. (2018). 77(13 Supple) [conference proceedings].[IF : 43. Tapas Patra, Syamsundar Mandal, Neyaz 9.130] Alam, Nabendu Murmu. 2018. 37. Sayantan Bhattacharyya, Debarpan Mitra, Clinicopathological trends of colorectal Sudipta Ray, Nirjhar Biswas, Samir Banerjee, carcinoma patients in a tertiary cancer centre Biswanath Majumder, Saunak Mitra Mustafi, in Eastern India. Clinical Epidemiology and Nabendu Murmu. January 2019. Reversing Global Health. 6 (1)- 39- 43. effect of Lupeol on vasculogenic mimicry in 44. Islam S, Dasgupta H, Roy A, Alam N, murine melanoma progression. Mandal G K, Roychoudhury S, Panda C K.: Microvascular Research. Volume 121, Pages Skin mediates Human Papilloma Virus viii 52-62.

CNCI Annual Report 2018‐19 ANNEXURE

(HPV) infection in breast: A report of four Mandal S, Murmu N. 2019. Alterations in cases. Indian Journal of Case Reports, 4(2), biomarkers associated with oral squamous 98-102, 2018. cell carcinoma and lymph node metastasis due to chronic exposure to chewing tobacco. 45. Sharma S; Mishra, Chhimwal J; Patial V, Sk Pathology and Oncology Research, 19, 224. U. H., Dendrimer conjugated podophyllotoxin supresses DENA induced 53. Sen. S, Gajagowni J.G. , Pandey J.K., HCC progression by modulation of Dasgupta P., Sahni A, Gupta S, MP S., Ravi inflammatory and fibrogenic factors. B. 2019, Effectiveness of pectoralis major Toxicology Research, 2019, 8, 560-567 myocutaneous flap in the surgical management of oral cancer: A retrospective 46. Shomes Mozumder, Shirish Dubey, Kinshuk studyJ Stomatol Oral Maxillofac Chatterjee, Priyadarshan Kumar, Ankit Surg120(1):21-27 Khandelwal, Aniruddha Dam, Anup Kr Bhowmick. Reconstruction of Head and Neck 54. DasguptaP., Sen S., Srikanth H.S., Kamath G. Defects with Lower Trapezius Myocutaneous 2018 Sella Turcica Bridging As A Predictor Flap. Bengal Journal of Otolaryngology and Of Class II Malocclusion–An Investigative Head and Neck Surgery Vol 26, August 2018. Study J Stomatol Oral Maxillofac Surg119(6):482-485 47. Mittal Srabani Basu, P, Mandal Ranajit, Ghosh Ishita, Banerjee Dipanwita & Panda 55. Maji, S., Ghosh, I. 2018 Ameloblastic Chinmay & Biswas J. Enablers and Barriers Fibrosarcoma in Pregnancy: an Unreported of Follow-Up Care: An Experience from an Entity Indian J SurgOncol Volume HPV DNA Detection–Based Cervical Cancer 10, Issue 1, pp 180–183 Screening Program in Rural India. Journal of 56. MAJI, S.; GHOSH, 2018 I. Recurrent Global Oncology. 00-00. 10.1200/jgo.18.24200 Neuroglycopenia: Do Not Forget Non-islet (2018) Cell Induced Tumor Hypoglycemia. Middle 48. Banerjee Dipanwita, Mandal Amit & East Journal of Cancer, [S.l.], v. 9, n. 4, p. 344- Chakraborty Rashmi. Bevacizumab in 347, Gynaecological Malignancies: New Drugs in 57. Bhattacharjee P.K., Nanda D.P. 2018 Obstetrics and Gynaecology. April, 2018. prospective observational Study on FOGSI Focus; April,2018 Cholelithiasis in Patients with Carcinoma 49. Banerjee Dipanwita Taghavi Katayoun, Gall Bladder in a Tertiary referral Hospital in Mandal Ranajit, Maji Tapas et al. Eastern India Cancerjournal.net vol XX, issue Gynocular™ as a Field Colposcope: Real-life XX. Experiences from a VIA and HPV DNA- 58. Sahu S.K., Nanda D.P., Mandal S.S., based Cervical Cancer Screening Program in Chakraborty J., 2019, A Prospective Study of Rural India. Accepted in The Journal of Early Postoperative Course and Pathological South Asian Federation of Menopause Outcome of Modified D2 Gastrectomy- A Societies. 6. 52-56. 10.5005/jp-journals-10032- Single Institute Experience, IOSR-JDMS, vol 1136.2018 18, issue 4 ser.14, 47-58 50. Ranajit Mandal, Partha Basu. Cancer 59. Kumar N., Prasad P, Jash E, Jayasundar S, screening and early diagnosis in low and Singh I, Alam N, Murmu N, Somashekhar middle income countries- Current Situation SP, Goldman A, Sehrawat S 2018, cAMP and future perspective. Bundesgesundheitsbl regulated EPAC1 supports microvascular 2018 61: 1505-1512 (23rd October,2018) density. Angiogenic and metastatic 51. Mustafi SM, Murmu N, Biswas N, Ray S, properties in a model of triple negative Majumder B, Mitra D, Banerjee S, breast cancer, CarcinogenesisOct Bhattacharya S. 2018. Reversing effect of 2018,39(10):1245-1253 Lupeol on Vasculogenic mimicry in murine melanoma progression. Microvascular Book Chapter Research, 1, 77. 1. Bose A, Baral R. (2018) Neem Leaf 52. Mustafi SM, Ray S, Bhattacharya S, Sen S, Glycoprotein in Cancer Immunotherapy. In: ix

ANNEXURE CNCI Annual Report 2018‐19

“New Look to Phytomedicine” by Elsevier on Male Infertility: Preventive Therapeutic Publications, 391-408. Approach. In: Gargi Ganguly Mukherjee, Gautam Khastagir, Ratna Chattopadhyay, 2. Dr. Biswarup Basu co-authored a conference editors. Practical Guide in Andrology & proceeding on “Formulation development Embryology. 23rd ISAR, Kolkata; 2018. pp: and Characterization of Chitosan 117-127. Nanoparticles of an Antioxidant Phytoconstituent for the management of 4. Dipanwita Banerjee. Tumours of the Cervix cancer” with Harsheen Kaur, Misba Majood, uteri: Jeffcoat’s Principle of Gynaecology; Kalpana Nagpal in “6th World Congress on Page 553-72,9th Edition, 2018. ISBN: Nanomedical Sciences (ISNSCON-2018)”, 7- 9789352704774, Jaypee publishers. 11 Jan 2019, New Delhi. 3. Sreyashi Mitra, Nabendu Murmu, SM Rahman, Parag Nandi. Environmental effect

x

CNCI Annual Report 2018‐19 ANNEXURE Patents

1. An Organometallic Complex of Mercury for 2. An Organometallic Complex of the Treatment of Cancer. Supratim Ghosh Molybdenum for the Treatment of Cancer. and Upasana Das, Chittaranjan National Supratim Ghosh and Upasana Das, Cancer Institute Provisional Indian Patent Chittaranjan National Cancer Institute, Filed; Application no 201931006856 (Feb, Provisional Indian Patent Filed; Application 2019) no 201931006875 (Feb, 2019)

Gene Bank Submission

1. GenBank entry: Microsatellite repeat Intron 4 GEO with accession number GSE122697. of UIMC1, namely UIMC1_(GT)17-23 3. Landscape of genomic alterations in Indian (Accession Number MK163357- MK163359). Urinary Bladder cancer patients. 2. Global expression profile of uterine cervical Basu M., Ghosh A., Panda C. K.: NCBI GEO carcinoma in Indian patients. with accession number GSE122514 Contributor(s): Roychowdhury A., Samadder S., Chatterjee A., Roychoudhury S., Panda C. K. Submission Date: Nov 19, 2018; NCBI

xi

ANNEXURE CNCI Annual Report 2018‐19 Conference Presentations

Oral presentation World Neem Organization Seminar. Topic: A Glycoprotein from Neem Leaves holds Promise in Immune Dependent Cancer Invited lectures Therapy, Bangalore, December 2018. 1. Dr Madhumita Roy was invited to present a 7. Dr. R. Baral was invited to speak in 38th paper entitled ‘Isothiocyanates may Annual Convention of Indian Association for overcome platinum resistance in cervical Cancer Research (IACR). Topic: NLGP cancer’ in National Conference on New Ameliorates Tumor-Induced Arrest Of Dn2b Horizons in Cancer Biology, Ahmedabad To Dn3a Pro-T Cell Transition And Diversion Management Association, Ahmedabad, Of Pro-T Cells To Dendritic Cells By March 16-17, 2018. Regulating Notch1 And Ikaros Signaling, PGIMER Chandigarh, 2019. 2. Dr Sutapa Mukherjee was invited to present a paper entitled “Indian Spice Curcumin: A 8. Dr. Arpita Chandra presented an invited Rescue in Overcoming Chemoresistance in lecture in the National Seminar on Future of Breast Cancer Cells by Targeting Aurora India – Science & Technology, on 27th Kinases” in International Conference on February, 2019, in City College Campus on Advancement in Science & Technology, Cancer & Drug Resistance and she has also Visva Bharati, Santiniketan, September 3-4, chaired a Scientific Session 2018. “Medical/Veterinary & Pharmaceutical Sciences” on 27th February, 2019. 3. Dr Sutapa Mukherjee was invited to present a paper entitled “Serine Threonine Kinases: 9. Dr. Chinmay Kumar Panda was invited to Implications in Breast Cancer Using in vitro speak on “Molecular pathogenesis of Triple Model” in 43rd Annual Conference of Negative Breast Carcinoma: Strategy for Environmental Mutagen Society of India future therapeutics” in Indian Science (EMSI) and International Symposium on Congress Association, Kanpur Chapter “Impact of Environmental Mutagenesis in meeting on “Future India: Science and the Human Genome”, Organized by School Technology” held in Kanpur during of Bio Sciences & Technology, Vellore November 23-25, 2018. Institute of Technology (VIT), Vellore, India, 10. Dr. Chinmay Kumar Panda delivered his 31st January-2nd February, 2019. presidential lecture on “Emergence of 4. Dr. R. Baral was invited to speak in 1st precision medicine through systems biology International Conference on Immunology, in oncology: a step forward in modern 26-28th September, 2018, held at SRM biology” in 106th meeting of Indian Science Institute of Science and Technology, Tamil Congress, during held in Jalandhar, Punjab Nadu. Topic: NLGP Corrected Dendritic during January 3-7, 2019. Cell-CD8+ T Cell Crosstalk Prevents 11. Dr. Chinmay Kumar Panda was invited to Metastasis and Angiogenesis of Murine speak on “Analysis of molecular signature Melanoma and Carcinoma. during Uterine Cervical Carcinogenesis: 5. Dr. R. Baral was invited to speak in 30th Clinical and Prognostic implications” in 38th Annual Conference of the Physiological Annual convention of Indian Association for Society of India, 22-24th November, 2018, Cancer Research, at Chandigarh, on March 1- held at Serampore College, Serampore. 3, 2019. Topic: NLGP ameliorates tumor-induced 12. Dr. Chinmay Kumar Panda was invited to arrest of DN2b to DN3a pro-T cell transition speak on “Development of Precision Cancer and diversion of pro-T cells to Dendritic cells Medicine: Future Perspectives” in the by regulating Notch1 and Ikaros signaling. conference on Drug Discovery & 6. Dr. R. Baral was invited to speak in 1st Translational Medicine (DDTM-2019) held in xii

CNCI Annual Report 2018‐19 ANNEXURE

Annamalai University, Tamilnadu during India, 22-24th November, 2018. March 14-16, 2019. 5. Dasgupta S, Ghosh T, Dhar J, Nandi P, 13. Dr. Dona Sinha was invited to present a Chakravarti M, Guha I, Saha A, Majumdar S, paper entitled “Cellular and molecular Chakrabarti, Baral R, Bose A. Dual presence alterations associated with differential of pro-apoptotic RGS5-TGFb supports arsenic exposure” at Golden Jubilee proliferation of tumor-pericytes in tumor International Conference on Trends in microenvironment. In 2nd Annual Zoology; Jan 3-4; University of Burdwan; Conference on Recent Trends in Cancer 2019. Research, Early Diagnosis, Prevention and Therapy organized by CNCI, 4-5th Feb, 2019. 14. Dr. Kalyan Kusum Mukherjee was invited to talk on “Immunology and Cancer” at “UGC- 6. Sarkar A, Guha I, Nandi P, Saha A, Ganguly CPE sponsored International Conference on N, Das J, Gupta A, Mukherjee S, Baral R, Facets of Basic Sciences & Applications Bose A. NLGP immunotherapy promotes (FBSA)” organized by IQAC & Departments type-I diabetes mediated immune dependent of Botany, Chemistry, Computer Science, tumor restriction by modulating T-cell Electronics and Zoology of Bijoy Krishna metabolism and mormalises diabetes Girls College, Howrah. associated hepatic inflammation. In 2nd Annual Conference on Recent Trends in Participated lectures Cancer Research, Early Diagnosis, Prevention and Therapy organized by CNCI, 1. Mr Souvick Biswas presented a paper 4-5th Feb, 2019. entitled “Curcumin, a natural phytochemical, reverses acquired chemoresistance in breast 7. Sarkar A, Guha I, Nandi P, Saha A, Ganguly cancer cells by targeting Aurora Kinases” in N, Das J, Gupta G, Mukherjee S, Baral R, One day symposium of Society of Biological Bose A, NLGP immunotherapy promotes Chemists, Kolkata Chapter, Amity Type-I diabetes mediated immune University, Kolkata, September 8, 2018. dependent tumor restriction by modulating T cell metabolism and normalizes diabetes 2. Mr Archismaan Ghosh presented a paper associated hepatic inflammation. 38th entitled “Prevention of Arsenic induced skin Annual Convention of Indian Association for carcinogenesis by black tea” at 2nd Annual Cancer Research, March 1-3, 2019, PGIMER, Conference on Recent Trends in Cancer Chandigarh. Research, Early Diagnosis, Prevention and Therapy, World Cancer Day, Chittaranjan 8. Dasgupta S, Ghosh T, Dhar J, Nandi P, National Cancer Institute, 2019. Chakravarti M, Guha I, Saha A, Alum N, Majumdar S, Chakraborti P, Baral R, Bose A, 3. Sarkar A, Guha I, Nandi P, Saha A, Ganguly Dual presence of pro-apoptotic RGS5-TGFB N, Das J, Gupta A, Mukherjee S, Baral R, supports proliferation of tumor-pericytes in Bose A. NLGP Immunotherapy Normalizes tumor microenvironment. 38th Annual Diabetes-associated Hepatic Inflammation Convention of Indian Association for Cancer and Promotes Type-I Diabetes Mediated Research, March 1-3, 2019, PGIMER, Immune Dependent Tumor Restriction by Chandigarh. Modulating T Cell Metabolism. In International Conference on Immunology at 9. Bhuniya A, Gupta A, Saha A, Nandi P, Tamil Nadu, 26-28th Sept, 2018. Ganguly N, Bose A, Baral R. Tumor educated activated platelets promote vascular mimicry 4. Nandi P, Ghosh T, Dasgupta S, Das A, in mesenchymal stem cells for metastasis. Kundu S, Saha A, Dutta M, Majumder S, International Conference on Microscope & Baral R, Bose A. NLGP Prevents Tumor- XXXIX Annual Meeting of Electron induced Homing of Mesenchymal Stem Cells Microscope Society of India at in Tumor-draining Lymph Nodes by Down- Bhubaneshwar, July 18-20, 2018. regulating ERK-Akt-mediated CCR7 Signaling in B16 Melanoma. In 30th Annual 10. Dr. Arpita Chandra presented her work at Conference of the Physiological Society of 38th Annual Convention of Indian xiii

ANNEXURE CNCI Annual Report 2018‐19

Association for Cancer Research held in presentation entitled “Incidence of level IV Chandigarh from March 1st-3rd 2019, entitled metastases in early node negative oral “Unravelling the therapeutic potential of tongue cancer—is routine level IV clearance novel cobalt complex”. justified” at World Cancer Day CME held on 4th-5th February 2019 at CNCI. 11. Dr. Subhasis Barik presented his work at – Immunocon 2018 “Immunotherapy and 18. Dr. Puja Chatterjee presented a paper Advances in Immunology” at Translational entitled “Feasibility and compliance of Self- Health Science and Technology Institute sampling for HPV DNA detection in a (THSTI), Faridabad, India.(1st to 3rd cervical cancer screening project ” at 2nd November, 2018). Annual conference on recent trends in Cancer Research, Early diagnosis , 12. Dr. Subhasis Barik presented his work at – Prevention and Therapy on 4th February, International symposium on “Frontiers in 2019 held at CNCI and received the Second development and molecular medicine: Prize for the same. models to insights” at Biswa Bangla Convention Center, Kolkata, West Bengal, 19. Dr. Puja Chatterjee presented free Kolkata (March 1-3, 2019). communication (oral) titled “Association of Endometriosis with Mullerian Anomalies- A 13. Mr. Balarko Chakraborty delivered a lecture Retrospective Observational Study” in ICE titled “Role of Wnt-Beta Catenin Stem Cell 2019 organised by “Endometriosis Society Renewal Pathway in the development of India”, endorsed by “World Endometriosis Head and neck squamous cell carcinoma” Society” & supported by Jaipur Obstetrics & 2nd Annual Conference On “Recent trends in Gynaecological Society from 8th to 10th cancer Research, Early Diagnosis, Prevention March 2019 at B M Birla Auditorium, Jaipur and Therapy” held on 5th February (World and stood Third in this Category. Cancer Day), 2019 at CNCI, Kolkata. 20. Dr. Souradip Gupta presented a paper on 14. Dr. Nabendu Murmu delivered a lecture on Variation of Vascular Anatomy of ALT Flap “Molecular signalling mechanism on in APSICON, 2018, Lucknow. vasculogenic mimicry and effects of Lupeol on the tumor microenvironment in aggressive cancers” in 38th Annual Poster presentation Convention of Indian Association for Cancer Research at PGIMER, Chandigarh on 1st- 3rd 1. Mr. Atish Barua presented a poster on February, 2019. “Chemopreventive potential of Xanthone 15. Dr. Avik Biswas presented paper on“RBMX: isolated from Swertia chirata against DMBA a double-edged sword against Hepatitis C induced skin carcinogenesis” in 9th General virus and hepatocellular carcinoma” at Assemble and International Conference of International Symposium on “Frontiers in Asian Pacific Organization for Cancer development and molecular Prevention Conference, 19th to 20th April medicine:models to insights” held at Biswa 2018, Jeju Island, Korea. Bangla Convention Centre, Kolkata on March 2. Ms. Pritha Choudhury presented a poster on 1st – 3rd, 2019. “Cancer Stem Cell, the root cause of lung 16. Sayantan Bhattacharyya delivered an oral cancer and its prevention by eugenol” in 9th presentation on “Detection of nuclear p53 in General Assemble and International tumor tissues using a novel differential Conference of Asian Pacific Organization for staining technique.” at 2nd Annual Cancer Prevention Conference, 19th to 20th Conference on “Recent trends in Cancer April 2018, Jeju Island, Korea. research, early diagnosis, prevention and 3. Ms. Pritha Choudhury presented a poster on therapy” on 5th February, 2019 at “Prevention of lung cancer by eugenol and Chittaranjan National Cancer Institute, its effect on modulation of cancer stem cell” Kolkata. in 2nd Annual Conference on Recent Trends xiv 17. Dr. Kinshuk Chatterjee delivered an oral in Cancer Research, Early Diagnosis,

CNCI Annual Report 2018‐19 ANNEXURE

Prevention and Therapy”, 5th February 2019, Mimicry in Mesenchymal Stem Cells. In 14th CNCI, Kolkata. Indo-Australian Biotechnology Conference, Navi Mumbai, 22-23rd October, 2018. 4. Mr Souvick Biswas presented a paper (poster presentation) entitled “Aurora Kinases: 10. Chakravarti M, Gupta A, Sarkar A, Nandi P, Implication in chemoresistance and its Guha I, Saha A, Dasgupta S, Alum N, reversal by Curcumin” in 43rd Annual Chakraborti J, Baral R, Bose A, Tumor Conference of Environmental Mutagen Residing PD1high CD8+ T Cells Promote Society of India (EMSI) and International Expansion of Cancer Initiating Stem Like Symposium on “Impact of Environmental Cells, 38th Annual Convention of Indian Mutagenesis in the Human Genome”, Association for Cancer Research, March 1-3, Organized by School of Bio Sciences & 2019, PGIMER, Chandigarh. Technology, Vellore Institute of Technology 11. Saha A, Nandi P, Dasgupta S, Chakravarti M, (VIT), Vellore, India, 31st January-2nd Gupta A, Sarkar A, Dhar S, Bera S, Banerjee February, 2019. S, Baral R, Bose A, Intra-tumoral VEGF 5. Bhuniya A, Gupta A, Saha A, Nandi P, promotes switching of Th17 cells towards Ganguly N, Bose A, Baral R. Tumor educated Treg cells, 38th Annual Convention of Indian activated platelets promote vascular mimicry Association for Cancer Research, March 1-3, in mesenchymal stem cells for metastasis. 2019, PGIMER, Chandigarh. International Conference on Microscope & 12. Dhar S, Chakravarti M, Ghosh S, Sarkar M, XXXIX Annual Meeting of Electron Dasgupta S, Ghosh D, Bose A, Baral R, Microscope Society of India at Mukherjee KK, Tumor-Associated Myeloid Bhubaneshwar, July 18-20, 2018. Derived Suppressor Cells Promote 6. Nandi P, Ghosh T, Dasgupta S, Das A, Generation of Drug-Resistance in Non- Kundu S, Saha A, Dutta M, Majumder S, Hodgkin’s Lymphoma Patients. 38th Annual Baral R, Bose A. NLGP prevents tumor Convention of Indian Association for Cancer induced homing of mesenchymal stem cells Research, March 1-3, 2019, PGIMER, in tumor draining lymph nodes by down Chandigarh. regulating ERK/AKT mediated CCR7 13. Mukherjee KK, Dhar S, Chakravarti M, signalling in B16 melanoma. In international Bhattacharjee R, Bhanja S, Das S, Ghosh S, Conference on Microscope & XXXIX Annual Sarkar M, Dasgupta S, Ghosh D, Bose A, Meeting of Electron Microscope Society of Baral R, Tumor-Associated Myeloid Derived India at Bhubaneshwar, July 18-20, 2018. Suppressor Cells of Granulocytic Nature is a 7. Shayani Dasgupta et al., “TGFb within Potential Biomarker for Prognostication of tumor-microenvironment promotes survival Response in Treatment of Diffused Large B of altered pericytes by targeting RGS5- Cell Lymphoma. To be presented in: Annual induced pro-apoptotic signaling” on the Meeting of American Society of Clinical occation of 39th Annual Meeting of Electron Oncology, May 31-June 4, 2019, Chicago, Microscope Society of India at Mayfair Illinois. Convention Center, Bhubaneswar, 18-20th 14. Dr. Anindita Ghosh presented poster titled July, 2018. “Biological Investigations of Holarrhena 8. Dasgupta S, Ghosh T, Dhar J, Nandi P, Guha antidysenterica derived triterpene- 3, 4-seco- I, Saha A, Majumder S, Chakarbarti P, Baral lup-20(29)-en-3-oic acid for evaluating its R, Bose A. NLGP rescue TGFbeta mediated anticancer activity” at the 106th Indian switching of pro- to-anti apoptotic signaling Science Congress on Future India: Science & of RGS5 to normalize pericytes in tumor. In Technology" (New Biology Section) held at “Cell Death” Gordan Research Conference Jalandhar, India from 3-7 January 2019. 2018, Newry Maine, USA, August 6-11, 2018. 15. Dr. Anindita Ghosh presented poster titled 9. Bhuniya A, Gupta A, Saha A, Sarkar A, Bose “Experimental and theoretical studies of 1,3- A, Baral R. Tumor Educated Platelets dipolar cycloadditions of C-(1-naphthyl)-N- Promote Metastasis by Inducing Vascular Methyl nitrone” at the 106th Indian Science xv

ANNEXURE CNCI Annual Report 2018‐19

Congress on Future India: Science & Mismatch Repair Genes from Normal Technology" (Chemical Sciences Section) Cervical Epithelium to Invasive Cervical held at Jalandhar, India from 3-7 January Carcinoma (CACX)” at 1st annual meeting of 2019. Kolkata Gynecological Oncology conference held at Biswa Bangla Convention Centre, 16. Mrs. Rituparna Roy presented poster titled Kolkata from March 2-4, 2019. “Reactive oxygen species production triggers Plumbagin induced anti-proliferation and 23. Panchali Saha, Sinjini Sarkar, Dipanwita induces apoptosis in human cervical cancer” Ghosh, Pranab Kumar Sahoo, Sutapa at the 106th Indian Science Congress on Mahata, Vilas D. Nasare. Study of the 'Future India: Science and Technology' held expression levels of CEA, ki67 and p53 in in Jalandhar, Punjab from 3-7 January 2019. lung cancer at National Conference on “Emerging Trends in Non-Communicable 17. Mr. Balarko Chakraborty presented poster Diseases: Road to Prevention and Cure November titled “Analysis of Molecular Profile of Wnt- 17, 2018 at Institute of Management Beta Catenin Stem Cell Renewal Pathway studies,campus, NH-24, Adhyatmik Nagar, during development of Head and neck Ghaziabad-201015 (U.P) squamous cell carcinoma” at the 10th East Zonal Oncology Symposium held on 19th 24. Dipanwita Ghosh, Sutapa Mahata, Pranab January, 2019 at SGCCRI, Kolkata. Kumar Sahoo, Sinjini Sarkar, Dr. Asoke Roy, Partha Nath, Karabi Datta , Syamsundar

18. Mr. Balarko Chakraborty presented poster Mandal , Vilas D. Nasare Socio-demographic titled “Comparative Analysis of Wnt characteristics and use of Pap smear for Pathway Receptors/ Co-receptors and Their Cervical Cancer screening among women of Antagonists In Normal Oral Epithelium and Eastern part of India on 2nd Annual Conference Head and Neck Squamous Cell Carcinoma on Recent Treands in Cancer Research, Early (HNSCC) at Different Clinical Stages” at 38th Diagnosis, Prevention and Therapy on 4th and 5th Annual convention of Indian Association for February 2019 at Chittaranjan National Cancer Cancer Research held in Chandigarh, India Institute, Kolkata from March 1-3, 2019. 25. Pranab Kumar Sahoo, Sinjini Sarkar, 19. Ms. Debalina Mukhopadhyay presented Dipanwita Ghosh, Sutapa Mahata, Asoke poster titled “NOTCH1 signalling pathway Roy, Partha Nath, Karabi Datta, Syamsundar associated gene expression pattern in Mandal, Vilas D. Nasare Premalignant and primary tumors of head and neck squamous malignant lesions oral cavity in eastern India: cell carcinoma in Indian patients” at 10th East A hospital based study 2nd Annual Conference Zone Oncology Symposium held on 19th on Recent Treands in Cancer Research, Early January 2019 at Saroj Gupta Cancer Centre Diagnosis, Prevention and Therapy on 4th and 5th and Research Institute, Kolkata. February 2019 at Chittaranjan National Cancer 20. Ms. Debalina Mukhopadhyay presented Institute, Kolkata poster titled “Role of NOTCH1- HIF1α 26. Ranita Pal, Sinjini Sarkar, Dipanwita Ghosh, pathway in development of head and neck Pranab K. Sahoo, Sutapa Mahata, Kalyan K. squamous cell carcinoma” at 38th Annual Mukherjee, Partha Nath, Vilas D. Nasare. convention of Indian Association for Cancer MicroRNAs as prognostic biomarkers of Research held in Chandigarh, India from chemoresistance and chemosensitivity in March1-3, 2019. ovarian cancer patients undergoing st 21. Ms. Mukta Basu presented poster titled combinational therapy. I Annual Meeting of “High resolution genomic analysis revealed Kolkata Gynecological Oncology Trials and translational Research group ( KolGrTrg) on 2nd- alterations in FA-BRCA pathway in urinary 4th March 2019 bladder carcinoma” at the 38th Indian Association for Cancer Research held in 27. Depanwita Saha presented a poster on Chandigarh, India from March1-3, 2019. “Vasculogenic Mimicry in oral cancer: the role of EphrinA2 signalingpathway”in 38th 22. Ms. Priyanka Dutta presented poster titled Annual Convention of Indian Association for xvi “Analysis of the changes in profile of

CNCI Annual Report 2018‐19 ANNEXURE

Cancer Research at PGIMER, Chandigarh on 2019. 1st- 3rd February, 2019. 34. Dr. Gangotree Mohanty presented poster 28. Debarpan Mitra presented a poster on “In titled “HPV Prevalance and clearance in vitro and Ex vivo modelling delineates the cervix of asymptomatic population and combinatorial effects of Lupeol and 5- cervical lesions” at 1st annual meeting of Fluorouracil on breast cancer” at 2nd Annual Kolkata Gynecological Oncology conference Conference on “Recent trends in Cancer held at Biswa Bangla Convention Centre, research, early diagnosis, prevention and Kolkata from March 2-4, 2019. therapy” on 5th February, 2019 at 35. Patial V, Sharma S, Chhimwal J and Sk UH Chittaranjan National Cancer Institute, presented a poster on "Inhibition of Kolkata. hepatocellular carcinoma by dendrimer 29. Paramita Ghosh presented a poster on conjugated podophyllotoxin through “Madhucaindica inhibits breast cancer cell modulation of inflammatory and fibrogenic proliferation by modulating COX-2 factors in mice". 8th Annual Conference of expression” at 2nd Annual Conference on Indian Academy of Biomedical sciences “Recent trends in Cancer research, early (IABS) held at CSIR-NIIST, diagnosis, prevention and therapy”on 5th Thiruvananthapuram, Kerala 25th- February, 2019 at Chittaranjan National 27th February, 2019. Cancer Institute, Kolkata. 36. Dr. Shomes Mozumder presented a poster at 30. Sudipta Ray presented a poster on the Annual National Meet of the Foundation “Synergistic effect of Lupeol& Paclitaxel on for Head and Neck Oncology (FHNO) and HGF/c-Met Pathway in Oral Squamous Cell the International Federation of Head and Carcinoma” at 2nd Annual Conference on Neck Oncologic Societies (IFHNOS WORLD “Recent trends in Cancer research, early TOUR) held in Kolkata from October 25th - diagnosis, prevention and therapy” on 5th 28th 2018. February, 2019 at Chittaranjan National 37. Dr. Kinshuk Chatterjee presented a poster at Cancer Institute, Kolkata. the Annual National Meet of the Foundation 31. Depanwita Saha presented a poster on “The for Head and Neck Oncology (FHNO) and expression of cMET, Gab1 and pERK1/2 in the International Federation of Head and Oral Squamous Cell Carcinoma tissue and Neck Oncologic Societies (IFHNOS WORLD their association with Vasculogenic TOUR) held in Kolkata from October 25th - Mimicry.” at 2nd Annual Conference on 28th 2018. “Recent trends in Cancer research, early 38. Dr. Priyadarshan Kumar presented a poster diagnosis, prevention and therapy” on 5th at the Annual National Meet of the February, 2019 at Chittaranjan National Foundation for Head and Neck Oncology Cancer Institute, Kolkata. (FHNO) and the International Federation of 32. Dr. Gangotree Mohanty presented a poster Head and Neck Oncologic Societies entitled “Comparative evaluation of (IFHNOS WORLD TOUR) held in Kolkata prevalence and clearance of HPV in cervix of from October 25th - 28th 2018. asymptomatic Indian population and 39. Dr. Ankit Khandelwal presented a poster at cervical carcinoma patients” organized by the Annual National Meet of the Foundation 106th Indian science congress, held in for Head and Neck Oncology (FHNO) and Jalandhar, Punjab from January 3-7, 2019. the International Federation of Head and 33. Dr. Gangotree Mohanty presented poster Neck Oncologic Societies (IFHNOS WORLD entitled “Prevalance of high risk HPVs in TOUR) held in Kolkata from October 25th - cervical intraepithelial neoplasia (CIN) 28th 2018. patients of Indian population” in the 10th 40. Shri Bijan Kumar Mohanta attended & East Zonal Oncology Symposium held at presented two Poster presentations in 39th Saroj Gupta Cancer and Research Institute, Annual National Conference of Association Thakurpukhur, Kolkata on 19 th January, of Medical Physicists of India (AMPICON- xvii

ANNEXURE CNCI Annual Report 2018‐19

2018) held at Chennai Trade Center, Chennai dilemma and a treatment challenge, at from 02nd -4th November 2018. IMSOS (Indian Musculoskeletal Oncology Society) National Conference 8-10th March 41. Dr. Sagar Sen presented a poster on Spindle 2019, Kolkata. cell sarcoma of left ileum - a diagnostic

xviii

CNCI Annual Report 2018‐19 ANNEXURE Awards or Special Achievements

1. Mr. Atish Barua won Outstanding Poster 7. Mr. Anirban Sarkar got Sitaram Joglekar Presentation Award in the 9th General award for best oral presentation on the work Assemble and International Conference of entitled, “NLGP immunotherapy promotes Asian Pacific Organization for Cancer Type-I diabetes mediated immune Prevention, 2018, Jeju Island, Korea. dependent tumor restriction by modulating T cell metabolism and normalizes disbetes 2. Ms. Pritha Choudhury won first prize in 2nd associated hepatic inflammation.” In 38th Annual Conference on Recent Trends in Annual Convention of Indian Association for Cancer Research, Early Diagnosis, Cancer Research, March 1-3, 2019, PGIMER, Prevention and Therapy”, 5th February 2019, Chandigarh. CNCI, Kolkata. 8. Ms. Shayani Dasgupta was awarded the 1st 3. Mr. Souvick Biswas was awarded the 1st prize for poster presentation on the work prize in Poster Competition from Springer entitled, “TGFbeta within tumor Nature at 43rd Annual Conference of microenvironment promotes survival of Environmental Mutagen Society of India and altered pericytes by targeting RGS5 induced International Symposium on Impact of pro-apoptotic signaling ” on the occasion of Environmental Mutagenesis in the Human International Conference on Microscope & Genome at VIT, Vellore, India during the XXXIX Annual Meeting of Electron period of 31st January-2nd February, 2019. Microscope Society of India at Bhubaneswar, 4. Mr. Anirban Sarkar got the 1st prize for July 18-20, 2018. best oral presentation on the work entitled, 9. Ms. Sukanya Dhar was awarded the Third “NLGP Immunotherapy Normalizes prize for poster presentation (Rosche Diabetes-associated Hepatic Inflammation Scholar in Training) on the work entitled, and Promotes Type-I Diabetes Mediated “Tumor-Associated Myeloid Derived Immune Dependent Tumor Restriction by Suppressor Cells Promote Generation of Modulating T Cell Metabolism” on the Drug-Resistance in Non-Hodgkin’s occasion of International Conference on Lymphoma Patients.” In 38th Annual Immunology at Tamil Nadu, 26-28th Sept, Convention of Indian Association for Cancer 2018. Research, March 1-3, 2019, PGIMER, 5. Ms Shayani Dasgupta got the 1st prize for Chandigarh. best oral presentation in SRF category on the 10. Ms. Shayani Dasgupta had obtained CSIR work entitled, “Dual presence of pro- Travel Grant and Conference fee waiver from apoptotic RGS5-TGFb supports proliferation organizers for attending conference in “Cell of tumor-pericytes in tumor Death” Gordan Research Conference 2018, microenvironment.” In 2nd Annual Newry Maine, USA, August 6-11, 2018. Conference on Recent Trends in Cancer Research, Early Diagnosis, Prevention and 11. Ms. Suchisnigdha Datta was awarded the Therapy organized by CNCI, 4-5th Feb, 2019. 2nd prize for her oral presentation “Redox regulation of Nrf2 in lung cancer cells by 6. Mr. Anirban Sarkar got the 1st prize for EGCG: Implication in cancer therapeutics” at best oral presentation in JRF category on the 2nd Annual conference on recent trends in work entitled, “NLGP immunotherapy cancer research, early diagnosis, prevention promotes type-I diabetes mediated immune and therapy. Feb 4-5, 2019. dependent tumor restriction by modulating T-cell metabolism and mormalises diabetes 12. Dr. Kalyan Kusum Mukherjee was awarded associated hepatic inflammation.” In 2nd for “Outstanding Scientist Award” by Annual Conference on Recent Trends in International Organization of Scientific Cancer Research, Early Diagnosis, Research and Development (IOSRD) on 29th Prevention and Therapy organized by CNCI, September 2018 at Chennai, India. 4-5th Feb, 2019. xix

ANNEXURE CNCI Annual Report 2018‐19

13. Dr. Kinshuk Chatterjee was awarded 1st Prevention and Therapy on 4th February, prize for oral presentation for original 2019 held at CNCI and received the Second article entitled “Incidence of level IV Prize for the same. metastases in early node negative oral 15. Dr. Puja Chatterjee presented free tongue cancer—is routine level IV clearance communication (oral) titled “Association of justified” at World Cancer Day CME held on Endometriosis with Mullerian Anomalies- A 4th-5th February 2019 at CNCI. Retrospective Observational Study” in ICE 14. Dr. Puja Chatterjee presented a paper 2019 organised by “Endometriosis Society entitled “Feasibility and compliance of Self- India”, endorsed by “World Endometriosis sampling for HPV DNA detection in a Society” & supported by Jaipur Obstetrics & cervical cancer screening project ” at 2nd Gynaecological Society from 8th to 10th Annual conference on recent trends in March 2019 at B M Birla Auditorium, Jaipur Cancer Research, Early diagnosis , and stood Third in this Category.

xx

CNCI Annual Report 2018‐19 ANNEXURE PhD awarded

1. Ms. Tithi Ghosh was awarded PhD (Science) supervision of Dr. C K Panda. degree in the year 2019 from University of 6. Mr. Kaustav Dutta was awarded PhD Calcutta for her thesis titled "An effort to (Science) degree in the year 2018 from reduce the immunosuppressive effects of University of Calcutta for his thesis titled mesenchymal stem cells in cancer by neem leaf "Arsenic and the risk of carcinogenesis: A study glycoprotein: Focus on T cells" under the among the rural population of West Bengal" supervision of Dr. Rathindranath Baral. under the supervision of Dr. Dona Sinha. 2. Mr. Kaushik Banerjee was awarded PhD 7. A thesis titled “A prospective observational (Science) degree in the year 2019 from study on image guidance with cone beam CT Jadavpur University, Kolkata, for his thesis for Intensity modulated radiotherapy for titled "Evaluation of Efficacy of Some Transition head and neck cancer“ was submitted by Dr. Metal Chelates as Anti-Cancer Drugs" under Priyanka Biswas (Guide: Dr. Debarshi Lahiri the supervision of Dr. Soumitra Kumar Co-Guide: Dr. Sanjoy Roy, Dr. Dilip Kumar Choudhuri. Ray) to National Board Examinations (NBE), 3. Dr. Srabani Mittal was awarded PhD degree New Delhi and was accepted by the NBE. in the year 2018 from West Bengal University 8. A thesis titled “A prospective comparative of Health Sciences for her thesis titled study on the three different dose "Cumulative risk of high grade cervical fractionation schedules of intracavitary high intraepithelial neoplasia among high-risk human papilloma virus positive women detected by dose rate brachytherapy in the treatment of hybrid capture ii assay: a population based locally advanced cervical carcinoma.” was prospective study" under the supervision of submitted by Dr. Pinakin Thakorbhai Dr. C K Panda. Tandel (Guide: Dr. Kalyan Kusum Mukherjee Co-Guide: Dr. Tapas Maji, 4. Md. Saimul Islam was awarded PhD Dr.Dilip Kumar Ray) to National Board (Science) degree in the year 2018 from Examinations (NBE), New Delhi. University of Calcutta for his thesis titled

"Analysis of HPV profile and molecular 9. A thesis titled “A randomized comparative mechanism of beta-catenin activation in Triple study of outcome of treatment for locally Negative Breast Cancer in Indian patients" advanced head and neck squamous cell under the supervision of Dr. C K Panda. carcinoma treated by concurrent chemoradiation with conventional 5. Mr. Sudip Samadder was awarded PhD fractionation vs accelerated fractionation of (Science) degree in the year 2018 from External beam radiotherapy“ was submitted University of Calcutta for his thesis titled by Dr. Srikanya Chavitipalli (Guide: Dr "Analysis of regulation of self renewal pathways Tapas Maji Co-Guide: Dr. Debarshi Lahiri, and EGFR expression in uterine cervical Dr.Dilip Kumar Ray) to National Board carcinoma of Indian patients" under the Examinations (NBE), New Delhi.

xxi

ANNEXURE CNCI Annual Report 2018‐19 DNB awarded

1. Dr. Sayoni Bhanja successfully passed DNB 3. Dr. Srikrishnadevarayulu Rangineni Radiotherapy from CNCI, Kolkata. successfully passed DNB Radiotherapy from CNCI, Kolkata. 2. Dr. Deepsikha Goyel successfully passed DNB Radiotherapy from CNCI, Kolkata.

Conference/Symposium/Workshop organized

1. World Immunology Day was organized at are attended from different Institutions of CNCI on 1st May 2018 to increase awareness West Bengal. on Immunology among students. Eminent 3. One Workshop on “Right to natural Death immunologists delivered lectures in this and Passive Euthanasia” was held at the occasion. auditorium of the Chittaranjan National 2. Annual meeting of Indian Association for Cancer Institute in collaboration with ‘West Cancer Research and a Mini Symposium Bengal Society for study of Pain’ on Saturday was organized at CNCI on 14th September the 23rd June, 2018, with Padma Shree Dr M 2018 where distinguished cancer researchers R Rajagopal as the Chief Guest Speaker.

Administration of funds granted by Government of India & Government of West Bengal for welfare of cancer patients

No of patient Amount of grants Financial Year benefited involved

2018-19 382 Rs.1,21,80,181.00

xxii

CNCI Annual Report 2018‐19 ANNEXURE Patient Care Facilities Diagnostic facilities Synergy) with electron beam treatment facility A. Pathological Laboratory facilities 2. 16 slice CT simulator 1. Clinical Biochemistry with Auto-Analyzer 3. Ir-192 HDR after-loading brachytherapy machine (Integrated brachytherapy unit). 2. Cytology & Histopathology Section 4. Besides these, there are two bunkers ready B. Radiological facilities and acquisition of one low energy Linear accelerator and one Telecobalt machine is

1. X-ray – Three units, one for general under process. radiography, one for fluoroscopy and special procedures and one mobile X-ray at 5. Treatment Planning Systems TPS (CMS-XIO, ITU. Monaco, Oncentra), dosimeters and calibration instruments like Unidos E

2. Computerisd Radiography system with laser electrometers, 3-D RFA water phantom camera for digital films. (MP3-M, PTW), fluence analysis dosimetry 3. Ultrasonography- Two units: one B & W, one system (2D array), Film dosimetry system colour Doppler. etc. 4. Mammography unit (analogue model). 6. 3D Conformal Treatment with Multileaf Collimator (MLC), Intensity Modulated

5. Guided (USG) interventions such as FNAC, Radiation Therapy (IMRT), Image Guided biopsy, drainage. Radiation Therapy (IGRT), Volumetric 6. Review reporting of imaging (CT/MRI) done Modulated Arc Therapy (VMAT) and SBRT outside. treatments. 7. CT SCAN with CT Simulator C. Chemotherapy facilities C. Other diagnostic facilities 1. Day Care and Indoor Chemotherapy services 1. Pulmonary Function Test 2. Paediatric Oncology Section 2. Colposcopy Other facilities D. Blood Bank 1. Palliative Care services for pain relief. 2. ‘Ruma Abedona Hospice’, a city based NGO, Therapeutic facilities helps the patients of this hospital and their care givers with careful and effective A. Surgical facilities counseling as and when required. 1. Gastrointestinal & Genitourinary surgeries 3. Early detection and screening camps 2. Breast cancer surgeries 4. Evening pay clinic 3. Surgery for various peripheral soft tissue sarcomas Government schemes

4. Lobectomy for lung cancers 1. Empanelment of CNCI in Swasthya Sathi 5. Head and neck surgeries (state sponsored medical insurance scheme) for all modalities of Cancer treatment as an 6. Gynaecological oncological surgeries “A” category hospital. B. Radiotherapy facilities 2. Rashtriya Arogya Nidhi (RAN) fund to provide free chemotherapy for patients with

1. Dual Energy Linear accelerator (ELEKTA BPL status. xxiii

ANNEXURE CNCI Annual Report 2018‐19 General Administration, Accounts & Ancillary Departments

Dr. Jayanta Chakrabarti, MBBS, MS, DNB(Surgical Oncology) Director Dr. Sankar Sengupta Medical Superintendent Dr. D. P. Jena Administrative Medical Officer Shri Sudhin Kumar Bandyopadhyay Senior Administrative Officer

Director’s Section Ward Master’s Section Shri Debanjan Sarkar, Private Secretary Shri Bhola Pal, Lab. Helper Shri Basanta Mahapatra, Lab. Helper Shri Ashish Bagchi, Lab Helper (Died in harness on 28.02.2019) Shri Hiralal Balmiki, Lab. Helper (Retired on 30.6.2018) Shri Sarju Das, GDA Shri Sambhu Halder, Lab. Helper Shri Pakul Guchait, GDA (VR on 28.02.2019) General Administration Shri Asim Kumar Chakravarty, GDA Smt. Saraswati Nayak, GDA Smt. Jyoti Singh, Hindi Officer Smt. Sumitra Routh, GDA Shri Jayanta Sikder, Office Superintendent Shri Purnendu Roy, GDA. Smt. Sipra Sarkar, Office Superintendent Shri Karunakar Nayak, GDA Shri Awadhesh Kumar Singh, Personal Assistant Smt. Sumitra Das, GDA Shri Probir Kr. Pramanick, Sr. Caretaker (Retired on 31.7.2018) Smt. Rekha Gachhit, GDA Shri Prasanta Sarkar, Sr. Caretaker Shri Rabin Pramanik, GDA Shri Ujjwal Kr. Barui, Head Clerk Shri Sanjoy Das, GDA Shri Sailesh Kr. Singh, LDC (PwD) Shri Babulal Hela, GDA (Retired on 30.6.2018) Smt. Soma Das, Storekeeper Shri James John, GDA (Retired on 30.11.2018) Shri Malay Das, Daftari Shri Ramanand Mishra, GDA (Retired on 28.02.2019) Smt. Arati Dey, GDA Shri Krishan Mallik, GDA Shri Monojit Das, Lab. Helper Shri Swapan Paul, GDA (Retired on 31.7.2018) Shri Jagannath Das, Gardener Shri Harihar Nayak, GDA Accounts Section Shri Tapan Saha, GDA Shri Shankar Naskar, GDA Shri Chandan Kumar Sinharay, Accounts Officer Smt. Munni Hela, GDA Shri Shaibal Bhaduri, Assistant Accounts Officer Smt. Jhuma Lama, GDA Shri Atal Behari Mahanti, Accountant Shri Dipak Biswas, GDA Shri Sumit Kr. Majumdar, Head Clerk Shri Sara Nayak, GDA Shri Sunil Kr. Jha, Accountant Shri Animesh Nath, Accountant Maintenance Department Shri Asitava Bhattacharya, LDC Shri Swarup Ghosh, AC Attendant Shri Rambilash Yadav, Lab. Helper Shri Bidesh Roy, Electrician (PwD) Shri Ujjal Roy, Lab. Helper Smt. Punia Devi, GDA xxiv

CNCI Annual Report 2018‐19 ANNEXURE Store and Purchase Smt. Rumi Dutta (Sarkar), Staff Nurse Shri Samson Soren, Store Supervisor Smt. Chirosree Sarkar (Mukherjee), Staff Nurse Shri Ganesh Kundu, GDA Smt. Bijali Mondal, Staff Nurse Smt. Samita Saha, Staff Nurse Academic and Computer Facility Smt. Banhishikha Das, Staff Nurse Dr. Sutapa Mukherjee, Academic Coordinator Smt. Sarmila Kora, Staff Nurse Shri Kalyan Shankar Roy Chowdhury T.O.‐Scientific Smt. Kakoli Bhattacharjee, Staff Nurse Shri Ranjit Singh, Telephone Operator Smt. Moushumi Chakraborty(Choudhuri), Staff Nurse Smt. Baranali Sarkar, Staff Nurse Nursing Staff Smt. Soma Jana, Staff Nurse Smt. Malika Barui(Mukherjee), Asst. Nursing Supdt. Smt. Krishna Singha, Staff Nurse Smt. Dalia Biswas, Nursing Sister Smt. Kumkum Sarkar (Bhowmick), Staff Nurse Smt. Krishna Dey, Nursing Sister Smt. Pamela Maity (Chowdhuri), Staff Nurse Smt. Bandana Chakraborty, Nursing Sister Smt. Rekha Sardar, Staff Nurse Smt. Rita Rana, Nursing Sister Smt. Sipra Pal, Staff Nurse Smt. Krishna Roy Chowdhury, Nursing Sister Smt. Chaitali Mondal (Guha), Staff Nurse Smt. Japamala Maity, Nursing Sister Smt. Ratna Karmakar, Staff Nurse Smt. Rita Dutta, Nursing Sister Smt. K. Sandhya Barui, A N M (Retired on 31.01.2019) Smt. Uma Majumder, Nursing Sister Shri Mukesh Kumar Dhakar, Staff Nurse Smt. Priya Bhattacharya, Nursing Sister Smt. Jayita Das, Staff Nurse Smt. Tanu Ghosh (Chanda), Nursing Sister Shri Om Prakash, Staff Nurse Smt. Swati Ghosal, Nursing Sister Shri Kamal Singh Choudhury, Staff Nurse Smt. Alpana Maity, Nursing Sister Smt. Sudeshna Bag, Staff Nurse Smt. Tapati Burman, Nursing Sister Smt. Sikha Jana, Staff Nurse Smt. Sujata Majumder, Staff Nurse Shri Anil Kumar Sharma, Staff Nurse Smt. Debjani Dutta (Debangshi), Staff Nurse Smt. Beauty Pradhan, Staff Nurse Smt. Purnima Mondal (Sarkar), Staff Nurse Smt. Arpita Mukherjee, Staff Nurse Smt. Kabita Ghosh (Bali), Staff Nurse Shri Suraj Mal, Staff Nurse Smt. Soma Chatterjee (Mukherjee), Staff Nurse Shri Suresh Kumar, Staff Nurse Smt. Piyali Bandyopadhyay, Staff Nurse Shri Pradeepan P., Staff Nurse Smt. Kabita Bera (Maity), Staff Nurse Shri Naveen Tailor, Staff Nurse Smt. Sandhya Das, Staff Nurse Shri Mukesh Kumar, Staff Nurse Smt. Tapati Ghosh, Staff Nurse Smt. Nitu Kumari, Staff Nurse Smt. Manjula Tudu, Staff Nurse Smt. Sonali Nath, Staff Nurse Smt. Runa Sanyal, Staff Nurse Shri Prem Chand Bairwa, Staff Nurse Smt. Sonali Bhunia, Staff Nurse Shri Rajpal Raigar, Staff Nurse Smt. Sharmila Das, Staff Nurse Shri Sitaram, Staff Nurse Smt. Sarbani Das, Staff Nurse Shri Kuldeep Meena, Staff Nurse Smt. Arpita Dey (Das), Staff Nurse Shri Murari Kumar Jha, Staff Nurse

xxv

ANNEXURE CNCI Annual Report 2018‐19

xxvi